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ABSTRACT 
The cause of the degeneration of nerve cells, and the loss of specific synaptic connections, 
that underlies the emergence and progressive development of dementia in sufferers of 
Alzheimer's disease remains elusive. Furthermore, although individually the B-amyloid 
plaque, neurofibrillary tangle and dystrophic neurite, pathological hallmarks of the disease, 
have been extensively investigated, the mechanism that links these structures also remains 
to be defined. This thesis, therefore, sought to address three aims that were principally 
associated with the relationship between the pathological structures and the mechanism 
underlying Alzheimer's disease. Firstly, to determine the neurochemical and morphological 
diversity of abnormal neurites associated with B-amyloid plaque formation in the early and 
late stages of Alzheimer's disease. Secondly, to examine the relationship between 
apolipoprotein E immunolabelling and 13-amyloid deposition, neuritic plaques and 
neurofibrillary tangles using immunofluorescent double labeling techniques. Finally, to 
develop an in vitro experimental model that mimics the effects of B-amyloid plaques on 
surrounding neuronal processes. 
The major conclusions from these investigations were that the dystrophic neurites 
associated with subsets of B-amyloid plaques develop through a distinct morphological and 
neurochemical sequence. This sequence of change is intimately linked to various 
components of the neuronal cytoskeleton, including neurofilaments. The similarity between 
these changes and those present within axons undergoing a response to physical damage 
lead to the development of a new hypothesis that B-amyloid plaque deposition causes 
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physical damage to surrounding neurites which results in the formation of dystrophic 
neurites. This hypothesis was further supported by results obtained from an in vitro model 
of physical damage. In summary, this study further clarified the relationship between 13- 
amyloid plaques and dystrophic neurites, particularly with regard to determining the role of 
specific cytoskeletal changes. Identification of the earliest pathological changes that occur 
in Alzheimer's disease is necessary for the development of effective therapeutic strategies 
aimed at preventing or slowing the ongoing neuronal changes that ultimately lead to cell 
death and dementia. 
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Chapter 1 
INTRODUCTION 
Alzheimer's disease (AD) is the major cause of dementia in late middle-aged and elderly 
individuals, affecting approximately 11% of the population over 65 years and up to 50% of 
individuals over 85 years (Hof & Morrison, 1994). The main locus of effect for this disease is 
the cerebral cortex, whereby dementia results from the degeneration of select subgroups of 
neurons. The disease process selectively damages brain regions and neural circuits critical for 
cognition and memory, including neurons in the neocortex, hippocampus, amygdala, basal 
forebrain cholinergic system and brainstem monoaminergic nuclei (Ulrich, 1985; Braak & 
Braak, 1991; Price et al., 1991; Vickers et al., 1992a; Hof et al., 1995). Ultimately, this 
degeneration results in a loss of connectivity of crucial cortical circuits, thereby resulting in 
widespread cognitive impairment. 
Sufferers of AD experience gradually increasing forgetfulness, decreasing attention span and 
alterations in mood, often with frustration and agitation. The interval between initial diagnosis 
and death can vary considerably, usually between three and fifteen years and with this decline 
comes an increasing dependence on primary carers and health-care system assistance. 
Consequently, AD imposes both a considerable social and financial burden on the population. 
It is estimated that there are three to four million patients in the USA alone who currently have 
AD and that number is expected to double in the next twenty years (Roses, 1995). Currently 
there are no treatments available which have proven to be effective in slowing or interrupting 
the progression of AD. 
There are specific abnormal structures that occur in the brains of individuals with AD 
including extracellular accumulations of B-amyloid into plaque like deposits and intracellular 
neurofibrillary changes in both the cell bodies (neurofibrillary tangles (NFTs)) and also 
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associated nerve cells processes (dystrophic neurites (DNs)). A major obstacle hindering 
research and treatment development is the lack of understanding of the cellular mechanisms 
underlying the neuronal pathology of this neurodegenerative disorder. This thesis will, 
therefore, seek to investigate the relationship between these pathological hallmarks of AD with 
a particular emphasis on the association between I3-amyloid plaques and clusters of abnormal 
or dystrophic neurites. The implications of this relationship will be discussed with regards to 
defining the role of neurofilaments (NFs) in not only the development of DNs but also in the 
mechanism underlying AD as a whole. 
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BACKGROUND 
A number of different neuronal cytoskeletal proteins are altered in the development of 
neurofibrillary pathology in AD. There is evidence that a modified form of the microtubule 
associated protein, tau, is an integral component of paired helical filaments (PHFs), the major 
component of the NFT (Wischik et al., 1988). Furthermore, an increasing body of literature 
now implicates the NF triplet protein as the first cytoskeletal element to undergo change in 
AD, preceding the development of more classical tau pathology (Vickers et al., 1996). In 
addition, a correlation between a neuron's content of the NF triplet protein and its subsequent 
vulnerability to pathology development (Vickers et al., 1992a, 1994a) and degeneration 
(Morrison et al., 1987; Hof et al., 1990; Hof & Morrison, 1990) has been reported. 
Cumulatively, these results suggest that alterations in the neuronal cytoskeleton, particularly 
the NF triplet proteins, contribute to the pathogenesis of AD. Therefore, the structure and 
function of the normal cytoskeleton as well as the profound cytoskeletal changes that occur in 
neurons and their processes in AD are the major themes discussed in the following review of 
the literature. 
1.1 	Neuronal Cytoskeleton 
Many of the changes that occur in AD and ultimately result in nerve cell death, connection 
loss and dementia involve components of the neuronal cytoskeleton. The cytoskeleton is an 
intracellular structure which occurs in most vertebrate cells. Specialised cytoskeletons 
contribute to many cellular functions, including maintenance of mechanical integrity and 
wound healing in epidermal cells, cell polarity in simple epithelia, contraction in muscle cells, 
hearing and balance in the inner-ear cells, neuromuscular junction formation between muscle 
cells and motor neurons and axonal transport in neurons. This skeleton is composed of three 
main fibrillar components namely microtubules (MTs) (25 nm diameter), microfilaments 
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(MFs) (5 nm diameter) and intermediate filaments (IFs) (10 nm diameter). It has been 
established that the first two classes are involved in a variety of cellular events including cell 
division, locomotion, protoplasmic streaming, cellular polarity and anchorage. However, a well 
defined function of ifs cannot be given at present. 
One of the unique properties of neurons that enables them to form complex nervous systems 
is their ability to extend long cytoplasmic processes, axons and dendrites, which allow cells to 
communicate with other cells in a highly specific manner. The growth and maintenance of 
these processes is critically dependent on the neuronal cytoskeleton. In addition to the 
development and maintenance of neuronal morphology the neuronal cytoskeleton also has 
more dynamic roles in the transport of materials in both directions along axons and dendrites, 
in cell division in developing neurons and in mediating plastic changes in neuronal 
morphology and function in the adult brain. These changes may underlie the long term 
modifications required for learning and memory. 
1.1.1 Microtubules 
Neuronal MTs have many functional roles. They are likely to be involved in cell division and 
motility during development, the growth of axons and dendrites, the maintenance of neuronal 
morphology, transport of components along axons and dendrites and neuronal plasticity. MTs 
are structurally and functionally polar with a fast growing (plus) and a slow growing (minus) 
end. In axons they are uniformly oriented with their plus-ends pointing toward the distal end, 
whereas in dendrites, their orientations are mixed (Baas et al., 1988). 
MTs isolated from brain contain a number of polypeptide components including dimers of a-
and 13- tubulin, which assemble to form a linear polymer, a heterogeneous collection of 
proteins, known as microtubule associated proteins (MAP), and a third class of proteins 
known as 'motor proteins'. Molecular variation in MT composition occurs at both the level of 
the forms of a- and 13- tubulins present and the nature of the associated MAPs. 
4 
Chapter 1 
a- and B- tubulin are each encoded by up to six different genes. The protein tubulin can also 
be modified in several ways; phosphorylation, acetylation, detyrosination and glutamylation. 
These factors combine to result in considerable tubulin diversity. In the elongation of axons of 
the neuron, tubulin molecules are transported toward the end of pre-exisiting MTs via a 
mechanism called slow axonal flow/transport. Two different hypotheses have been presented 
to explain this mechanism; the transport of soluble monomers and /or oligomers versus the 
transport of polymerised MTs (Kobayashi et al., 1998). 
Cytoskeletal organisation and dynamics depend on protein self-associations and interactions 
with regulatory elements such as MAPs. The MAP family includes large proteins - MAP1A, 
MAP 1B (also known as MAP5), MAP1C, MAP2 and MAP4, which have a comparatively 
high molecular weight range, between 180 and 350 kDa and smaller components like tau and 
MAP2C, which have lower molecular weights within the range of 30-60 kDa (Fulton, 1984; 
Lewis et al., 1988). Both groups possess a similar carboxy-terminal amino acid sequence, 
which acts as the MT binding site (Lewis et al., 1988). 
Expression of the various isoforms is dependent on the stage of development and 
differentiation of the neuron (Matus, 1988). Further to this, the cellular localisation of 
individual MAPs is quite specific. MAP3 (270 kDa) is specific to astroglial cells and NF rich 
axons (Parysek et al., 1984). MAP5 (320 kDa) is localised to neuronal axons, dendrites and 
cell bodies but not terminals (Riederer et al., 1986). MAP4 (270 kDa), in contrast to the other 
neuronal MAPs, has a ubiquitous distribution (Mandelkow & Mandelkow, 1995). The most 
widely studied of the MAPs are MAP2, which consist of two isoforms (a and b), of 
approximate molecular weight of 280 kDa, and is found only in nerve cell bodies and 
dendrites (Bernhardt & Maths, 1984), and tau, which is 55-62 kDa and is generally believed 
to be only associated with axonal MTs (Binder, 1985). MAP2 and tau share homologous 
repetitive motifs in the carboxy-terminal region that contribute to MT binding, however, 
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MAP2 has a much larger extension towards the amino-terminus. MAP4 also resembles 
MAP2 and tau in having a homologous repeat domain that interacts with MTs (Mandelkow & 
Mandelkow, 1995). 
Initially, tau was described by Weingarten and colleagues (Weingarten et al., 1975) as a heat 
stable protein that co-purified with tubulin through repeated cycles of polymerisation and 
facilitated the formation of MTs. Studies of cloned mouse (Lee et al., 1988), human (Goedert 
et al., 1989) and bovine (Himmler et al., 1989) tau revealed a family of proteins derived from 
alternatively spliced transcripts of a single gene, located on the long arm of chromosome 17 
(Neve, 1986) with predicted molecular masses between 35 and 40 kDa. In the human brain 
this alternative splicing gives rise to the expression of six different isoforms (Goedert et a1., 
1989). Isoforms contain either three or four imperfect sequence repeats of 31 or 32 amino 
acids in the carboxy-terminal region of the molecule that mediate, due to the presence or 
absence of exon 10 in the mRNA (Goedert et al., 1989), the binding of tau to MTs (Butner & 
Kirchner, 1991). 
Investigations have demonstrated that MAPs are capable of contributing to the assembly and 
stability of MTs in vivo, that is, cells transfected with MAP2 (Ferralli et al., 1994) and tau (Lee 
& Rook, 1992; Bramblett et al., 1993) all had increased MT stability. Experiments showing 
that cells failed to form neuritic processes containing stable MTs when treated with anti-sense 
strategies designed to decrease the cellular synthesis of these MAPs provides further evidence 
. that tau and MAP2 are MT - stabilising proteins in vivo (Caceres & Kosik, 1990; Dinsmore 
& Soloman, 1991). Other in vivo studies suggest that the claim that tau and MAP2 act to 
stabilise MTs may be too simplistic. Hirokawa's laboratory showed that homozygous tau-
knockout mice contained no immunologically recognisable tau, yet the mice were 
phenotypically normal, with very subtle differences in MT polymer, neurons, axons or MT-
dependent functions (Harada et a1, 1994). This result suggests that in circumstances where 
there is no tau, the stabilisation of MTs may be achieved by other MAPs. 
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It has also recently become clear that the phosphorylation of specific sites rather than the 
overall extent of phosphorylation, may be an important factor in modulating the ability of tau 
to bind MTs and promote MT stabilisation. For example, phosphorylation of tau by cAMP-
PK decreases tubulin binding, while phosphorylation by CaMKII does not alter this 
parameter (Johnson, 1992). Similarly phosphorylation of specific tau residues differentially 
affects the activity of tau on MT assembly (Brandt et al., 1994). 
The MAPs have also been implicated in the interaction of MTs with other cytoskeletal 
elements and cellular organelles (Hirokawa, 1982; Hirokawa et al., 1988). Studies using 
quick-freeze, deep etch electron microscopy have confirmed that MAPs form structural side-
arms which interconnect MTs with MTs and other cytoplasmic elements (Hirokawa, 1982; 
Hirokawa et al., 1988). Investigations into the mechanism of membranous organelle 
movement along MTs in anterograde fast axonal transport (Brady et al., 1982) led to the 
discovery of unidirectional cytoplasmic MT-based motor proteins (Paschal et al., 1987), so 
called because they generate movement along MTs using the chemical energy of adenosine 
tri-phosphate hydrolysis. Examples include lcinesin which acts as a motor for anterograde fast 
axonal transport (Bloom et al. 1988) and dynein which is thought to be the motor for the 
retrograde transport of membranous organelles in fast axonal transport (Schroer et al., 1989). 
Recent evidence also suggests that the motor proteins may affect the organisation of dendritic 
MTs (Sharp et al., 1995, 1996). 
1.1.2 Microfilaments 
Actin MFs play a direct role in a variety of cell processes. They are by far the major 
cytoskeletal component on the leading edge of the growth cone and with MTs are a major 
constituent of the cytoskeleton of presynaptic nerve terminals (Hirokawa et al., 1989). The 
protein actin has also been demonstrated to be in great abundance in dendritic spines (Matus 
et al., 1982). Actin was first characterised as a self-assembling 43 IcDa protein with a single 
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nucleotide binding site. Actin-associated proteins have been implicated in the regulation of 
filament assembly (eg profilin (Blikstad et al., 1980), stabilisation (eg tropomyosin (Gunning 
et al., 1998), crosslinking and bundling (eg brain spectrins fodrin and spectrin (Riederer et 
al.,1986) and filament-membrane linking or anchoring (eg ankyrin (Nelson & Lazarides 
1984). 
The force generation for projection and retraction of processes from growth cones during 
neuronal development is likely to be provided by the actin network. The growth cone 
lamellipodia and filopodia, which perform the initial scanning movement, are rich in MFs. In 
contrast, MTs form the core of the growth cone base (Brandt, 1998). Actin filaments are 
intrinsically polar, highly dynamic structures which are able to quickly assemble and 
disassemble. They are capable of exerting net movement through a process known as 
"treadmilling", which involves the assembly of filaments at one site (plus-end) and 
disassembly at the other (the minus-end). This assembly process produces the force for 
growth cone mobility (Forscher et al., 1992). 
The growth associated protein 43, (GAP43) is tightly associated with the growth cone 
membrane skeleton, which via regulation of actin polymerisation is responsible for causing 
directional changes in axon growth. GAP43 co-sediments with actin filaments and its 
phosphorylation, on serine 41 by protein lcinase C, is spatially regulated so that 
phosphorylated GAP43 is found in areas where growth cones make productive stable contacts 
with other cells. In contrast unphosphorylated GAP43 which binds calmodulin, is always 
found in parts of the growth cone which are retracting (He et al., 1997). 
1.1.3 Intermediate filaments 
Of the three major constituents of the cytoskeleton, Ws remain the least understood with 
respect to structure and function. IFs generally constitute approximately one percent of total 
protein, although in some cells, such as neurons and epidermal keratinocytes, IFs are 
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especially abundant accounting for up to 85 percent of the total protein of fully differentiated 
cells (Fuchs & Cleveland, 1998). 
Despite their diversity, members of the IF superfamily share a common structure in which 
three distinct domains can be identified, a central rod of conserved length and sequence (about 
310 amino acid residues) (Steinert & Roop, 1988) occurring in a helical conformation, 
flanked by a non-helical amino-terminal headpiece of variable length and a non-helical 
carboxy-terminal tail showing considerable length differences between different IF proteins. 
The highly conserved rod domain has been proposed to be the organising centre for filament 
assembly, as well as for other shared structural and morphological characteristics of the IF 
proteins. Variability in the molecular weights and functions of IFs found in different cell types 
has been attributed to the hypervarible carboxy-terminal and amino-terminal domains of these 
proteins. IF assembly, unlike MT or ME assembly, does not appear to require co-factors or 
associated proteins (Schliwa & Potter, 1986). It remains uncertain as to whether all IF 
polypeptides are incorporated into the IF network as they are synthesised, or whether they 
exist in a post-translational soluble form in the cytoplasm from which filaments are formed 
(Schliwa & Potter, 1986). 
NFs correspond to the IF component of the neuronal cytoskeleton and can be further 
subdivided into subclasses based on their molecular and genetic structure, as well as their 
specific expression in different cells and in development. They are usually found in bundles, 
are long and unbranched and appear to be of constant diameter. Under electron microscopy 
thin, wispy protrusions can be seen forming bridge-like structures between adjacent filaments. 
Such side-arms are absent from the 10 nm filaments of other cell types. 
At least four IF types have been identified so far in central or peripheral neurons, including the 
NF triplet (class IV of the five major IF classes defined by sequence analysis), vimentin (class 
peripherin (class HI), a-internexin (class IV) and nestin (a novel "sixth" class). These 
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subtypes are variably and differentially expressed in accordance with the neurons changing 
demands for plasticity and stability of cell shape as they migrate, elaborate neurites, and 
establish a permanent fibre trajectory. The postnatal replacement of the transitional forms, 
such as vimentin, peripherin and a-internexin by the NF triplet proteins and the subsequent 
modification of the NF composition and structure during development coincide with a shift in 
demand for plastic, intermediate networks to a need for more stable filaments to support the 
highly polar morphologies characteristic of mature neurons. 
The protein vimentin (52-58 kDa) is abundant in most central nervous systems (CNSs) before 
they differentiate. During this period vimentin filaments mediate cell division and changes in 
cell shape and may also assist in initial neurite outgrowth (Nixon & Shea, 1992). Peripherin 
(56-61 kDa) appears in some neurons, particularly those of the peripheral nervous system, 
after their final division and after migrating cells have reached their destination (Escurat et al., 
1990). Like vimentin, the expression of peripherin is increased after axotomy (Oblinger et al., 
1989) suggesting a principal role for this IF protein in maintaining plasticity during outgrowth 
and regeneration. a-internexin (66 kDa), another of the neuronal filaments, helps maintain 
plasticity during outgrowth and regeneration (Patcher & Liem, 1985). It persists as the 
dominant IF system in small calibre axons. The most recently described of the neuronal IF 
family is `nestin' or neuroepithelial stem cell protein (Lendahl et al., 1990). It functions in 
neuroblast migration and is expressed only in the early developing nervous system in radial 
glial cells, the progenitors of both neurons and g,lia. The final class associated with the 
nervous system are the NF triplet proteins. Due to the association between this class of IF 
protein and AD (Dahl et al., 1982; Perry et al., 1985; Cork et al., 1986; Haugh et al., 1986; 
Miller et al., 1986, Dickson et al., 1988; Masliah et al.,1993b; Vickers et al.,1994b; Su et al., 
1996) more detailed discussions of their structure, assembly, phosphorylation patterns and 
dynamics will be given below. 
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1.2 	Neurofilament triplet 
The most widely studied NF proteins in the CNS are collectively referred to as the NF triplet 
proteins, which form heteropolymers thought to be composed of varying combinations of NF-
M (160 kDa) and NF-H (200 lcDa) subunits with NF-L (68 IcDa) mw subunits (Lee et al., 
1993). These subunits are both genetically and structurally interrelated. As the triplet proteins 
are, collectively, the most predominant neuronal IF, the combined heteropolymer of all three 
subunits is often referred to as a 'NF' although strictly it is just one type of NFs. This system 
of nomenclature will be adopted for the purpose of this review. 
NFs arise at a time in late embryonic development when neurites are growing but have not yet 
reached their targets (Tapscott et al., 1981). Normally NFs extend throughout the axon, 
dendrites and soma of a cell but are absent from the nerve terminals due to the action of 
proteases (Schlaepfer, 1987). Those subunits localised to the soma and dendrites are 
dephosphorylated on their carboxy-terminal domains whereas NFs within the axon are 
predominantly phosphorylated (Torack et al., 1996; Vickers, 1997). In the past it has been 
thought that NFs primary role in neurons was structural ie maintaining axonal calibre 
(Hoffman et al., 1987). Other studies have suggested that NFs may be involved in other 
cellular functions including the control of ionic balance, regulation of chemical processes and 
the distribution of information amongst the major cellular domains (Schlaepfer, 1987). 
However, more recently, gene targeting studies studies suggest that NFs are not required for 
axogenesis and that individual NF proteins play distinct roles in filament assembly and in the 
radial growth of axons (Hirokawa & Takeda, 1998; Julien, 1999). 
1.2.1 Structure 
Each of the three triplet proteins conforms to the standard structure of the IFs in that they have 
three structural domains consisting of an amino-terminal region, an a-helical central rod or 
core domain and a carboxy-terminal region ie a head-rod-tail organisation (Figure 1.1). The 
amino-terminal of each of the NF triplet subunits is similar to that of the other neuronal IFs. 
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Figure 1.1 
Diagramatic representation of the amino acid sequences of the three NF triplet subunits. The 
vertical lines within coil 2 indicate areas where the heptad pattern is broken due to the insertion 
of an extra amino acid. The blue areas correspond to areas in which the sequences are 
particularly rich in glutarnic acid whilst the green segments represent areas in which the 
sequence contain variable numbers of lysine-serine-proline repeats, KSP regions. At the end 
of NF-M is a domain with a high concentration of lysine and glutamic acid, KE region, this 
area is represented by the yellow bar. The carboxyterrninus of NF-H (red box) is rich in 
lysine, glutamic acid, as in NF-M, and also proline. Modified from Shaw, 1991. 
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This domain is comprised predominantly of B-sheet and B-turn structures, consists of 60-100 
amino acids and is particularly rich in serine, glycine, alanine and arginine and contains several 
proline residues. Arginine is notably abundant in this region, predicting that the domain as a 
whole would have a basic pH. There is only minor homology between amino-head sequences 
of the NFs. The central core domain is relatively highly conserved (45-60% sequence 
homology) between the three NF triplet polypeptides and with other IF proteins. It is 
approximately 37 kDa in size, consists of 310-330 amino acids, and has an a-helical coiled-
coil secondary structure. The central domain consists of long amino acid sequences exhibiting 
a heptad repeat of hydrophobic amino acids. In NF-L there are major breaks at two regions 
within the core. The two breaks or linkers, which contain proline residues, split the core into 
three regions, coil la, lb and 2. NF-M and NF-H are unusual in that the break in the heptad 
repeat at coil la doesn't occur, so that these proteins have a single unbroken coil 1 (Lee et al., 
1988a). 
In contrast to the other IF subunits known, which consist of subunits with molecular weights 
around 50 kDa, the NF triplets are relatively large. The greater mass of NF-H and NF-M, in 
particular, is due to long extensions of sequence on the carboxy-terminal side of the conserved 
core domain (Lasek et al., 1985). The length of this carboxy-terminal tail domain is also 
responsible for much of the biochemical variability that exists between the NF triplet subunits. 
On the basis of distinct types of amino acid sequence, the carboxy-terminal appears to be 
made up of four distinct subregions. The initial segment, which contains proline and is neutral 
or slightly basic, is consistent between the three subunits and is proposed to have a role in 
acting as a hinge for the carboxy-terminal domain so that it can extend away from the plane of 
the central domain (Shaw, 1991). The second region is variable in length and contains many 
charged residues such as g,lycine, alanine, lysine and, in particular, glutamic acid which may 
act to electrostatically repulse the structure away from the central domain. NF-L only contains 
these first two regions. The third region of the carboxy-terminal domain of NF-M and NF-H 
is characterised by variable numbers of the lysine-serine-proline repeat motif and is, therefore, 
13 
Chapter 1 
often termed the KSP region or segment. In mammalian NF-M, there are two distinct sets of 
KSP sequences which are separated by a further glutamic acid rich sequence. In NF-H, in rats 
for example, the number of KSP containing sequences may be more than 50 (Dautigny et al., 
1988). The size of this region is greater in NF-H than NF-M. The final region, at the extreme 
carboxy-terminus of NF-H is a region rich in lysine, glutamic acid and proline which is 
approximately 20 kDa in size (Lee et al., 1988a). Lack of sequence homology in this region 
between species suggests that the function of this region is not vitally important. In NF-M this 
final region is also rich in glutamic acid and lysine (KE), however, there is no proline present. 
In contrast to NF-H this region is highly conserved in sequence between species, however, 
similar motifs are not found in other proteins, therefore suggesting a NF specific function. 
1.2.2 Axonal transport and Assembly dynamics  
NFs are obligate heteropolymers requiring NF-L with either NF-M or NF-H for polymer 
formation (Lee et al., 1993). In vitro reassembly studies showed that purified NF-M and NF-
H proteins do not form IF structures alone (Geisler & Weber, 1981; Liem & Hutchinson, 
1982; Hisanaga & Hirokawa, 1990b; Hirokawa, 1991). NF-L subunits were capable of 
forming filaments in vitro. Negative staining revealed that these filaments had a relatively 
smooth structure. Reassembly in the presence of all three subunits produced filaments with 
rough walls and sidearm projections (Liem & Hutchinson, 1982; Hisanaga & Hirokawa, 
1988,1989). More recent studies have shown that NF-L can associate with stoichiometric 
amounts of NF-M and NF-H, again supporting the idea that all three subunits are integral 
components of the NF structure (Cohlberg et al., 1995). 
Although NF-L forms the backbone of the complete NF polymer, NF-M and NF-H integrate 
in the peripheral dimer arrays, which leaves their tails/sidearms protruding up to 30 nm away 
from the filament backbone and enables them to associate with other NFs and MTs in the 
axoplasm. The 10 nm filament is constructed by two coiled - coil dimers of protein subunits 
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lining up in a staggered fashion to form an antiparallel tetramer. Eight tetramers pack together 
in a helical array to make a rope-like 10 nm filament. 
The co-ordinated expression of genes for NF-L and NF-M precedes that of NF-H (Carden et 
al., 1987). In developing immature axons, NFs contain only NF-L and NF-M subunits, but in 
mature axons they contain all three subunits. Whether NF-H can be incorporated into pre-
existing immature filaments as the axon matures, and whether NF-H subunits in the filaments 
of mature axons can undergo dynamic exchange with an unassembled pool of NF-H in 
certain neuronal compartments (such as the perikaryon) are yet to be determined definitively. 
Following their synthesis in the perikaryon, NFs are moved into and through axons via slow 
axonal transport at a rate which varies (depending on the group of neurons, the age of the 
animal, and the location along the nerve) between 0.25 and 3 mm/day (Hoffman et al., 1983; 
Nixon & Logvinenko, 1986). Initial investigation of transport of NFs, measuring only the 
peak of the transported component, concluded that all three NF subunits were transported 
together in a single wave, which led to the proposal that NFs moved as polymers containing all 
three subunits (Hoffman & Lasek, 1975; Black & Lasek 1980). More recent examination has 
revealed the presence of a second pool of essentially stationary NFs within axons. This lead to 
the conclusion by some that the system is more dynamic than first proposed and that subunit 
exchange can occur (Nixon & Logvinenko, 1986; Nixon et al., 1987, 1994a). Investigations 
utilising fluorescently tagged NF-L subunits demonstrating rapid exchange of subunits 
between filaments and biotin tagged NF-L showing incorporation along the full length of 
existing NFs have supported this proposal (Angelides et al., 1989; Okabe et al., 1993). Similar 
results were found with NF-H although exchange of this subunit occurred faster than with 
NF-L (Takeda et al., 1994). However, there is disagreement regarding the fraction of filaments 
in the slower unassembled pool, estimated by one group to be as much as one third of the total 
newly synthesised pool (Nixon & Logvivnenko, 1986) and by another to be a negligible 
amount (Lasek et al., 1992). A more recent analysis of NF movement reports that the slow rate 
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of axonal transport of NFs may the result of rapid movements interrupted by prolonged 
pauses (Wang et al., 2000). These results help to reconcile many previous apparently 
conflicting results (Brady, 2000). 
1.2.3 Phosphorylation 
The NF triplet subunits are among the most highly phosphorylated neuronal proteins known 
(Wible, et al., 1989). They are continually modified in a complex pattern after synthesis by 
kinases, phosphatases and proteases which are modulated differently at various levels along 
the axon (Sternberger & Sternberger, 1983; Nixon & Lewis, 1986; Lee et al., 1987; Nixon et 
al., 1987). NF phosphorylation typically occurs relatively late in postnatal brain development 
(Carden et al., 1987) and is likely to coincide with the final establishment of specific axonal 
pathways. Site specific phosphorylation or dephosphorylation within different polypeptide 
domains of each NF subunit is believed to play a key role in modifying NF size, morphology 
and dynamics, subunit polymerisation and exchange, axonal transport and interactions with 
other cytoskeletal proteins, especially in damage and disease states (Hisanaga & Hirokawa, 
1990a; Sihag & Nixon, 1991). 
For the NF subunits, major in vivo phosphorylation sites in the amino-terminal head domain 
have been identified within [Ser55 on NF-L and within a phosphopeptide starting at Ser44 on 
NF-M (Sihag & Nixon 1990, 1991)] or adjacent to [a phosphopeptide starting at 5er25 on 
NF-M (Sihag & Nixon, 1990)] the sequences essential for in vivo assembly. The phosphate 
on Ser55 of NF-L displays rapid turnover immediately following NF-L synthesis in neurons 
(Sihag & Nixon, 1991), suggesting that head domain phosphorylation may block premature 
assembly prior to transport in neurites. These sites are acted upon by kinases distinct from 
those associated with carboxy-terminal phosphorylation. The amino-terminal sites in vitro 
have been found to be targeted by second messenger dependent protein kinases including A 
kinase (Hisariaga et al., 1994) and the cyclic AMP dependent phospho-kinase, PK A 
(Dosemeci & Pant, 1992). 
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Addition of most phosphate groups to the tail region of the NF triplet subunits takes place 
after they enter the axon and it continues throughout their journey. Multiple isoforms of NF-
H and NF-M result from their differential phosphorylation at carboxy-terminal sites (Lee et 
al., 1987). Carden and colleagues (1987) predicted that phosphorylation induced extension of 
the carboxy-terminal domains of NF-H and NF-M away from the NF backbone would 
increase the distance between NFs thereby making effective space occupying structural 
supports in large calibre axons. However, Hisanga and Hirokawa (1989) found that removal 
of 90% of carboxy-terminal phosphates on NF-H subunit had no effect on the extended 
configuration of the side arm. The carboxy-terminal phosphorylated sites are preferred 
substrates for the second messenger independent kinase(s) associated with NFs eg cyclin 
dependent lcinase (Hisanaga et al., 1991). 
Both the level and phosphorylation state of NF-H have also been proposed to regulate the rate 
of NF transport. Phosphorylation of the NF-H tail domain occurs following the entry of the 
NFs into the axon and increases during transport (Nixon et al., 1987). The extent of 
phosphorylation of the KSP repeat domain also correlates with the slowing of the transport 
rate (Nixon et al., 1994b). A proposed mechanism to account for this slowing phenomena 
associated with phosphorylation of NF-H is that the phosphorylated tail domain of NF-H acts 
as a cross bridge between NFs (Hirokawa et al, 1984; Hisanaga & Hirokawa, 1988). 
The amino-terminal head region of both NF-L and NF-M isolated from rat spinal cord are 
also modified by glycosylation (Dong et al., 1993). Three of four identified sites lie in the 
amino-terminal head region, and all three are located within (Ser27 on NF-L and Thr48 on 
NF-M) or near (Thr21 on NF-L) the domain essential for in vivo NF assembly. Similar 
modifications are present in the NF-H head and tail although precise sites have not yet been 
identified (Dong et al., 1993). These results indicate that other post-translational 
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modifications, independent of phosphorylation, may also play important roles in NF assembly 
and function. 
1.3 	Cytoskeletal responses to injury 
Components of the cytoskeleton, particularly MTs and NFs, have been shown to undergo a 
series of alterations in response to neuronal damage. Many of these changes are thought to be 
preparative for an attempt at adaptive sprouting or regeneration. The changes that occur are 
dependent on the cellular compartment in which the cytoskeletal component is situated and 
also the type and severity of the injury. 
In the axon, mild injury resulted in focal NF misalignment, followed by organelle and NF 
accumulation with concomitant swelling, representing impaired axoplasmic transport (Pettus 
& Povlishock, 1996). In more severe trauma, however, NFs initially became compacted and 
lamination was maintained before misalignment and swelling occurred. From these studies it 
was concluded that NFs undergo a significant increase in packing density following injury 
which is likely to be due to the loss of carboxy-terminal domains from the NF-M and NF-H 
subunits (Pettus & Povlishock, 1996). It has been proposed that retrograde transport of these 
cleavage products (Schlaepfer, 1987) may act as feedback signals to the cell body where they 
may alter NF gene expression (Traub et al.,1985). Other more recent studies suggest that the 
NF compaction may be a result of dephosphorylation of the side-arms, not cleavage 
(Okonkwo et al., 1998). 
Various other phosphorylation associated changes have been noted in the NF response to 
injury. Interestingly the reactive axonal swellings, bulbs, that occur post-injury can be labelled 
with antibodies to dephosphorylated NFs. These epitopes are normally expressed only in the 
soma and dendrites (Meller et al., 1993a, 1993b, 1994; King et al., 1997). In contrast 
phosphorylation-dependent NF epitopes, normally localised to the axonal domain 
(Sternberger & Sternberger, 1983), appear in the cell bodies of acutely damaged CNS and 
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PNS neurons (Moss & Lewkowicz, 1983; Drager & Hofbauer, 1984; Goldstein et al., 1987; 
Rosenfeld et al., 1987; Shaw etal., 1988; Tetzlaff et al., 1988; Koliastos et al., 1989; Mansour 
et al., 1989; Klosen et al., 1990; Martin et al., 1990; Yamada & Hazama, 1993). In addition, 
accompanying injury, there is a generalised hypertrophy or accumulation of NFs within the 
cell bodies (Torvilc, 1976; Schlaepfer, 1987; Silveira et al., 1994). 
The terminals of physically injured neurons also exhibit NF associated changes. This cellular 
compartment, through the action of proteases such as calpthns, is normally devoid of NFs 
(Schlaepfer, 1987). However, following injury there is a tendency for NFs to accumulate 
within the terminals of injured axons (Gray & Hamlyn 1962; Guillery, 1965). Inhibition of 
protease activity has also been shown to lead to an accumulation of NFs within synaptic 
terminals (Roots, 1983). These results suggest that post-injury calpains localised to this distal 
region are ineffective ( Meller et al., 1993b). 
The changes that occur post-injury to the other major component of the cytoskeleton, MTs, 
are quite different to those exhibited by the NFs. Trauma sufficient to compromise axolemmal 
permeability is linked with a dissolution (Maxwell et al., 1997) or reduction in number (Meller 
et al., 1987) of MTs within damaged axons. Phosphorylated tau has also been localised to 
damaged central neurons (Kanayama et al., 1997). Due to the role of this protein in mediating 
interactions between elements of the growth cone cytoskeleton (Ditella et al., 1994) this 
accumulation is thought to be linked to preparation for a regenerative attempt by the injured 
cell. 
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1.4 	Pathological Hallmarks of AD 
The cytoskeletal alterations that occur within neurons post-injury exhibit a striking similarity 
to many of the changes that occur in AD, particularly in the early stages of the disease 
process. Furthermore, there is distinct link between aspects of the cytoskeleton, such as NFs 
and MTs, and the development of a number of hallmarks of AD. AD is characterised by the 
presence of extracellular deposits of insoluble B-amyloid protein as plaques, as well as 
intracellular cytoskeletal pathology, such as NFTs and DNs. The pathological mechanism 
linking these hallmark structures is yet to be defined, however, abnormal processing of both 
NFs and MTs have been implicated in playing a role in the development of both DNs and 
NFTs. 
1.4.1 Plaques 
The deposition of dense plaques of B-amyloid in the brain is an accepted pathological 
hallmark of AD, however, there is considerable diversity of opinion regarding the significance 
of plaque formation to the aetiology of the disease. Plaques are extracellular structures with 
complex molecular and cellular components. Their major constituent is B-amyloid, a peptide 
of 39-43 amino acids, 4 kDa, that is produced by proteolytic cleavage of the larger amyloid 
precursor protein (APP) by proteases referred to as B- and y- secretase (Glenner & Wong, 
1984; Masters et al., 1985). Cleavage of APP at the amino-terminus is thought to be by 13- 
secretase and at the carboxy-terminus by y -secretase (Haass et al., 1993a, 1993b). APP is a 
large membrane spanning glycoprotein expressed in a variety of cells (Selkoe et al., 1988). 
The physiological role of APP is unclear. It has been proposed to have roles in cell-cell or 
cell-matrix adhesion, trans-membrane signal transduction, growth factor-like activity for neural 
cells after secretion, neuronal development and protection against excitotoxicity (Breen et al., 
1991; Masliah et al., 1992; Narindrasorasalc et al., 1992; Arai et al., 1994). 
APP occurs in numerous different isoforms, which arise from alternative splicing of a single 
gene. The shortest of the major isoforms (695 amino acids) is expressed almost exclusively in 
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neurons, whereas the other two common forms (751 and 770 amino acids, respectively) are 
expressed in both neural and non-neural cells. Additional heterogeneity of the APP 
polypeptides arises from their post-translational modifications, including sulphation, 
phosphorylation and both N- and 0-linked glycosylation (Pahlsson et al., 1992, Tomita et al., 
1998). These modifications occur during the trafficking of the protein through the secretory 
pathway. APP is co-translationally translocated into the endoplasmic reticulum via its signal 
peptide and then matured during passage through the Golgi by acquiring sulphate, phosphate 
and sugar groups, following which a minor percentage of mature molecules is transported to 
the plasma membrane via secretory vesicles. At the cell surface the APP molecules have a 
diverse metabolic fate. 
Some APP molecules undergo proteolysis by an unidentified protease designated a-secretase, 
which cleaves between lysine 687 and leucine 688, releasing the large soluble ectodomain (a-
APP). The remaining 10 kDa fragment can also undergo cleavage by y-secretase to release a 
peptide known as p3 (Figure 1.2). Alternatively, initial cleavage of the APP molecule may 
occur after methionine 671, by B-secretase, resulting in the secretion of a truncated APP 
molecule, B-APP (Seubert et al., 1992). Finally, the remaining 12 kDa fragment may then 
undergo cleavage via y-secretase within the hydrophobic domain at either valine 711 or 
isoleucine 713 that release the 40- or 42- residue B-amyloid peptides respectively (Figure 1.2). 
Approximately 90% of secreted B-amyloid peptides are A131-40, a soluble form of the peptide 
whereas approx 10% of secreted 13-amyloid peptides are AB1-42 and A131-43. The latter two 
species are highly fibrillogenic, readily aggregated, and deposited early and selectively in 
amyloid plaques (Mann et al., 1995, 1997). Currently, the precise cellular origin of the B-
amyloid that forms plaques and the reason for its misprocessing and conversion to an 
insoluble state remains largely unknown. 
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Figure 1.2 
APP metabolism is illustrated in the above diagrams. The Non-Amyloidogenic Pathway 
illustrates the generation of p3 via the secretory pathway and the action of a- and y- secretase. 
The Amyloidogenic Pathway shows the steps by which full-length A131-42 is produced in the 
endosomal-lysomal pathway through the action of p- and y- secretase. Modified from 
Dickson, 199'7. 
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The substance 13-amyloid has a number of characteristic biophysical properties, including high 
content of cross B-pleated sheet and twisted fibrils 7.5 to 10 rim in diameter, at the 
ultrastructural level (Terry et al., 1964). Two major carboxy-terminal variants of B-amyloid, 
AB1-40 and AB1-42(43), ending at Va140 and A1a42 respectively, have been identified in 
amyloid deposits in AD brain (Kang et al., 1987; Roher et al., 1993b). The major form of B-
amyloid produced during normal physiological metabolism of most cells is AB1-40 (Haass et 
al.,1992). This is the most soluble of the peptides and is present in nanomolar concentrations 
in biological fluids (Seubert et al., 1992) including cerebrospinal fluid, plasma and urine. A 
shift to relatively greater production of AB1-42 is apparently associated with significant 
pathology. This shift has been detected in cells of subjects with early onset AD (Scheuner et 
al., 1996) and in genetically engineered cells containing genes not associated with direct 
mutations of APP (Citron et al., 1997), which suggests that changes in the ratio of AB1- 
42/AB1-40 may be of fundamental importance to AD pathogenesis (Citron et al., 1997). It was 
also shown that AB1-42 self aggregates into amyloid fibrils in vitro much faster than AB1-40, 
suggesting that the carboxy-terminal properties of B-amyloid determine its aggregation 
potential and are thus important factors underlying B-amyloidogenesis (Jarret et al., 1993). 
Immunocytochemical studies utilising antibodies directed to the various carboxy-terminal 
regions of B-amyloid, demonstrate that more diffuse plaques are positive with antibody AB1- 
42 than to AB1-40, while dense-core plaques were equally labelled with both antibodies 
(Iwatsubo et al., 1994; Fukomoto et al., 1996). Based on these results, it has been proposed 
that either diffuse plaques represent an earlier stage of amyloid deposition and additional 
proteolytic events occur in dense-core plaques, or initial deposits of Af31-42 serve as a nidus 
for the co-precipitation of the more soluble AB1-40. Further to this, when investigating the 
chronological relationship regarding deposition of 13-amyloid protein species A131-40 and 
AB1-42(43), in Downs syndrome brains using end-specific monoclonals that recognize both 
species, it was found that the B-amyloid species initially deposited in the brain as plaques is 
A131-42(43) and AB1-40 only appears a decade later (Iwatsubo et al., 1995). These 
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morphological observations were supported by protein analysis which revealed the most 
abundant peptide to be Af31-42 (Roher et al.,1993a), while similar analyses from brains with 
mostly diffuse amyloid revealed abundant AI317-42 (Gowing et al., 1994). 
Whether APP, from which the B-amyloid protein of neuritic plaques derives, is synthesised by 
neurons (Probst et al., 1991; Papolla et al., 1992), by other brain cells (Siman et al., 1989) or 
is derived from a systemic source (Selkoe, 1989) remains controversial. Recent studies, using 
rat hippocampal neurons and human NT2N neuronal cell lines show that B-amyloid appears 
to be produced in endosomes or late Golgi: the endoplasmic reticulum is a site for production 
of AB1-42 (Cook et al., 1997; Hartmann et al., 1997). Considerable evidence supports a model 
in which APP, internalised from the plasma membrane, is subject to B-secretase cleavage 
within the late Golgi or endocytic compartments. Subsequently, y-secretase cleavage of the 
residual approx 100 amino acid, membrane-bound fragment within the transmembrane 
domain leads to the formation and release of B-amyloid into the extracellular space (Koo et al., 
1996). 
A large array of other molecules have been found to interact with 13-amyloid both in vitro and 
in vivo. These include a- 1 -antichymotrypsin, albumin, apoE, apoJ, apoA-I, serum amyloid P, 
complement components, laminin, transglutaminase, heat-shock proteins, acetylcholinesterase, 
gangliosides and proteoglycans (Terry et al., 1994; Dickson, 1997). In addition B-amyloid 
fibrillar aggregates can also act as a nidus for the recruitment of astrocytes and microglia. 
The majority of plaques in AD can be classified into four morphological types: diffuse, 
primitive, classic and compact or dense-cored. These plaques differ not only in their 
morphology but also in their association with other cell types and pathological inclusions such 
as PHFs, and the region of the brain in which they are predominantly located. Two 
hypotheses have been proposed to explain the formation of these plaque types. Firstly, that 
one type of plaque is converted into another, ie that the four plaque types represent stages in 
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the life history of a single type of plaque (Ikeda et al., 1990). Secondly, that each plaque type 
evolves independently of the others and, therefore, unique factors are involved in their 
formation (Armstrong, 1998). The subset of B-amyloid plaques that are associated with 
reactive microglia and astrocytes and dystrophic neuritic processes (Terry et al., 1994; 
Dickson, 1997) are referred to as neuritic plaques. Neuritic plaques may occupy as much as 
10% of the volume of the cortex in patients with AD (Verano et al., 1990). Within these 
neuritic plaques there is pronounced loss of synapses and severe distortion of those that 
remain (Masliah et al.,1990, 1991a,1991b). 
The presence of plaques in the neocortex of apparently non-demented elderly persons is often 
accepted as part of normal aging (Arrigada et al., 1992b), therefore, making the determination 
of the pathological significance of such structures difficult. Other investigators suggest that 
because cerebral deposition of B-amyloid may be a key mechanism in the development of AD, 
the presence of B-amyloid containing plaques may represent presymptomatic or unrecognised 
early symptomatic AD (Morris et al., 1996, 1991; Price & Morris, 1999). Cases exhibiting 
this early pathology have been rated 0.5 on the Washington University Clinical Dementia 
Rating (CDR) scale (Berg, 1988), by which a CDR score of 0 indicates no cognitive 
impairment and a CDR score of 0.5, 1, 2 or 3 indicates questionable, mild, moderate, or severe 
dementia, respectively. The length of such a preclinical phase is likely to vary between 
individuals, and may be influenced by genetic susceptibility factors as well as environmental 
influences. 
1.4.2 Neurofibrillary tangles 
Profound cytoskeletal changes occur in neurons and their processes in AD. Accumulations of 
straight and paired helical filaments, in the cell bodies of neurons, predominantly perinuclear 
region, closely encircling the nucleus, results in the formation of another of the pathological 
hallmarks, the NFT. Similar filaments in neuronal cell processes are referred to as neuropil 
threads (Braak et al., 1986; Braak & Braalc, 1988). The filamentous NFT structure is highly 
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insoluble, therefore, another pathological correlate of AD is the presence of intracellular PHF 
accumulations and ghost or tombstone tangles in the extracellular space after nerve cell death 
has occurred. 
PHF are composed of filaments approximately 15 nm in diameter, and, when paired they have 
an average period of 160 nm and a maximum width of 24 rim (Kidd, 1964; Wisniewski et al., 
1976). Using initially immunocytochemical based investigations (Grundke-Iqbal et al., 1986a; 
Kosik et al., 1984) and later conclusively by protein chemical techniques (Wischik et al., 
1988; Lee et al., 1991) these abnormal fibrous structures have been shown to contain the 
microtubule associated protein, tau. In a normal neuron, tau promotes MT assembly and 
stabilisation. PHF-tau differs from normal adult tau by containing a higher proportion of 
isoforms encoded by transcripts with exon 3, having fewer isoforms and displaying a more 
acidic isoelectric charge (Ksiezak-Reding et al., 1990). In solution, normal tau lacks secondary 
structure or defined shape, however, it tends to associate into antiparallel dimers, and in this 
form may be prone to assembly into PHF (Wine et al., 1992). 
Tau isolated from soluble PHFs is extensively and abnormally phosphorylated compared to 
normal tau at both Ser/Thr-Pro and non-Ser/Thr-Pro sites (Grundke-Iqbal et al., 1986b; 
Morishima-Kawashima et al., 1995). Interestingly, many of the same sites are also 
phosphorylated in foetal tau (Goedert et al., 1993; Morishima-Kawashima et al., 1995). In 
1980, Jameson and collegues presented data suggesting that increasing the phosphorylation 
state of MAPs decreases their ability to promote MT assembly. Since this, subsequent studies 
have indicated that the phosphorylation of specific sites, rather than the overall extent of 
phosphorylation, is the important factor in modulating the ability of tau to bind MTs and 
promote microtubule assembly (Johnson et al., 1992; Drewes et al., 1995). Although the 
hyperphosphorylation of tau in both soluble and insoluble PlIFs is well documented, the 
relationship between abnormal phosphorylation of soluble cytosolic tau and the formation of 
insoluble PHFs is unclear at present. Other investigators have suggested that the majority of 
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PHF-tau may not be abnormally phosphorylated (Wischik et al., 1995), particularly in the 
early stages of neurofibrillary pathology (Bondareff et al., 1995) and that phosphorylation 
may in fact protect tau from aggregation (Schneider et al., 1999). 
The pathogenesis of AD has been shown to not only involve the abnormal 
hyperphosphorylation but also the glycosylation (the enzymatic covalent attachment of 
carbohydrates) of tau in PHFs. Unlike normal tau, the abnormally phosphorylated tau is 
glycosylated. The glycan(s) maintain the helically of PHFs, but does not have any apparent 
direct effect on the ability of tau to promote the assembly of MTs. Removal of glycans by 
enzymatic deglycosylation converts PHFs into bundles of straight filaments (Wang et al., 
1996). 
Immunological studies have shown localisation of variety of different proteins with the NFT 
structure. These include NF-M and NF-H subunits (Dahl et al., 1982; Perry et al., 1985; Cork 
et al., 1986; Haugh et al., 1986; Miller et al., 1986), tubulin (Schwab & McGeer, 1998) 
vimentin (Yen et al., 1983), MAP2 (Kosik et al., 1984), tau (Grundke-Iqbal et al., 1986a), B-
amyloid (Masters et al., 1985), lactotransferrin (Kawamata et al., 1993), amyloid-P component 
(Duong et al., 1989) and ubiquitin (Perry et al., 1987; Bancher et al., 1989, 1991). However, 
such studies suffer from the inherent inability to distinguish between molecules that form an 
integral part of the PHF and material that is associated with or adheres to the filamentous 
structures. This problem is compounded by the fact that some antibodies used to label NFs 
have been shown to cross-react with tau (Ksiezak-Reding et al., 1987; Nukina et al.,1987), 
thereby making it difficult to determine the extent to which this class of [Fs is incorporated 
into the NFT structure. 
Despite this controversy, abnormal phosphorylation of NF proteins has been proposed to be 
an important prerequisite for the formation of NFTs. Utilising antibodies that were developed 
against differentially phosphorylated NF proteins (Stemberger & Stemberger 1983; Cork et 
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al., 1986; Lichtenberg-Kraag et al.,1992) it has been shown that an abnormal accumulation of 
dephosphorylated NFs corresponds to a subcomponent of the early forms of NFTs. This 
labelling was shown to be distinct from parts of the structure labelled with either antibodies to 
tau or stained with thioflavine S (Vickers et al., 1992b, 1994b). Other groups have also shown 
that antibodies to NF proteins that do not cross-react with tau, label NFTs (Lee et al., 1988b; 
Zhang et al., 1989; Schmidt et al., 1990; Nakamura et al., 1997). Further to this, there is strong 
evidence that neurons containing the NF triplet protein, in association neocortices as well as 
medial temporal lobe structures, show a high degree of vulnerability to develop NFTs (Vickers 
et al., 1992b, 1994b) and degenerate (Morrison et al., 1987; Hof et al., 1990; Hof & Morrison, 
1990). The cortical neurons that contain this cytoskeletal protein are principally a subset of 
pyramidal neurons in layers II, ifi and V (Morrison et al., 1987; Campbell & Morrison, 1989; 
Hof et al., 1990; Hof & Morrison, 1990; Vickers & Costa, 1992; Hiscock et al., 1998) and 
connectivity studies in non-human primates have shown that they provide specific 
corticocortical projections (Campbell et al., 1991; Hof et al., 1995). Cortical neurons that lack 
the NF triplet, such as inhibitory interneurons immunolabelled for specific calcium-binding 
proteins, do not develop NFTs and show relatively lower susceptibility to degeneration in AD 
(Ferrer et al., 1991; Hof & Morrison 1991; Hof et al., 1991a, 1993; Fonseca & Soriano, 
1995; Sampson et al., 1997). Cumulatively, these results suggest a role for NFs in the 
formation of the NFT structure. 
It has been suggested that the density of NFTs may be a better correlate of dementia severity 
than the density of plaques (Arriagada et al., 1992a; Bierer et al., 1995; Berg et al., 1998). 
Further to this, data accumulated by Thal and collegues (1998) show that neuronal 
cytoskeletal alterations progressively increase with advancing dementia until the end stage of 
AD in contrast to the frequencies of plaques and cortical microglial cells, and are, therefore, 
preferable for staging. Many of the cytoskeletal alterations occurring in NFTs have also been 
identified in the abnormal neuritic processes or DNs associated with plaques. Because NFT, 
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DNs and neuropil threads contain these similar filamentous constituents, it is likely that the 
genesis of these inclusions is the result of common mechanisms. 
1.4.3 Dystrophic Neurites 
A widely recognised pathological phenomenon in AD research is the association between 
degenerating cell processes, or DNs, and the B-amyloid plaque (Hof & Morrison, 1994). The 
precise neuronal alterations that lead to DN formation are unknown, and it is not clear as to 
whether they represent abnormally sprouting dendrites or axons or some combination of both. 
Currently the balance of evidence suggest that they represent altered, probably abnormally 
sprouting axons (Masliah et al., 1993a; Praprotnik et al., 1996; Vickers et al., 1996). 
Although DNs occur independently in the aged brain, in sites such as dorsal column nuclei in 
the lower medulla, the pars reticularis of the substantia nigra, the ventral pallidum, the cortex of 
the limbic lobe and the amygdala, they are concentrated in the vicinity of B-amyloid plaques. 
Dystrophic type neurites are found not only in neuritic plaques in AD, but also in aged 
humans and other mammals (Tekirian et al., 1996) and in plaque-bearing APP transgenic mice 
(Masliah et al., 1996a), however, PHF-tau immunoreactive neurites are specific to humans and 
highly characteristic of AD (Dickson et al.,1988). 
The heterogeneous nature of the epitopes expressed in DNs and the variable morphology of 
these abnormal structures has been noted by a number of investigators. The differential 
expression of these types of DNs throughout the course of AD is of particular interest as it 
provides clues as to the pathogenic mechanisms that may be involved in the development of 
this pathological structure. Reports have indicated that DNs may be distinguished by either 
tau- or NF- abundant forms (Dickson et al., 1988; Masliah et al.,1993b; Vickers et al.,1994b; 
Su et al., 1996). Similarly, some synaptic markers, and the APP are present in DNs that lack 
either NFs or tau (Yasuhara et al., 1994; Wang & Munoz, 1995; Saunders et al., 1998). 
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Recent investigations have shown that the occurrence of PHF-tau immunoreactive DNs as 
well as neuritic plaques are highly correlated with the severity of dementia in AD (Dickson et 
al., 1995; Cummings et al., 1996b). NF-triplet proteins have also been demonstrated in DNs 
(Dickson et al., 1988; Arai et al., 1990; Cras et al., 1991; Schmidt et al, 1991; Masliah et al., 
1993b; Schmidt et al., 1994; Vickers et al., 1994b; Su et al., 1996, Nakamura et al., 1997; Su et 
al., 1998). Further to this, it has been shown in AD cases that NFs are present in a subset of 
plaque-associated abnormal neurites that are largely distinct from those that are labelled with 
tau antibodies and stained with thioflavine S (Dickson et al., 1988; Masliah et al., 1993b; 
Vickers et al., 1994b; Su et al., 1996, 1998; Nakamura et al., 1997). Studies have concluded 
that early DN forms are associated with profound neurofilamentous changes in the absence of 
tau abnormalities (Vickers et al., 1996). Others have indicated that significant tau pathology is 
a relatively late event in DN formation (Benzing et al., 1993; Su et al., 1996). 
Accumulation of APP in DNs associated with 13-amyloid plaques has been noted by a 
number of investigators (Perry et al., 1988; ; Ghiso et al., 1989; Ishii et al., 1989; Cras et al., 
1990; Shoji et al., 1990; Cole et al.,1991; Cras et al.,1991; Joachim et al., 1991; Martin et al., 
1994; Yasuhara et al., 1994; Wang & Munoz, 1995; Zhan et al., 1995; Saunders et al., 1998). 
Findings suggest that APP accumulations in plaque associated neurites occurs prior to tau 
accumulation and is therefore more closely related to the appearance of neuritic dystrophy 
(Ishi et al., 1989; Cummings et al., 1992; McGeer et al., 1992). 
The DNs in many neuritic plaques have also been observed to be labelled by anti-
synaptophysin or anti-chromagranin A (CgA) antibodies (Masliah et al., 1989; Brion et al., 
1991). It has been hypothesised by Brion and collegues that as synaptic vesicles, like other 
membranous organelles, move along MTs (fast neuroplasmic transport), their accumulation in 
abnormal plaque neurites might be indicative of axoplasmic flow disturbances in these 
neurites. Others have suggested, based on the localisation of such synaptic markers and 
growth associated proteins such as GAP43 to plaque associated DNs (Masliah et al., 1991b), 
30 
Chapter 1 
that abnormal neurites in plaques exhibit sprouting phenomena (Probst et al., 1983; Geddes et 
al., 1986). Antibodies to ubiquitin have also consistently been shown to detect DNs in AD 
cases (Perry et al., 1987). Current studies suggest that one of the major functions of ubiquitin 
is its involvement in protein degradation. Localisation of this protein to DNs has been 
suggested to indicate that the degradative pathway may be ineffective in removing these 
pathological structures in the AD brain (Perry et al., 1987). 
Central to the understanding of DNs is determining how the deposition of B-amyloid protein 
either leads to or is related to these lesions. While our knowledge of both B-amyloid protein, 
tau and the other components of neurofibrillary pathology has vastly expanded, the 
relationship between the pathological lesions of AD remains elusive. 
1.5 	Mechanisms of AD pathogenesis 
1.5.1 Amyloid cascade hypothesis 
A common viewpoint is that the central pathological event in AD is the deposition of B-
amyloid as amyloid fibrils within plaques and cerebral blood vessels (Selkoe, 1994). The 
finding of accumulations of B-amyloid in the cortex of non-demented individuals (Morris et 
al., 1991, 1996) in the absence of neurofibrillary changes has lead to the conclusion that 
depositions of amyloid precedes the development of other pathological changes. This 
assumption is the basis of the amyloid cascade hypothesis. 
There are a number of lines of evidence on which this hypothesis is based. Cerebral B-
amyloid deposition is an invariant feature of AD, and the form of B-amyloid deposit which is 
associated with the neuritic plaques is substantially more abundant in the brains of AD cases 
when compared to age matched control brains (Haass et al.,1992; Roher et al., 1993a; Gowing 
et al., 1994; Scheuner et al., 1996). In further support of the hypothesis is the finding that at 
least two genetically defined forms of AD appear to be caused by specific mutations in the 
APP gene, altered APP metabolism or expression and subsequent accelerated B-amyloid 
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deposition (Selkoe, 1994). Finally, it is claimed that other than B-amyloidosis, no compelling 
pathogenetic agent that can be said to be etiologic for AD has emerged. 
Amongst those investigators that support the amyloid-cascade hypothesis, there is a lack of 
consensus regarding the mechanism by which B-amyloid kills neurons. Some progress has 
been made in studying the toxic effects of B-amyloid in cell cultures which induces the 
generation of DNs (Pike et al., 1992). Proposed mechanisms include toxicity mediated by; 
induction of reactive oxygen species (Behl et al., 1994), activation of microglia (Meda et al., 
1995), its stimulation of tyrosine phosphorylation of focal adhesion kinase (Zhang et al., 
1994), inhibition of surface phosphorylation by protein kinase C (Hogan et al., 1995), 
inhibition of ubiquitin-dependent protein degradation (Gregori et al., 1995), induction of 
inflammatory responses (London et al., 1996) or enhancement (Arias et al., 1995) or 
inhibition of neurotransmitter release (Kar et al., 1996). Further controversy exists as some 
investigators suggest the mechanism of neuronal death exerted by the toxic B-amyloid is 
apoptotic whilst others propose a necrotic pathway (Suzuki, 1997; Gervais et al., 1999). 
A number of criticisms have been directed towards the in vitro models of amyloid toxicity. A 
primary concern is that the concentration of amyloid used in almost all of the in vitro 
neurotoxic studies has been between 1 and 100 pg/ml, which is as much as 10 000 times the 
concentration of total B-amyloid in the human CSF (Neve & Robakis, 1998). Further 
problems concern the specificity of the assays utilised. Most of the toxicity studies have 
utilised peptides that might behave differently from peptides generated in vivo. Interestingly, 
experiments in which neurons were grown on brain tissues from AD patients showed that 
neuronal survival was the same as that for controls (Carpenter et al., 1993). In addition, 
cortical and hippocampal neurons grew without inhibition on B-amyloid depositions formed 
from synthetic B-amyloid peptide. Finally, if B-amyloid exerts a widespread toxic effect, then a 
falling gradient of damage from plaque out into neuropil might be expected, but such a 
gradient has not been seen (Terry et al., 1991). Evidence of amyloid toxicity has not been 
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satisfactorily revealed in vivo despite frequent in vitro demonstrations. Consequently the 
mechanism by which B-amyloid exerts its effects in AD remains controversial. 
1.5.2 Cytoskeletal hypothesis 
In contrast to the amyloid hypothesis, others investigators believe B-amyloid deposition is 
incidental and does not correlate with disease progression (Arriagada et al., 1992a; Teny, 
1996). Furthermore, neuronal pathology such as NFTs, which are neuroanatomically localised 
to the areas of the brain affected by AD, are more likely to be the primary event of the disease 
leading to dementia (Arnold et al., 1991). 
The theory that neuritic dystrophy precedes B-amyloid deposition is, however, less popular. 
Evidence in favour of this hypothesis is that DNs can be seen in primates (Martin et al., 1994) 
and in young Downs Syndrome brains (Mattiace et al., 1991) before B-amyloid is detected. It 
is also clear that neuronal changes similar to those in neuritic plaques can be detected in the 
aged brain in certain locations completely independent of amyloid. These sites include the 
dorsal column nuclei in the lower medulla, the pars reticularis of the substantia nigra, the 
ventral pallidum, the cortex of the limbic lobe and in the amygdala (Dickson et al., 1990). 
As mutations of the APP gene are associated with fewer than one tenth of one percent of 
- 
Alzheimer patients, and all four of the AD related genes that have been identified interact by 
various means with the cytoskeleton, Terry (1996) proposed a mechanism by which 
alterations in the cytoskeleton are the pathological initiating factor in AD. He suggests that 
dementia is the result of an initial deficiency in polymerised MTs, due the formation of PHF- 
tau. This destabilisation of the cytoskeleton, particularly the microtubular system in the 
perikaryon causes breakdown of the Golgi apparatus into small fragments which will have an 
effect on processing and targeting of proteins and, thus, on the processing of APP. This 
abnormal processing may well lead to abnormal amounts of B-amyloid which is subsequently 
deposited in the extracellular space. The loss of MTs would have a major effect on axoplasmic 
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flow, resulting in diminished supply of substrate to the distant terminals in axons and 
dendrites and, therefore, the formation of dystrophic changes in the from of synaptic loss and 
degeneration, disconnection and finally dementia. 
Although there is considerable evidence supporting both the amyloid cascade hypothesis and 
alternative cytoskeletal based systems as mechanisms for AD, enough definitive evidence is 
yet to be presented for either case. AD is likely to be a multi-factorial disease which should be 
approached from many perspectives, however, lack of consensus regarding the proposed 
mechanisms suggests that important aspects of the disease remain elusive. 
1.6 	Risk factors for AD 
Although the pathological mechanisms linking the hallmarks of AI) is yet to be clearly 
defined a number of risk factors have been outlined. The two best investigated are increased 
age and a positive family history. 
1.6.1 Aging 
Age is the single most important risk factor for dementias of all kinds including AD. 
Approximately 95% of cases of AD occur in individuals >60 years of age (Katzman & 
Kawas, 1994). All studies conducted to date consistently indicate a steep increase in both 
prevalence and incidence of AD with age. The age-specific prevalence of AD is generally 
higher for women than for men, which implies that specific gender-related hormones may also 
have an effect on AD development (Katzman & Kawas, 1994). 
1.6.2 Genetic 
A significant proportion of AD cases are termed familial AD (FAD) due to their genetic 
aetiology. 'Causative' gene defects have been identified in three early onset (<60 year) FAD 
genes located on chromosome 1, 14 and 21. Chromosome 21 contains the gene for APP. Six 
different mutations have been identified in the APP gene of FAD cases, however, overall these 
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mutations are responsible for only a small proportion (2%) of all FAD cases published. The 
majority of early-onset FAD cases have been associated with mutations in two novel genes 
which have been termed presenilin 1 (PSI) on chromosome 14 and presenilin 2 (PS2) on 
chromosome 1 (Table 1). Early-onset FAD accounts for about 5-10% of all cases and is 
notable clinically for its highly aggressive nature with early age at onset (typically <60 yrs), 
shorter duration of survival, and more prominent myoclonus, seizures, and aphasia (Jacobs et 
al., 1994). In 1993 Allen Roses and colleagues identified Apo64, the allele encoding the 
protein ApoE4, as a 'susceptibility' gene for late-onset (>60 yrs) AD. 
-APP 
The APP gene encompasses approximately 400 kb of deoxyribonucleic acid (DNA), contains 
19 exons, and encodes several alternatively spliced APP mRNA. The localisation of this gene 
to chromosome 21 appeared to explain the observation that patients with trisomy 21 (Down's 
syndrome) incur 13-amyloid deposits and develop classical AD neuropathology at a relatively 
early age (eg 4th 5 th decade of life) (Mann et al., 1989; Iwatsubo et al., 1995). Close genetic 
examination of this gene in families with autosomal dominant AD resulted ultimately in the 
identification of six different missense mutations in APP, five associated with FAD (Chartier-
Harlin et al., 1991; Goate et al., 1991; Murrel et al., 1991; Hendricks et al., 1992; Mullan et al., 
1992) and one with the neuropathologically related syndrome of hereditary cerebral 
haemorrhage with amyloidosis of the Dutch type (Levy et al., 1990) (Figure 1.3). APP 
mutations in FAD families display a complete penetrance in that they cause dementia in every 
individual carrier. Mutations in the gene encoding APP have been shown to either cause an 
elevated production of total 13-amyloid (Citron et al., 1992; Cai et al., 1993; Citron et al., 1994) 
or an increase in the more fibrillogenic A131-42 (Suzuki et al., 1994; Tamaoka et al., 1994). 
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Figure 1.3 
Schematic diagram of the membrane spanning, multi-domain glycoprotein APP (isoform 770 
as indicated by the presence of both the Kunitz protease inhibitor domain (KPI) and the 
additional OX domain spliced into the extracellular region. The 13-amyloid peptide region (red 
box) contains part of the transmembrane domain and part of the extracellular domain of APP. 
The six missense mutations identified within the APP molecule, five associated with FAD and 
the sixth the related disease of hereditary cerebral haemorrhage with amyloidosis of the Dutch 
type, are indicated in blue. The proteolytic cleavage sites, and their associated enzymes, are 
represented by the vertical black arrows at the bottom of the diagram. Modified from Kwok, 
1998. 
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Table 1.1 
Familial AD mutations 
Chrom. 	Mutation 	Biochemical Cause 	Molecular effect 	Age of 
onset 
21 	APP6701671 (Swed) Potentiation of 
	
Increased AB1-42(43) 	50s 
B-secretase 	 and AB1-40 production 
APP692 (Flemish) 	Inhibition of 
	
Increased A13 1-42(43) 
a-secretase 	 production 
APP716 (Florida) 
	Alteration of y-secretase Increased AB1-42(43) 
cleavage site 	 production 
APP717 (London) 
	Alteration of y-secretase Increased AB 1-42(43) 
cleavage site 	 production 
14 	PSI mutations 	Alteration of APP 
	
Increased AB1-42(43) 	40s and 
processing 	 production 	 50s 
1 	PS2 mutations 	Alteration of APP 
	
Increased A131-42(43) 	50s 
processing 	 production 
19 	ApoE4 
	
Increased B-amyloid 
	
60s and 
polymorphism 	 plaque density 	older 
(Chartier-Harlin et al., 1991; Goate et al., 1991; Murrel et al., 1991; Mullan et al., 1992; 
Hendricks et al., 1992; Strittmatter et al., 1993a; Haas et al., 1994; Levy-Lahad et al., 1995; 
Rogaev et al., 1995; Sherrington et al., 1995) 
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The clinical and neuropathological characteristics of patients with FAD-related APP mutations 
share several features, including onset typically before 60 years of age (mean family onset 
between 43-55 years), autosomal-dominant inheritance fully penetrant by the early 60s, and 
clinical and pathological phenotypes indistinguishable from individuals with sporadic AD. 
Although APP mutations are virtually 100% penetrant, mutations in this gene are responsible 
for only a small proportion of all published cases of early onset FAD. 
-Presenilins 
The discoveries that the APP and ApoE genes were implicated in the early-onset and late-
onset forms of familial AD, respectively, left open the question of which genes could explain 
the large majority of early-onset AD cases. Linkage analysis, followed by positional cloning 
lead to the identification in 1995 of two highly homologous FAD genes, PS1 and PS2 located 
on chromosomes 14 and 1, respectively (Levy-Lahad et al., 1995; Rogaev et al., 1995; 
Sherrington et al., 1995). The PSI and PS2 genes encode predicted proteins of 463 and 448 
amino acids, respectively. These proteins are 67% identical and are ubiquitously expressed, 
however, their normal function is not yet known. Recently, however, it has been hypothesised 
that PS proteins regulate APP processing. This theory is supported by studies showing that 
the normal cleavage of APP is dependent upon the expression of PSI (De Strooper et al., 
1998, 1999). 
Both PSs are serpentine proteins with six to nine predicted transmembrane domains arranged 
as one large and several small hydrophilic loops (Figure 1.4). Although unknown, they could 
conceivably function as receptors, ion channels or pores, or intracellular membrane proteins 
with specific functions. In situ hybridisation experiments, have demonstrated that the 
expression patterns of PS1 and PS2 in the brain are extremely similar to each other and that 
messages for both are primarily detectable in neuronal populations. Immunochemical analyses 
indicate that PS1 and PS2 are similar in size and are localised to similar intracellular 
compartments (endoplasmic reticulum and golgi complex) (Kovacs et al., 1996). These 
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Figure 1.4 
Schematic diagram of the predicted structure of PS1. Immunocytochemical analysis has 
indicated that both the amino- and carboxy-tenninal ends of both the PS1 and PS2, as well as 
a portion of the large hydrophillic loop, projects into the cytosol of the cell. The pathogenic 
mutations in the PS1 gene are indicated by red circles. Regions of major clusters of missense 
mutations are located in transmembrane domain 2 and on the amino-terminal side of the 
normal proteolytic cleavage site. Modified from Kwok, 1998 
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findings are consistent with roles for both PS1 and PS2 in facilitating the processing and /or 
intracellular trafficking of proteins undergoing post-translational modification in the 
endoplasmic reticulum and Golgi complex. Recently it has been suggested that the PSs may 
traffic proteins such as APP and Notch to the appropriate cellular site where y-secretase acts 
(Hardy & Israel, 1999). 
At least 41 mutations in PS1 and two in PS2 have been identified in FAD kindred (Hardy, 
1997; Kwolc, 1998). With one exception, all of the PS1 and PS2 mutations are missense 
mutations that result in a single amino acid substitution. The age of onset of AD in families 
harbouring PS1 mutations is quite young, ranging from 29-56 years, whereas the age of onset 
in cases with PS2 mutations is somewhat older (40+ years). The vast majority of these 
mutations occur in or immediately adjacent to transmembrane domains. 
Tanzi and coworkers (1997) have shown that, in the case of PS2, the carboxy-terminal 
fragment is found in detergent insoluble fractions, suggesting a cytoskeletal association. This 
finding raises the possibility that PS cytoplasmic domains may interact with the cytoskeleton, 
which could influence, for example, vesicle trafficking and endoplasmic reticulum calcium 
regulation. In addition Busciglio and collegues (1997) described an association between the 
carboxy-terminal fragment of PS1 and NFTs, also indicating an interaction between the PS s 
and the cytoskeletal elements (possibly tau protein) in AD. 
There are, at present, three main hypotheses as to how mutations in the genes encoding the 
PSs contribute to AD pathology: 1) PS mutations result in altered APP processing and 
increased levels of 13-amyloid and/or the 1-42 form of 13-amyloid, 2) PS mutations promote 
apoptotic cell death pathways by enhancing levels of oxidative stress and 3) PS mutations 
cause aberrant subcellular calcium regulation which promotes excitotoxic and apoptotic 
cascades. These hypotheses are not mutually exclusive and may all prove to be more or less, 
correct. 
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Mutations in all three of the known pathogenic genes, the APP gene, PSI gene and the PS2 
gene have in common the fact that they alter APP processing such that an increased amount of 
A131-42(43) is produced (Citron et al., 1992; Cat et al., 1993; Citron et al., 1994; Suzuki et al., 
1994; Tamaoka et al., 1994; Scheuner et al., 1996; Citron et al., 1998; Mehta et al., 1998; De 
Jonghe et al., 1999). These data provide the strongest possible evidence that the amyloid 
cascade hypothesis for the etiology and pathogenesis of AD is fundamentally correct. With 
regard to prevalence rates, mutations in the APP and PS genes clearly do not account for all 
cases of early onset FAD. A subset of early onset FAD is still genetically unaccounted for by 
known defects in these genes (Cruts et al., 1998). Recently two other candidate AD genes, 
alpha-l-antichymotrypsin (Kamboh et al., 1995) and bleomycin hydrolase (Montoya et al., 
1998) have been reported to predispose to increased risk for AD perhaps by operating in 
conjunction with other mutations. The candidacy of both these genes as AD loci awaits further 
testing and confirmatory studies. 
-ApoE 
Apolipoproteins, in general, are lipid carrier molecules that serve a variety of functions 
throughout the body, including maintenance of the structure of lipoprotein particles and 
regulation of the metabolism of several different lipoproteins. Apolipoprotein E (ApoE), in 
particular, is unique among the apolipoproteins in that it has a special relevance to nervous 
tissue. The mature form of ApoE, present in human plasma and cerebrospinal fluid, is a single 
glycosylated 37 kDa polypeptide composed of 299 amino acids. ApoE mRNA is most 
abundant in the liver, followed by the adrenal glands and brain. 
There are three allelic variants of the ApoE gene (62, 63 and 64) located at chromosome 19, 
each encoding a different isoform of ApoE inherited in a co-dominant fashion at a single 
genetic locus. The ApoE3 isoform has a cysteine at position 112 and an arginine at position 
158; ApoE4 has arginine at both positions; and ApoE2 has cysteine at both positions. The 63 
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allele is most common in the general population, found in approximately 78% of people, 
whereas the e4 allele is found in approximately 15% and the 62 allele in approximately 7% 
(Mahley et al., 1988). Epidemiological studies found that 1) carriers of the 64 allele have an 
increased risk of developing AD in an allele dose-dependent manner (Corder et al., 1993), 2) 
the ApoE 64 genotype decreases the age of onset of the disease, and finally 3) the inheritance 
of the 64 allele correlates with increased deposition of B-amyloid in blood vessels and plaques 
and a greater density of neuritic plaques in the cerebral cortex (Rebeck et al., 1993; Schmecel 
et al., 1993; Corder et al., 1994). Further to this, it has also been demonstrated that inheritance 
of the 62 allele decreases the risk, and increases the age of onset, of AD (Corder et al., 1994). 
Although the ApoE genotype can indicate a degree of susceptibility, the s4 allele is 'neither 
necessary nor sufficient to cause disease'. This is illustrated by the large percentage 
(approximately 50%) of individuals who develop AD without having inherited the 64 allele 
and the observation that a number of very elderly individuals are cognitively and 
neuropathologically normal despite inheriting that gene (Rebeck et al.,1994; Blacker 1997). 
This susceptibility, however, can be further compounded by other AD risk factors including 
age and a history of head trauma (Mayeux et al., 1995). 
Several lines of evidence, independent of genetic associations, have implicated the actual 
protein ApoE in the pathology of AD. Immunohistochemical studies have shown that ApoE is 
localised to the pathological hallmarks of AD such as B-amyloid plaques (Wisniewski & 
Frangione, 1992; Kida et al., 1994; Gearing et al., 1995; Sheng et al., 1996) and NFTs 
(Benzing & Mufson, 1995; Han et al., 1994) and might promote B-amyloid induced 
fibrillogenesis and microglial activation (Wisniewski et al., 1993; Barger & Harmon, 1997). 
Various mechanisms have been proposed to account for these interactions and suggest means 
by which inheritance of the 64 allele increases the risk of AD development. 
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A number of mechanisms have been proposed by which the ApoE4 isoform may affect 
amyloid deposition. Both E3 and E4 isoforms were found to bind synthetic B-amyloid, 
forming a complex that resisted dissociation by boiling in SD S (Sodium Dodecyl Sulphate). 
An oxygen mediated complex was implicated because binding was increased in oxygenated 
buffer, reduced in nitrogen-purged buffer, and prevented by reduction with dithiothreitol or 2- 
mercaptoethanol (Strittmatter et al., 1993a, 1993b). Similarly, although B-amyloid can 
assemble into filaments spontaneously, addition of ApoE resulted in a ten to twenty fold 
increase in filament formation, as determined by light scattering and electron microscopy, with 
ApoE4 showing the highest catalytic activity (Ma et al., 1994). Based on these results, it has 
been hypothesised that ApoE4 acts as a 'pathological chaperone', that is, by binding to 3- 
amyloid, it increases amyloid deposition and thus increases the formation of plaques 
(Wisniewski & Frangione, 1992; Ma et al., 1994). This proposal is further supported by 
observations that inheritance of the e4 allele is associated with increased levels of B-amyloid 
plaque deposition along blood vessels and in the brain parenchyma (Rebeck et al., 1993; 
Schmechel et al., 1993; Corder et al., 1994; Olichney et al., 1996). 
Another proposed mechanism linking ApoE with 13-amyloid, suggests that 64 homozygotes 
have a reduced ability to suppress B-amyloid formation, therefore, greater deposition occurs 
(Evans et al., 1995). Finally, a third group have suggested that the ApoE4 isoform 'clears' 13- 
amyloid less effectively and by doing so enables amyloid deposition and plaque formation 
(Rebeck et al., 1993). This was concluded after it was found that plaques and reactive 
astrocytes were strongly immunoreactive for both ApoE and the low density lipoprotein 
receptor related protein (LRP). LRP is one of the specific lipoprotein receptors for ApoE. It 
was suggested that ApoE/B-amyloid complexes may be taken up by LRP expressed on 
activated astrocytes and on neurons, mediating clearance of B-amyloid from the neuropil. 
Despite variations in conclusions made from the specific data obtained, collectively these 
investigations suggest that the ApoE4 isoform is kinetically different to ApoE3 and ApoE2 
and, therefore, imply that ApoE with deficient functioning might play a role in plaque 
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formation and possibly neurodegeneration. Independent of this controversy regarding 
potential function of the molecule, it has been an important objective of many investigators to 
demonstrate or refute a link between13-amyloid and ApoE. 
In summary, four genes have been implicated to date in familial forms of AD: three that, when 
mutant, cause autosomal dominant forms of the disease (APP, PS1, and PS2) and one in 
which a naturally occurring polymorphism represents a major genetic risk factor for the 
development of the disease (ApoE). However, despite the genetic associations it should be 
remembered that the familial form of AD is relatively infrequent and the majority of AD cases 
(50-85%) are sporadic. 
1.6.3 Head Trauma 
Head injury, either a single episode leading to unconsciousness or hospitalisation, or repeated 
head injury, as in the case of boxers, is a risk factor for AD (Heyman et al., 1984; Mortimer et 
al., 1985; Graves et al., 1990; Mortimer et al., 1991; Katzman & Kawas, 1994). In addition, 
neuropathologic lesions, such as NFT, that occur following repetitive head injury, as 
experienced by boxers (Lampert & Hardman, 1984; Roberts et al., 1990; Tolcuda et al., 1991; 
Geddes et al., 1996, 1999) or by individuals demonstrating self-abuse behaviour involving 
head injury (Hof et al., 1991b), are similar to those in AD, raising the possibility of a common 
pathogenesis. It is also notable that head injury and ApoE genotype may act synergistically to 
increase risk for AD (Mayeux et al., 1995) and that poor clinical outcome from head trauma is 
associated with inheritance of 64 alleles (Jordan et al., 1997; Teasdale et al., 1997; Friedman et 
al., 1999). 
1.7 	Models of AD 
The lack of an adequate animal model has been a serious impediment to the understanding of 
AD and the development of therapeutic drugs. Traditionally models of aged animals, as a 
means of studying pathological age dependent lesions, have been utilised, as have in vitro 
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systems investigating the effects of B-amyloid on nerve cells. However, more recently, a 
number of transgenic animals have been developed to model aspects of AD pathology. 
1.7.1 Aging animals 
Perhaps the simplest of the animal models considered over past years are those which utilise 
aged animals to investigate the pathological lesions commonly associated with AD. Aged dogs 
(Wisniewslci et al., 1970; Cummings et al., 1993, 1996a), cats (Cummings et al., 1996c), bears 
(Tekirian et al., 1996) and primates (Wisniewski et al., 1973; Heilbroner & Kemper, 1990; 
Martin et al., 1994; Nakamura et al., 1995) have all been shown to have B-amyloid deposits. 
These deposits, in aged dogs and cats particularly, were found to exist purely of diffuse 13- 
amyloid and were not shown to develop into the neuritic pathology of AD as evidenced by 
silver staining or altered tau immunolabelling. Altered neurites were, however, found within 
plaques in aged dog brain ultrastructurally (Wisniewski et al., 1970). Considerable variation in 
susceptibility exists between different breeds of dogs, with the boxer breed being the most 
susceptible. In primates these species based differences are even more dramatic with Squirrel 
monkeys developing primarily vascular amyloid with age (Walker et al., 1990) as compared to 
Rhesus monkeys who develop not only diffuse amyloid deposits but also neuritic plaques 
with age, with little vascular amyloid (Walker et al., 1990). This cross-species variation within 
dogs and monkeys may reflect a similar heterogeneity within humans. 
None of the early investigations of aging animals, including primates, revealed NFT of the 
PHF-type that predominates in AD (Wisniewski et al., 1970, 1973). More recently tau 
positive NFT have been detected in aged bears (Tekirian et al., 1996), sheep (Nelson & Saper, 
pro simianprimates 
1995), goats (Braak et al., 1994) and —A 	t(Giannakopoulos et al., 1997) thereby 
increasing their usefulness as models of AD pathology. 
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1.7.2 Lesion models 
Various groups have sought to create animal models for the behavioural impairments found in 
AD by selectively inducing lesions in areas known to degenerate in the AD brain, with 
significant impact on known functions (Wisniewski et al., 1982; Dahl et al., 1980). These 
models, although effective for modelling Huntingtons disease (Davies & Roberts, 1988; 
Sanberg et al., 1989) and aspects of Parkinson's disease (Mendez & Finn, 1975), may have a 
number of major drawbacks for modelling AD. Neurodegeneration in AD is widespread and 
many neurotransmitter systems are involved, therefore, although the toxin based lesions offer 
the opportunity to study the consequences of particular cell loss, they do not address the 
fundamental causes of neurodegeneration in AD. Further to this, the lesions produced by 
cholicine or aluminium do not adequately reproduce authentic AD-like pathological inclusions 
(Dahl et al., 1980; Wisniewski et al., 1982). 
1.7.3 13-amyloid toxicity models 
In vitro culture models of AD, where large volumes of amyloid have been added directly to 
neurons resulting in cell death, have been claimed to model the proposed toxic effect of 13- • 
amyloid in AD (Pike et al., 1993). The toxicity induced in this model is dependent on both the 
volume and fibrillar state of the amyloid added, as smaller volumes, more closely resembling 
those present in the brain, and non-fibrillar forms of the protein have been found to have no 
effect. Models utilising the injection of 13-amyloid into the aged Rhesus monkey cortex have 
also been developed (Geula et al., 1998). In these investigations it was found that both the age 
and species of the animal, and the fibrillar state of the 13-amyloid injected, affected the 
pathological outcome. This may account for differing results in earlier 13-amyloid 
microinjection studies (Podlisny et al., 1993, Kowall et al., 1992). It was shown that 
microinjection of plaque-equivalent concentrations of fibrillar, but not soluble, 13-amyloid in 
the aged Rhesus monkey cerebral cortex results in profound neuronal loss, tau 
, phosphorylation and microglial proliferation (Geula, et al., 1998). 
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1.7.4 Transgenic models  
The identification of various genetic risk factors and familial mutations associated with AD 
have made it possible, with varying degrees of success, to construct transgenic mice 
expressing genetic factors which either promote or cause aspects of the disease. Models based 
on gene knockout techniques provide important insights into the function of specific genes in 
vivo whereas transgenic mice harbouring and over expressing mutant forms of the genes 
associated with AD in humans are a valid tool to model and study the pathophysiological role 
of those genes. Although transgenics based on the PSI and PS2 mutations and the ApoE E4 
allele risk factor have been developed, most transgenic studies have focussed on the APP 
gene. 
One of the first reported transgenic mice lines was designed to express the human 751 amino 
acid isoform of APP (hAPP751) under regulation by the neuron-specific enolase promoter 
(Quon et al., 1991). These mice showed deposits labelled by antibodies to 13-amyloid and 
sometimes stained by thioflavine S but not stained by Congo red. Elderly animals from this 
line demonstrated larger B-amyloid deposits and tau immunolabelled DNs (Higgins et al., 
1994, 1995). Similarly other early models, expressing the 104 amino acids of hAPP695 under 
the regulation of the dystrophin neural promoter (Kammesheidt et al., 1992) and the first 104 
carboxy-terminal amino acids of hAPP regulated by the NF-L promoter (Nalbantoglu et al., 
1997), also showed age dependent neuronal alterations ie deposits of 13-amyloid, degenerating 
axons and dendrites and loss of neurons. However, while these constructs lead to age-related 
neurodegeneration, it is yet to be shown whether the abnormal neuronal changes match 
authentic AD specific nerve cell pathology. 
At present there have been four groups which have developed transgenic mouse models that 
faithfully replicate the congophilic, amyloid fibril plaques of AD (Games et al., 1995; Hsiao et 
al., 1996; Sturchler-Pierrat et al., 1997; Moechars et al., 1999). Table 1.2 summarises the 
various pathological changes that were noted in these models in addition to B-amyloid 
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deposits. It is clear from the combined studies that aging, in addition to the overexpression of 
APP bearing known FAD mutations, is essential for the emergence of a specific feature of 
AD-like pathology, the B-amyloid plaque. The 13-amyloid plaques, of the transgenic models, 
have also been found to be associated with anbonormal neurites variably labelled for APP, 
synaptophysin, NFs and in two studies (Sturchler-Peirrat et al., 1997; Moechars et al., 1999), 
abnormal tau characteristics suggesting a pathological effect. However, there is no evidence of 
AD-specific PHFs within affected neurons, obvious neuron loss around plaques or NFTs. 
This pathological profile suggests that either APP misprocessing is not the central event in 
AD pathology (Terry, 1996) or that the pathology demonstrated by APP transgenic mice may 
model preclinical AD, which is characterised by the presence of B-amyloid plaques associated 
with NF immunopositive DN but not extensive neurofibrillary pathology or neuronal 
degneration (Morris et al., 1996; Price & Morris 1999; Vickers et al., 2000). Further aging, 
for several more years, may therefore be required before these models exhibit the full 
spectrum of Alzheimer's associated pathology. 
Recent reports indicate that immunisation of the young APP717 transgenics, developed by 
Games and collegues with 13-amyloid peptides essentially prevented plaque formation, neuritic 
dystrophy and astrogliosis and that treatment of older transgenic animals also markedly 
reduced the extent and progression of these AD like neuropathologies. This highlights the 
value of a model of the early stages of the disease and raises the possibility that immunisation 
with B-amyloid may be effective in preventing and treating AD (Schenk et al., 1999). Before 
such a conclusion can be made, however, experiments determining whether depletion of the 
amyloid plaques is accompanied by an improvement in the behavioural/neurophysiological 
impairments, and a reduction in nerve cell death must be performed (St. George-Hyslop & 
Westaway, 1999). 
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Table 1.2 
Transgenic lines demonstrating AD-like histopathology 
FAD construct 	AIS 	NFT 	PFIF 	Dystrophic Neurites 
plaques NF 	APP Tau 
hAPP717 
(Games et al., 1995) 
hAPP(Swed) 
(Hsiao et al., 1996) 
hAPP(Swed)+ hAPP717 	 ND 
(Sturchler-Pierrat et al., 1999) 
hAPP(Swed)/ hAPP717 	 ND 
(Moechars et al., 1999) 
ND — not determined 
Transgenic mice that overexpress FAD-linked mutations in human PS1 or PS2 have proven 
more valuable than those utilising 'knockout' technology with regards to providing further 
information associated with AD pathogenesis. These transgenic mice demonstrate increased 
levels of the AB1-42/43 peptide in the brain relative to transgenic expressing the human 
wildtype PS and non-transgenic animals but do not result in amyloid plaque development 
(Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Oyama et al., 1998; Qian et al., 
1998). However, crossing such animals with transgenic mice with the Swedish APP mutation 
leads to earlier B-amyloid deposition in the brain (Borchelt et al., 1997; Holcomb et al., 1998). 
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The reason for the degeneration of nerve cells, and the loss of specific synaptic connections, 
that underlies the emergence and progressive development of dementia in sufferers of AD 
remains elusive. Furthermore, although individually B-amyloid plaques, NFTs and DNs have 
been extensively investigated, the mechanism that links these hallmark structures also remains 
to be defined. Due to their proposed role in the the development of the earliest pathological 
changes in nerve cells, and also the correlation between a neurons content of this protein class 
and its subsequent vulnerability to neurofibrillary pathology and degeneration, a 
comprehensive understanding of the role of NFs in the AD process is crucial. This thesis will, 
therefore, seek to address three aims that are principally associated with the role of NFs in the 
development of plaque associated pathology and the mechanism underlying AD. 
Specific Aim 1 
To determine the neurochemical and morphological diversity of abnormal neurites 
associated with kamyloid plaque formation in the early and late stages of AD. 
Double labelling immunohistochemistry will be utilised to investigate neuritic plaques. A 
battery of mouse monoclonal and rabbit polyclonal antibodies directed to cytoskeletal and 
synaptic markers, will be used to establish the sequence of changes that occur within abnormal 
plaque associated neurites as AD progresses. Confocal microscopy will be used to perform 
detailed analysis of the morphology of B-amyloid plaques in both preclinical and end-stage 
AD and to investigate the interaction between tau and NFs within individual DNs. 
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Specific Aim 2 
To examine the relationship between ApoE immunolabelling and J3-amyloid deposition, 
neuritic plaques and NFTs using immunofluorescent double labelling techniques. 
Although the inheritance of certain ApoE alleles has been recognised as a genetic risk factor 
for AD, the role of ApoE in the pathology underlying this disease is unclear. Several reports 
have emphasised the association of ApoE with either B-amyloid plaque formation or the 
development of neurofibrillary pathology. Utilisation of multiple label immunohistochemical 
methods will enable the direct examination of the localisation of ApoE immunoreactivity 
relative to B-amyloid plaques, DNs and NFTs. Determination of the role of the ApoE protein 
in AD may be crucial for elucidating the sequence of pathological events that ultimately result 
in dementia. 
Specific Aim 3 
To develop an in vitro model that mimics the effects of kamyloid plaques on surounding 
neuronal processes. 
It has recently been proposed that the formation of B-amyloid plaques in the brain causes 
physical damage to surrounding axons, and that it is the chronic stimulation of the 
stereotypical reaction of neurons to physical damage that leads to the cytoskeletal alterations 
that underlie neurofibrillary pathology and neurodegeneration (King et al., 1997; Vickers, 
1997; King et al., 2000; Vickers et al., 2000). Therefore, newly developed cell culturing 
techniques will be utilised to investigate the stereotypy of neuronal cells to damage with a 
particular emphasis on the changes associated with NFs. 
In summary, this study will seek to further clarify the relationship between B-amyloid plaques 
and DNs, particularly with regard to determining the role of NFs within this relationship. 
Identification of the earliest pathological changes that occurs in AD is necessary for the 
development of effective therapeutic strategies aimed at preventing or slowing the ongoing 
neuronal changes that ultimately lead to cell death and dementia. 
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METHODS 
2.1 Tissue source and processing 
Human brain tissue was obtained from multiple sources as indicated in Table 2.1 and 2.2. 
Brains were either perfusion-fixed with 2% picric acid / 4% paraformaldehyde, or blocks of 
cerebral cortex were immersion-fixed in 4% paraformaldehyde. Throughout this thesis a 
total of fourteen confirmed AD cases were used (Table 2.2). This diagnosis was made 
according to the CERAD (Consortium to Establish a Register for Alzheimer's Disease) 
criteria (Mirra et al., 1991). In addition thirteen preclinical AD cases were also used (Table 
2.1). The preclinical cases were defined by the presence of widespread B-amyloid 
immunoreactive plaques in the neocortex, with the distinction that these plaques could not 
be defined as 'neuritic' based on thioflavine S staining or immunolabelling with PHF-tau or 
ubiquitin antibodies (Vickers et al., 1996; Saunders et al., 1998). Thus, these preclinical 
cases do not conform to CERAD criteria for diagnosis of clinical AD (Mirra et al., 1991). 
These preclinical cases also lacked neocortical NFTs. Cryopreserved blocks (30% sucrose 
solution) of the superior frontal gyms (SFG) from each of the cases were sectioned on a 
freezing microtome (Leica CM1325) at 40-50 Rm. No differences were observed in the 
immunolabelling profile for the various antibodies across varying post-mortem to fixation 
intervals (PMI) or different fixation protocols. 
52 
Chapter 2 
Table 2.1 
Summary of preclinical AD cases 
Age Sex PMI Cause of Fixation Source 
(y) (hrs) death details 
70 F 4.4 Cardiac failure 2 University of Tasmania, Hobart 
61 M 19 Heart disease 2 University of Sydney, Sydney 
62 M 24 Cardiac failure 2 University of Sydney, Sydney 
71 M 32.5 Cardiac arrest 2 University of Sydney, Sydney 
59 F 6 Cardiac failure 1 NH&MRC Brain Bank, Adelaide 
80 M 20 COAD 1 NH&MRC Brain Bank, Adelaide 
78 F 18 Cardiac failure 1 NH&MRC Brain Bank, Adelaide 
86 F 25 Pneumonia 1 NH&MRC Brain Bank, Adelaide 
90 M 2.16 Resp. failure 2 Sun Health Research Institute, USA 
81 F 3 Cardiac arrest 2 Sun Health Research Institute, USA 
84 M 3 Cardiac arrest 2 Sun Health Research Institute, USA 
78 M 2.25 Pneumonia 2 Sun Health Research Institute, USA 
91 M 3 Cardiac failure 2 Sun Health Research Institute, USA 
1. Perfusion-fixed with 2% picric acid/ 4% paraformaldehyde 
2. Blocks of cerebral cortex, immersion-fixed in 4% paraformaldehyde 
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Table 2.2 
Summary of AD cases 
Age Sex PMI Cause of Fixation Source 
(y) (hrs) death details 
65 M 3 AD 1 NH&MRC Brain Bank, Adelaide 
71 F 13 AD 1 NH&MRC Brain Bank, Adelaide 
73 M 6.5 AD 1 NH&MRC Brain Bank, Adelaide 
72 F 4 AD 2 Sun Health Research Institute, USA 
66 M 2.8 AD 2 Sun Health Research Institute, USA 
84 F 3 AD 2 Sun Health Research Institute, USA 
76 M 3.5 Heart Failure 2 Sun Health Research Institute, USA 
83 M 3.5 Leukaemia 2 Sun Health Research Institute, USA 
86 F 4 Cancer, AD 2 Sun Health Research Institute, USA 
88 M 7 Failure to thrive 2 Sun Health Research Institute, USA 
92 F 2.25 Pneumonia 2 Sun Health Research Institute, USA 
74 F 2 Pneumonia 2 Sun Health Research Institute, USA 
74 M 2.75 Resp. failure 2 Sun Health Research Institute, USA 
83 M 2.83 Dementia, AD 2 Sun Health Research Institute, USA 
1. Perfusion-fixed with 2% picric acid/ 4% paraformaldehyde 
2. Blocks of cerebral cortex, immersion-fixed in 4% paraformaldehyde 
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2.2 Immunohistochemistry 
Immunohistochemistry, particularly the indirect fluorescent method, is utilised throughout 
this thesis for the visualisation and localisation of a variety of proteins associated with AD 
and the neuronal response to injury. The indirect immunohistochemical method principally 
has two steps. The initial stage involves the incubation of a tissue preparation or cell 
monolayer with a 'primary' antibody, typically an immunoglobulin of the gamma type 
(IgG), that binds specifically to an antigenic site. Tables 2.3 and 2.4 show the range of 
primary antibodies utilised throughout the following investigations. The preparation is then 
incubated with a 'secondary' antibody that specifically binds to IgGs of the primary 
antibody host species (Table 2.5). For the fluorescent method, this second antibody is 
conjugated to a fluorophore that emits fluorescent light when exposed to a particular 
wavelength of light. Some secondary antibodies are conjugated to the vitamin biotin which 
will, in turn, bind, to an avidin (egg-white glycoprotein)- fluorophore complex. This 
fluorescent method was utilised to allow for colocalisation studies. The specific primary 
and secondary antibodies utilised in the individual inviestigations are given in the following 
chapters. 
Prior to antibody incubation, tissue sections and fixed cell monolayers were washed for 
three, ten minute intervals in a solution of isotonic phosphate buffered saline, 0.01 M PBS. 
Tissue sections and cell monolayers were then incubated with primary antibodies on a slow 
rotating shaker platform for two to three hours at room temperature and then for a further 
twelve to eighteen hours (overnight) at 4°C. Primary antibodies were diluted in a diluent 
solution of 0.01 M PBS containing 0.3% Triton X-100 (Sigma). After incubation with the 
primary antibodies preparations were washed three times over 30 minutes in PBS before 
incubating for approximately two hours in the, biotinylated or fluorophore-conjugated, 
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Table 2.3 
Immunohistochemical markers — mouse monoclonal primary antibodies 
Code 	 Reactivity 	 Dilution 	 Source 
SMI32 	dephosphorylated NF-M & NF-H 	1:1000 Sternberger Monoclonals Inc. 
SMI312 	phosphorylated NF-M & NF-H* 	1:1000 Sternberger Monoclonals Inc. 
SMI310 	phosphorylated NF-H 	 1:2000 Sternberger Monoclonals Inc. 
RT97 	phosphorylated NF-M & NF-H 	1:500 Boehringer Mannheim 
B-amyloid 	13-amyloid 	 1:500 	DAKO 
ApoE 	apolipoprotein E 	 1:500 	Boehringer Mannheim 
GFAP 	glial fibrillary acidic protein 	1:2000 DAKO 
Ferritin 	human ferritin 	 1:5000 ICN Biomendicals Inc. 
GAP43 	growth associated protein 43 	1:1000 Boehringer Mannheim 
MAP2 	microtubule associated protein 2 	1:1000 Boehringer Mannheim 
*cocktail of mouse monoclonal antibodies 
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Table 2.4 
Immunohistochemical markers — rabbit polyclonal primary antibodies 
Code 	 Reactivity 	 Dilution 	Source 
R-NFH 	 minimally dephosphorylated NF-H 	1:500 	Serotec 
R-NFM 	 phosphorylation independant NF-M 	1:500 	Serotec 
Tau 	 4R tau 	 1:2000 	DAKO 
CgA 	 large synaptic vesicles 	 1:500 	DAKO 
13-amyl oi d 	B-amyloid 1-42(43) 	 1:500 	Zymed 
B-amyloid (pan) 	all B-amyloid peptides 	 1:500 	QCB 
ApoE 	 apolipoprotein E 
	 1:2000 	DAKO 
Ubiquitin 	ubiquitinated filaments 
	 1:100 	DAKO 
Calretinin 	calretinin 
	 1:2000 	Swant 
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Table 2.5 
Secondary antibodies 
Lot Reactivity Raised in Conjugate Dilution Source 
F1206 Mouse IgG Horse FITC 1:200 Vector 
J0311 Rabbit IgG Goat Biotin 1:200 Vector*I 
H0118 Mouse IgG Goat Biotin 1:200 Vector*I 
036(101) Mouse IgG Goat HRP 1:2000 DAKO 1 
115(302) Rabbit IgG Goat HRP 1:2000 DAKO 1 
FITC - fluorescien isothiocyanate 
* visualised with streptavidin Texas Red (Amersham 1:200) (fluorescence) 
t visualised with the chromogen, 3, 3' diaminobenzidine (DAB) (Sigma) (peroxidase) 
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secondary antibodies diluted in the same diluent solution at room temperature on the shaker 
platform. Any incubations with conjugated fluorophores were performed in the dark to 
preserve the intensity of labelling. This incubation was again followed by a series of three, 
ten minute washes in PBS. If a biotinylated second antibody was used, the tissue was 
further incubated in streptavidin Texas Red for two hours followed by three more PBS 
washes. Control preparations with the primary antibody omitted were processed in 
conjunction with all investgations. Tissue preparations were mounted on glass slides using 
`Permafluor' mounting medium (Immunotech). Labelled coverslips were similarly prepared 
by mounting face down on glass slides with Permafluor. 
For single labelling chromogen-based invesitgations, a similar protocol was used as that 
outlined above. Prior to primary antibody incubation, the endogenous peroxidase acitivity 
was abolished by placing sections in a mix of 3% hydrogen peroxide (Sigma) and absolute 
methanol (BDH Chemicals) 1:3 for fifteen minutes. The material was then incubated in the 
primary antibody diluted in the standard diluent solution for approximately twelve to 
eighteen hours. After washing, the material was incubated for approximately two hours 
with the appropriate biotinylated mouse-specific or rabbit-specific secondary antibodies 
(Table 2.5) diluted in the standard diluent solution. This incubation was again followed by 
a series of three, ten minute washes in PBS. Material was then incubated in an Avidin 
Biotin Complex / Horse Radish Peroxidase (HRP) amplification solution (DAKO) for one 
hour at room temperature on a shaker platform. Following washing in PBS labelling was 
visualised by exposure to a solution of the chromogen 3', 3 diaminobenzidine (DAB) 
(Sigmafast tablet kit, Sigma). When the correct labelling intensity was reached, the material 
was washed in a PBS solution to stop the precipitation reaction. Sections were mounted on 
glass chrome alum-gelatine subbed slides. Mounted sections were allowed to dry onto 
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subbed slides overnight before being rehydrated in MilliQ ® water for fifteen minutes. This 
was followed by dehydration through increasing concentrations of ethanol (three minutes in 
70%, 3 minutes in 95%, three minutes in 100% and a further five minutes in 100% 
ethanol). The slides were then cleared with two, five minute immersions in xylene before 
coverslipping using Eukitt (Carl Zeiss) mounting media. 
2.3 Immunoblots 
Samples of unfixed frozen pons from a non-demented control case and cortex from an AD 
case were homogenised in cold PBS using a hand held homogeniser (Jencons Scientific). 
Homogenised tissue was stored in aliquots at -20°C. Prior to separation, aliquots were 
diluted in Laemmli sample buffer (Bio-Rad Laboratories) 1:4 (wt / vol) with 5% B-
mercaptoethanol (Bio-Rad Laboratories), heat treated for five minutes at 95°C and then 
cooled on ice for five minutes. Twenty microlitres of this sample was separated on a 7.5% 
polyacrylamide gel using SDS-PAGE (polyacrylamide gel el ectrophoresis) (Mini-
PROTEAN° II system, Bio-Rad Laboratories). Broad range biotinylated molecular weight 
standards (Bio-Rad Laboratories) were also run on each gel to allow protein size 
determination. For protein separation, a voltage of 90V was applied at room temperature 
until completion. After separation, proteins were transferred to nitrocellulose sheets (Bio-
Rad Laboratories) using a Mini Trans-Blot® Electrophoretic transfer Cell (Bio-Rad 
Laboratories). For transfer, a voltage of 100V was applied for 70 minutes at 4°C. After 
rinsing in Tris Buffered Saline with Tween (TTBS), membranes were saturated with a 
blocking solution of 5% skimmed milk in TTBS for one hour. Again after rinsing in TTBS, 
membranes were cut into strips and each strip incubated overnight with primary antibody 
diluted in blocking solution. After the primary antibody incubation the strips were washed 
in TTBS and incubated with the appropriate HRP conjugated mouse-specific or rabbit- 
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specific secondary antibodies (Tables 2.3 and 2.4) diluted in blocking solution for two 
hours. Following secondary antibody incubation and a final series of washes in Tris 
Buffered Saline (TBS), the blots were treated a solution of the chromogen DAB (Sigmafast 
tablet kit, Sigma). After development the strips were washed briefly in MilliQe before using 
an Apple Colour One scanner to digitally record the result. 
2.4 Cortical cell culture 
Primary dissociated cortical cells were prepared using standard culture procedures (Banker 
& Goslin, 1991) in a media selective for neuronal cells, Neurobasal' (Gibco BRL, Life 
Technologies) (Brewer et al., 1993; Brewer, 1995, 1997). Pregnant Hooded Wistar rats 
(eighteen days gestation) were killed by carbon dioxide exposure. Embryos were rapidly 
removed using sterile techniques, and, after removal of skull and meninges, the neocortical 
hemispheres were dissected, and placed in 10 mM N-2-Hydroxethypiperazine-N'-2- 
ethanesulphonic acid (HEPES) buffer (BDH Chemicals) with 0.25% trypsin (BDH 
Chemicals) at 37°C for 20 minutes. After initial enzymatic digestion, dissociation was 
completed via trituration using pipettes of decreasing caliber. Prior to plating viability of 
the cell suspension was assessed using trypan-blue (Sigma, Cell Culture) dye exclusion. 
Cells were then plated at a density of 5.0 x 10 5 cells/cm2 on glass coverslips (Fisher 
Scientific) in an initial plating media, consisting of NeurobasalTM media (Gibco BRL, Life 
Technologies), 2% B27 supplement (Gibco BRL, Life Technologies), 10% foetal calf 
serum (FCS) (CSL Ltd) 0.5 mM L-glutamine (Gibco BRL, Life Technologies), 25 EIM 
glutamate (Gibco BRL, Life Technologies) and 3 ml/L gentamicin (David Bull 
Laboratories, Faulding). Coverslips had previously been acid treated (two hours in 69% 
nitric acid (BDH Chemicals) prior to extensive washes in MilliQ ® water) and preincubated 
overnight with poly-L-lysine (Sigma) (1 mg/ml in borate buffer, pH 7.4), rinsed and 
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covered with 2 ml of the initial plating media. Cultures were kept in an incubator (Imbros) 
at 37°C in a humidified atmosphere of 5% CO2 . After one day in vitro (DIV 1), the initial 
plating media was replaced with a 'subsequent', serum free, growth media containing 
NeurobasalTM, 2% B27 supplement, 0.5 mM L-glutamine and 3 ml/L gentamicin. This 
culture media was replenished every three days by removing one third of the volume of 
media and replacing with new 'subsequent' growth media. Before immunohistochemical 
labelling the cell monolayers were fixed in solution of 0.01 M PBS and 4% 
paraformaldehyde (BDH Chemicals). 
2.5 Image Analysis 
Fluorescence-labelled preparations were viewed with a Leitz Dialux 22EB epifluorescence 
microscope equipped with specific filter blocks for the selective visualisation of fluorescein 
isothiocyanate (FITC) and Texas Red / tetramethyl rhodamine isothiocyanate (TRITC). The 
maximum excitation wavelengths, at which the fluorophores are visualised, are 440 nm and 
660 nm respectively. The difference in these wavelengths enables the visualisation of both 
anti-mouse primary antibodies (FITC-conjugated) and anti-rabbit antibodies (Texas-Red 
conjugated) within the same speciman. By using different combinations of primary 
antibodies, and their respective secondary antibodies, the colocalisation of markers within 
various structures were examined. The third filter set, UV, of the Leitz Dialux microscope 
was utilised for the visualisation of thioflavine S labelled material. Images from this 
microscope were digitally captured using a CCD camera (Ikegami ICD-4CE, Tsushinki Co) 
attached to a Power PC Macintosh computer running the NTH Image Analysis program 
(version 1.61). Adobe Photoshop (version 4.0 and 5.5) was utilised to prepare figures from 
collected images. These figures were printed on an Epson Stylus Colour 800 printer. 
Alternatively, photos of the material immunolabelled with the indirect fluorescence method 
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were taken with a Wild Leitz camera attached to the Leitz Dialux microscope. Similarly, 
chromogen labelled material was also viewed on an Olympus microscope (BX50) fitted 
with a camera. Kodak TMAX black and white film was used in both cameras. Black and 
white film was developed using Kodak developer and fixer. Negatives were printed on 
Ilford multi-grade glossy photographic paper. 
2.6 Confocal Microscopy 
Confocal microscopy was performed using an Optiscan F900e krypton/argon scanning laser 
system attached to an Olympus microscope (BX60) and an Hewlett Packard Pentium II 
computer. The Optimate 5.2 image analysis program was utilised to execute detailed 
measurements and analysis of the captured image sets. Figures were prepared from 
collected images using Adobe Photoshop 5.5 and printed using an Epson Stylus colour 800 
printer. 
2.7 Electron Microscopy 
Cell monolayers to be examined using electron microscopy were fixed in solution of 0.01 
M PBS and 2.5% gluteraldehyde (Probing & Structure) for 30 minutes. After fixation 
monolayers were washed twice in PBS for five minutes. Cells were then fixed in a solution 
of 1% osmium tetroxide (ProSciTech) for 30 minutes, and washed twice in MilliQ® water 
for five minutes each. The coverslips were then stained and treated with a solution of 4% 
uranyl acetate (BDH Chemicals) for 30 minutes followed by five minute periods of 
dehydration in 30%, 50%, 70%, 95% and two changes of 100% alcohol. After two 
successive washes in propylene oxide (BDH Chemicals), each for five minutes, the cells 
were infiltrated with a mix of 50% propylene oxide/50% Procure 812 resin (ProSciTech) 
and then left for eighteen hours. This solution was then replaced with 100% Epon resin, left 
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for four hours and then replaced with a fresh solution of 100% epon before embedding. 
After embedding (specific details given in appropriate chapters) cells were sectioned using 
a Leica Reichert Ultracut S microtome. Semi-thin sections (0.5 pm) were intially collected, 
stained with toludene blue (Reactifs RAL) and examined. Areas of interest were confirmed 
and ultra-thin sections (70 nm) cut and mounted on Formvar (Probing & Structure) coated 
single-slot copper grids (Bio-Rad Laboratories). Additional staining with 5% uranyl acetate 
for 30 minutes in the dark was performed and then staining with Reynolds lead citrate 
(Ajax Chemicals) for ten minutes in an anhydrous atmosphere, completed the processing 
procedure. Material was then examined on a Philips EM410 electron microscope. Photos 
were taken on electron microscopy plate film (Kodak 4489). Black and white film was 
developed using Kodak developer and fixer. Negatives were printed on Ilford multi-grade 
glossy photographic paper. 
All solutions specific to the above procedures are given in Appendix A. 
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THE NEUROCHEMICAL AND MORPHOLOGICAL DIVERSITY OF 
PLAQUE ASSOCIATED DYSTROPHIC NEURITES IN THE EARLY AND LATE 
STAGES OF ALZHEIMER'S DISEASE 
3.1 	Introduction 
A subset of B-amyloid plaques in AD are associated with clusters of abnormal neuronal 
processes referred to as DNs. The presence of these neuritic plaques has been considered to 
be a pathological correlate of dementia in AD (Mirra et al., 1991). However, determining the 
mechanistic link between these two hallmark changes remains a fundamental issue in AD 
research and, therefore, provided the focus for this initial investigation. 
Recent published reports have indicated that not all DNs are comprised of the same 
neurochemical constituents. For example, while it is generally accepted that the neurofibrillary 
pathology of AD is comprised of the abnormal form of the tau protein, numerous reports have 
indicated that DNs may be distinguished by either tau or NF abundant forms (Dickson et al., 
1988; Masliah et al., 1993b; Vickers et al., 1994b; Su et al., 1996). Similarly, some synaptic 
markers, and even APP, are present in DNs that lack either NFs or tau (Yasuhara et al., 1994; 
Wang & Munoz, 1995; Saunders et al., 1998). Recently, investigation of the brains of 
individuals who may be in a preclinical stage of the disease, characterised by the presence of 
cortical B-amyloid plaques but the absence of neocortical NFTs and pronounced dementia 
(Morris et al., 1996; Vickers, 1997), have indicated that early DN forms are associated with 
profound neurofilamentous changes in the absence of tau abnormalities (Vickers et al., 1996). 
Other studies have also indicated that significant tau pathology is a relatively late event in DN 
formation (Benzing et al., 1993; Su et al., 1996). 
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The purpose of this initial study was to investigate cortical DN formation and the localisation 
of a wide range of implicated proteins, including cytoskeletal and synaptic markers, at both the 
early and late stages of the AD disease process. Both pathological staging (Braak & Braalc, 
1991) and clinicopathological (Morris et al., 1996) studies indicate that the early, or 
preclinical, stage of AD is characterised by minor cognitive impairment and the presence of B-
amyloid plaques, but not tau-immunoreactive neurofibrillary pathology, in neocortical areas. 
This investigation, therefore, has a particular focus on the specific complement of NF epitopes 
present in DNs in early and late AD. This data provides new information on the 
neurochemical diversity of plaque associated DNs and suggests a sequence relating to the 
precise cellular changes that ultimately result in neuronal degeneration and dementia. 
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3.2 	Experimental procedures 
3.2.1 Case details 
The samples used in the immunohistochemical investigations included six cases of confirmed 
AD (66, 72, 76, 83, 84 and 86 years of age) and 8 preclinical AD cases (59, 61, 62, 71, 78, 80 
and 86 years of age) (Tables 2.1 and 2.2 for source and fixation details). 
3.2.2 Immunoblots 
To confirm the reactivity of the NF antibodies and to investigate previously purported cross 
reactivity between tau and phosphorylation-dependent NF antibodies (Ksiezak-Reding et al., 
1987; Mirra et al., 1991), Western blots were prepared and labelled with the individual 
antibodies used in this investigation. Standard Western blot protocol was utilised as outline in 
Chapter 2.3 using the following primary antibodies; SMI312 (control- 1:2000, AD - 1:1000), 
SMI32 (control - 1:2000, AD - 1:200), RT97 (control and AD - 1:2), R-NFM (control - 
1:2000, AD - 1:500) and R-NFH (control - 1:2000 and AD 1:1000). To further characterise 
the phosphorylation state of the two rabbit polyclonal antibodies, R-NFH and R-NFM, and to 
confirm the commercially specified phosphorylation states of the mouse NF antibodies, prior 
to primary antibody incubation the nitrocellulose blots were pretreated with alkaline 
phosphatase (12.5 lig/m1) (Sigma) in TTBS overnight at 37°C. Control blots (TTBS only) 
were processed concurrently. 
3.2.3 Immunohistochemistry 
Basic immunohistochemistry protocol was utilised for all investigation as outlined in Chapter 
2, any changes or additions to this protocol are described below. The distribution and degree 
of colocalisation of cytoskeletal proteins (NF, tau) was determined using double labelling 
immunohistochemistry with a selection of the primary antibodies indicated in Tables 2.3 and 
2.4. Rabbit antibodies to NF-H, NF-M, and 4Rtau (four MT binding domains) were 
combined alternatively with mouse antibodies to modified (phosphorylated (SMI312 and 
RT97) and dephosphorylated (SMI32)) NFs in all cases. The relationship between 
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cytoskeletal protein labelling and B-amyloid, as well as the synaptic marker, chromogranin A 
(CgA), was also investigated in all cases using double labelling immunofluorescence. Sections 
in which B-amyloid was to be visualised were pre-treated in 90% formic acid prior to 
incubation in either primary antibody. For all fluorescence labelling, mouse monoclonal 
antibodies were visualised with a horse anti-mouse secondary antibody conjugated to FITC 
whereas the rabbit polyclonals were visualised with a goat anti-rabbit antibody conjugated to 
biotin followed by streptavidin Texas Red (Table 2.5). 
For quantitation of the coexistence of cytoskeleta1 epitopes in DNs, one hundred plaques were 
considered for each of the antibody combinations. However, in some preclinical AD cases, 
due to the presence of limited plaque pathology, the maximum number of clustered DNs 
present was considered (50-100) for determining the extent of colocalisation. 
68 
Chapter 3 
3.3 	Results 
3.3.1 Immunoblots 
Western blot analysis of the reactivity of the NF antibodies supported both the commercial 
claims and the immunohistochemical observations that were made throughout the 
investigation. Both normal brain (without a neurological disorder) and AD brain were used as 
the protein source (Figure 3.1). Labelling of bands by both SMI312 and RT97, at 
approximately 200 kDa and 160 kDa, decreased after pretreatment with alkaline phosphatase, 
thereby suggesting that these antibodies are directed to phosphorylated NF-H and NF-M 
epitopes. Results were similar for samples of AD cortex tested. SMI32 labelled 
dephosphorylated NF-M and NF-H as previously outlined (Lee et al., 1988a; Vickers et al., 
1994b). The R-NFM antibody was specific in its labelling of NF-M at approximately 160 
kDa. This labelling was unchanged in the alkaline phosphatase pretreated blots. The R-NFH 
antibody labelled a number of bands at approximately 200 kDa. Labelling decreased slightly 
in the alkaline phosphatase pretreated blot suggesting that some epitopes recognised by R-
NFH were phosphorylation specific. 
3.3.2 Preclinical Alzheimer's disease 
All of the NF antibody markers revealed clusters of abnormal neurites in the `preclinical' 
cases. Double labelling also demonstrated that all of the NF immunoreactive (with mouse 
antibodies) clusters of abnormal neurites were present within 13-amyloid plaques, but that not 
all plaques in these cases were associated with DNs (Figure 3.2). These DNs had either a 
bulb- or ring-like morphology. R-NFM and R-NFH labelled abnormal neurites showed high 
degrees of colocalisation with all three mouse NF antibodies, SMI32, SMI312 and RT97 
(Table 3.1, Figure 3.3). This pattern of labelling was consistent throughout all preclinical 
cases. 
69 
Figure 3.1 
Western blots of control brain (pons) and AD brain (cortex) homogenates confirming the 
reactivity of the neurofilament markers. Lanes 1-3 show reactivity of SMI312 with normal 
brain (lane 1), normal brain after alkaline phosphatase treatment (lane 2) and Alzheimer's 
disease brain (lane 3). SMI312 labelled a band at approximately 200 kDa corresponding to 
NF-H. This labelling was not present in the alkaline phosphatase treated blot. Similar 
results were obtained using RT97 (lanes 4-6). Two bands were labelled by RT97 in the 
normal (lane 4) and AD (lane 6) homogenates at approximately 160 kDa and 200 kDa. 
Again, this labelling diminished after alkaline phosphatase pretreatment (lane 5). SMI32 
labelled a single band in the normal AD sample at approximately 200 kDa (lane 7), 
however, after alkaline phosphatase treatment two bands were labelled at approximately 
200 and 160 kDa (lane 8). Lane 9 shows the labelling of a single band at approximately 160 
kDa by the R-NFM antibody, this labelling pattern did not change with alkaline 
phosphatase pretreatment (lane 10). The R-NFH antibody labelled a series of bands at 
approximately 200 kDa in the normal brain homogenate (lane 11). This decreased slightly 
after dephosphorylation of the protein by alkaline phosphatase (lane 12). 
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Figure 3.2 
Double labelling for B-amyloid (A,C) and NFs (B,D) in a 70 year-old preclinical AD case. 
Arrows indicate ring-like structures labelled with either SMI32 (B) or SMI312 (D), 
localised with the plaques. Similarly, arrowheads show bulb-like DNs within the clusters of 
abnormal neurites also labelled by each of the NF antibodies. 
Scale Bar = 20 pm (A,B,C and D) 

Figure 3.3 
Double labelling for NFs (A,B,C) and a marker for synaptic change (D) in the superior 
frontal gyms of preclinical AD cases. A and B show double labelling with SMI312 (A) and 
R-NFH(B) in layer II of a 70 year-old preclinical AD case. The two markers for NFs 
showed complete colocalisation with regards to labelling of the abnormal neurites within 
the cluster. Labelling with RT97(C) and CgA(D) in the same case, show a cluster of 
abnormal neurites in which some individual neurites are colocalised for both markers 
(arrow). 
Scale Bars = 20 [im (A and B) and 10 p.m (C and D) 
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Table 3.1 
Colocalisation between cytoskeletal markers in plaque associated dystrophic neurites 
Labelling Preclinical AD 	 Late AD 
(n = 4) 	 (n = 6) 
(mean % colocalisation ± SE) 
R-NFH with SMI32 72.67 ± 16.50 76.40 ± 20.82 
S1VII32 with R-NFH 83.67 ± 6.66 98.80 ± 1.30 
R-NFH with SMI312 98.75 ± 1.89 96.83 ± 5.38 
SIV1312 with R-NFH 95.25 ± 4.27 94.17 ± 7.49 
R-NFH with RT97 84.00 ± 10.68 90.80 ± 6.83 
RT97 with R-NFH 95.50± 1.29 24.20 ± 5.50 
R-NFM with S1VH32 82.67 ± 1.53 83.00 ± 4.64 
SMI32 with R-NFM 95.33 ± 4.16 97.60± 5.37 
R-NFM with S1V1312 95.25 ± 4.11 97.00 ± 5.06 
SMI312 with R-NFM 97.75 ± 1.26 96.17 ± 5.85 
R-NFM with RT97 68.75 ± 3.86 83.17 ± 12.62 
RT97 with R-NFM 99.25 ± 7.93 17.50 ± 8.31 
PHF-tau with S1V1132 5.00 ± 2.00 
SMI32 with PHF-tau 0.5 ± 1.00 
PHF-tau with SM1312 15.20± 1.30 
S1VI1312 with PHF-tau 17.00 ± 6.78 
PHF-tau with RT97 71.40 ± 6.47 
RT97 with PHF-tau 84.00 ± 5.74 
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In contrast, double labelling verified that no neuritic plaques, identified by labelling with 
mouse antibodies to NFs, contained neurites labelled with the rabbit antibody to tau. 
Furthermore, there were no singular or clustered neurites labelled with the tau antibody in any 
part of these sections. 
CgA labelling was found to be granular and punctate but plaque-like in general morphology. 
In addition, larger bulbar neurites were often present within these plaque-like structures. The 
CgA labelled structures were particularly concentrated in layers II, Ill, V and VI. Double 
labelling demonstrated that the larger, bulbar CgA labelled structures co-existed with the 
clustered NF labelled neurites. However, NF and CgA immunoreactivity were localised 
generally to different structures (Figure 3.3). Occasionally, CgA labelling formed a 'cap' 
around NF immunoreactive neurites. 
3.3.3 Alzheimer's disease 
NF immunolabelling of DNs in AD cases was predominantly bulb-like, with very few ring-
like structures observed (Figures 3.4-3.6). Conversely, most AD cases demonstrated ring-like 
NF labelled structures throughout the neuropil, independent of the localisation of B-amyloid. 
The clustered abnormal neurites showed a high degree of colocalisation between the rabbit (R-
NFM and R-NFH) and mouse (SMI32 and SMI312) NF antibodies, independent of the 
phosphorylation state of the epitope at which the antibody was directed (76-98% colocalised) 
(Table 3.1, Figure 3.4). There was, however, a distinct discrepancy between the colocalisation 
patterns of RT97 and the rabbit NF antibodies (Table 3.1). In these cases although the 
majority of R-NFM and R-NFH labelled clustered DNs were also labelled for RT97 (83% 
and 90% colocalised, respectively) a much smaller proportion of RT97 labelled DNs were 
colocalised with the two rabbit antibodies (17% and 24% respectively). RT97 immunopositive 
clusters of DNs that had no R-NFM or R-NFH labelled structures within them were also 
present (Figure 3.4). Those DNs colocalised for both RT97 and one of the rabbit antibodies 
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Figure 3.4 
Double labelling for RT97 (A) and R-NFM (B) in layer II of the superior frontal gyms of a 
71 year-old AD cases shows a cluster of DNs immunoreactive for RT97 but not for R-
NFM. Labelling in the same case with SMI32 (C) and R-NFM (D) shows complete 
colocalisation of the two NF antibodies within a large cluster of abnormal neurites. The 
arrow head indicates autofluorescent lipofuscin pigment visualised with microscope filters 
for FITC and Texas Red. 
Scale Bar = 201.1m (A,B,C and D) 
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were globular or spherical in morphology whereas the RT97 labelled neurites that were not 
colocalised with the other NF markers were angular and elongated. A low degree of RT97 
labelling was present in NFTs throughout the cortical layers. 
Tau immunoreactivity was also present in DNs with an angular and elongated morphology. In 
AD cases, tau immunoreactive DNs were in considerably more abundance than NF labelled 
DNs. In addition, for most NF and tau double labelling combinations, immunolabelling for 
these cytoskeletal markers was localised to different DNs (Table 3.1). However, RT97 did 
show a high degree of colocalisation with tau (71%). For all other antibody combinations, 
colocalisation to individual DNs took the form of a bulb-like NF labelled structures with a tau 
immunoreactive central, or core, region (Figure 3.5). 
The density of CgA immunopositive structures was considerably greater in AD cases than in 
preclinical cases, however, the general laminar distribution remained constant with the majority 
of labelling occurring in layers II, ifi, V and VI. Most bulb-like CgA immunoreactive 
structures were not immunoreactive for NFs. However, the larger globular CgA labelled 
structures were consistently colocalised with larger bulb-like NF immunopositive DNs 
(Figure 3.6). CgA labelling did not colocalise with the angular and elongated DNs 
immunoreactive for RT97. 
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Figure 3.5 
Double labelling of abnormal neurites in a 72 year-old AD case at two different focal 
planes throughout a cluster of DNs. A) shows a cluster of predominantly SMI312 
immunoreactive DNs (green). A small core of tau labelling (red) can be seen within one of 
the neurites, as indicated by the arrows. B) shows that deeper within the cluster the same 
tau core is more prominent (arrow) and an additional NF immunoreactive neurite can also 
be seen to have an extensive tau immunoreactive central element (open arrow). 
Scale Bar = 40 um (A and B). 

Figure 3.6 
Relationship between NF (RT97) immunoreactive DNs (A) and labelling for the synaptic 
marker CgA (B) in layer III of the neocortex of a 73 year old AD case. Some neurites show 
colocalisation for both markers (arrow), whereas other distinct RT97 immunopositive 
neurites are unlabelled for CgA (arrowhead). 
Scale Bar = 2011m (A and B) 
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3.4 	Discussion 
A common phenomena associated with both preclinical and end-stage AD cases was the 
association between 13-amyloid plaques and clusters of DNs. All clusters of abnormal neurites 
were found to be localised with B-amyloid deposits, however, not all deposits were associated 
with DNs. Detailed analysis of this relationship revealed a significant morphological and 
neurochemical diversity with respect to the clustered DNs (Table 3.2). In preclinical AD cases, 
DNs were characterised by the presence of either NF or CgA labelling, with these markers 
only occasionally colocalised to the same neurite. Interestingly, NFs were found within both 
bulb- and ring-like structures, whereas CgA labelled neurites were bulbar. AD cases were 
characterised by the appearance of angular and elongated DNs that were labelled with the 
antibody to tau. In these cases, NF labelling was found in bulb-like structures, but not in rings, 
within plaques, and a further subgroup of DNs showed mostly exclusive CgA labelling. In 
addition, some NF immunolabelled bulb-like structures had a tau immunoreactive core. Of 
note, NF labelled rings were present throughout the cortical grey matter in AD cases. 
Table 3.2 
Neurochemical diversity of dystrophic newites 
DN 	Dystrophic Neurite 	Dystrophic Neurite Preclin. 	AD 
Type Neurochemistry Morphology 	AD 
1 	NF only 	 bulb- and ring-like 	I 	./ 
2 	APP colocalised with CgA 	globular / bulb-like 	I 	i 
3 	NF colocalised with CgA 	globular / bulb-like 	I 	.1 
4 	NF with PHF-tau or thioflavine core globular / bulb-like 	 J 
5 	Tau and/or thioflavine-S 	 elongated / angular 	 I 
Summarised from current chapter and Dickson et al., 1988; Masliah et al., 1993b; Saunders et 
al., 1998; Su et al., 1996; Vickers et al., 1994b; Vickers et al., 1996; Wang & Munoz, 1995. 
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These diverse morphological and neurochemical changes associated with the neuritic reaction 
to plaques may indicate important features of DN development. This process is likely to take 
many years, from the initial preclinical phase of an accumulating insoluble B-amyloid burden 
to the clinical stage characterised by the maturation of neurofibrillary pathology and eventual 
neuronal degeneration. These DNs showed a high degree of colocalisation of both 
phosphorylated and dephosphorylated NF epitopes. The presence of this mixture of epitopes 
is unusual as dephosphorylated epitopes are normally principally localised to the 
somatodendritic domain (Stemberger & Stemberger, 1983). These results show that 
phosphorylated and dephosphorylated NF epitopes can coexist in DNs, an observation that 
suggests a specific alteration in the processing of NFs. 
The presence of CgA labelled neurites within both AD and preclinical AD cases may 
represent a form of reactive sprouting and synaptogenesis. This sprouting reaction may 
require the absence of normal NF proteins (Tetzlaff & Bisby, 1989), explaining why CgA 
labelling forms a cap of reactivity over some NF labelled DNs, and why most CgA labelled 
DNs were not immunoreactive with NF antibodies. 
The data presented in this chapter indicates that the abnormalities in tau processing that 
contribute, for example, to the development of highly insoluble PHFs, may occur later in the 
disease process. These results extend previous findings (Masliah et al, 1993b; Vickers et al., 
1994b; Yasuhara et al., 1994) of the localisation of NF and tau immunolabelling to different 
subpopulations of DNs. However, the presence of NF labelled DNs with a core region of tau 
immunoreactivity strongly suggests that these abnormal neurites may mature through initially 
NF abundant forms to morphologically different DNs containing insoluble PHFs. A similar 
progression of molecular events have been proposed for NFT development (Vickers et al., 
1992b). This sequence of cytoskeletal alterations may be due to the close interrelationship of 
cytoskeletal proteins in nerve cells, including NFs with MTs (Letterier et al., 1982). Thus, the 
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abnormal processing or disruption of one cytoskeletal element may be expected to lead to 
changes in other cytoskeletal proteins. 
The absence of NF immunopositive rings in plaques in AD may be indicative of an earlier 
complete disintegration of severed distal axonal terminal segments. However, the presence of 
NF immunopositive rings throughout the grey matter in AD may result from the gradual 
anterograde degeneration of the whole axonal tree of affected neurons. Finally, RT97 was 
notable for its labelling of angular and elongated DNs in the AD cases. These DNs were also 
labelled for tau, indicating that the NF antibody may also be cross-reacting with specific PHF-
tau epitopes, as previously suggested (Ksiezak-Reding et al., 1987, Nukina et al., 1987). 
Whereas the stages of NFT formation and development have been widely investigated and 
acknowledged, similar detail regarding DN formation has not been established. The first 
experimental chapter of this thesis indicates that there are three subsets of DNs in AD, 
including predominantly NF, tau or synaptic forms. Investigation of the precise 
interrelationship between these DN subtypes using multiple labelling immunohistochemistry 
suggests that DNs may mature from NF-containing forms to the abnormal neurites containing 
profoundly altered cytoskeletal proteins such as tau. The synaptic markers may reveal a 
further subset of axons undergoing reactive synaptogenesis. These results confirm a role for 
NF in the development of the DNs associated with 13-amyloid plaques, further to this studies 
utilising preclinical AD cases suggest that an accumulation of NFs may represent one of the 
earliest pathological phenomena associated with the disease. 
Recent data has indicated that the same morphological and neurochemical heterogeneity, noted 
in the current investigation of plaque associated DNs, is present within axons undergoing a 
response to physical damage (King et al., 1997, 2000). Acute axonal injury in a rodent 
experimental model of brain trauma resulted in the formation of neurofilamentous bulb- and 
ring-like accumulations (Figure 3.7). Detailed immunohistochemical analysis revealed the 
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In this experimental model, a fine gauge needle is placed into the neocortex of anaesthetised 
adult rats (King et al., 1997). 
Figure 3.7 
NF immunolabelling of abnormal neuritic structures following physical damage in the 
rodent neocortex. Occasional bulb- (eg large arrow) and ring-like structures (eg arrowhead) 
labelled with R-NFH (A) are not labelled by SMI312 (B). The fine arrows in (B) indicate 
bulb- and ring- like strucutres labelled with SMI312 and also colocalised with R-NFH 
labelling (A). Ultrastructural analysis of the rat cortex post-injury revealed axons containing 
a number of multilamellar bodies and other degenerative structures, with a central core of 
NFs (C) (asterisk). Other investigators have described identical structures within DNs in 
AD (D) (Dickson, 1997). 
Scale Bar = 100 p.m (A and B) 
Magnification = 15800x (C and D) 
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same expression pattern of NF epitopes as that found in the preclinical and end-stage AD 
cases (Table 3.1 compared to Table 3.3) (King et al., 2000). Furthermore, ultrastructural 
analysis of the axons reacting to damage revealed changes such as abnormal mitochondria, 
multilamellated bodies and dense core vesicles that were identical to those observed in AD 
DNs (Terry et al., 1964; Masliah et al., 1993a; Dickson, 1997). Based on these similarities it 
has been proposed that 13-amyloid plaque deposition in AD may cause sufficient physical 
disruption to the surrounding neuropil to trigger the stereotypical reaction of nerve cells that 
follows physical injury, leading to abnormal axonal sprouting and associated cytoskeletal 
changes (King et al., 1997, 2000; Vickers, 1997). 
Table 3.3 
Colocalisation between NF epitopes in abnormal neuritc structures following physical damage 
to the rodent neocortex 
Labelling % Colocalisation 
R-NFH with SMI32 62.65 
S1V1132 with R-NFH 99.41 
R-NFH with SMI312 92.05 
S1V1312 with R-NFH 97.93 
R-NFH with RT97 82.70 
RT97 with R-NFH 99.20 
R-NFM with SMI32 71.20 
SMI32 with R-NFM 86.25 
R-NFM with S1VH312 90.65 
SMI312 with R-NFM 82.00 
R-NFM with RT97 75.50 
RT97 with R-NFM 91.95 
King et al., 2000 
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DETAILED ANALYSIS OF B-AMYLOID PLAQUE ASSOCIATED DYSTROPHIC 
NEURITES IN ALZHEIMER'S DISEASE USING CONFOCAL MICROSCOPY 
4.1 	Introduction 
Standard immunohistochemical methods and fluorescence microscopy were previously 
utilised to effectively analyse the exact complement of epitopes expressed within the 
clusters of abnormal neurites associated 13-amyloid plaques in AD. However, due to the 
limitations of the standard microscope, similarly detailed analyses of plaque and DN 
morphology and how these two pathological hallmarks of AD interact spatially could not be 
obtained. Therefore, in the present study confocal microscopy was utilised. This method of 
analysis allowed the optical sectioning of fluorescence-labelled tissue, even from relatively 
thick sections, thereby allowing the visualisation of complete plaques rather than isolated 
sections. Through the digital processing of this information it was possible to elaborate a 
three dimensional view of labelled elements and to examine in detail the abnormal changes 
in axons associated with 13-amyloid plaque formation and the effect of plaque development 
on surrounding processes. 
The heterogeneity of plaque morphology has been noted by a number of early investigators 
in the field of AD research (Wisniewski & Terry, 1973; Ulrich, 1985). This lead to the 
development of various different typing schemes that have been consistently modified and 
updated with the advent of more sensitive staining and immunolabelling methods. The form 
of microscopy utilised in individual investigations has also been recognised as an important 
contributor to the accurate description of plaque morphology. 
77 
Chapter 4 
Historically, the confocal microscope has been used to study a number of neurobiological 
phenomena. For example it has been used in conjunction with intracellular or membrane 
bound fluorescent dyes, to follow the growth and long-term changes of nerve terminals, and 
also with voltage and Ca' -sensitive indicator dyes to observe patterns of electrical activity 
(Reviewed by Fine et al., 1988). More recently it has been utilised in the field of AD 
research to investigate aspects of the pathological changes that occur. Masliah and 
collegues concluded, from their investigation of the alterations that occur in synapses and 
axons, that many of the tau abnormal neurites commonly localised with B-amyloid plaques 
were continuous with synaptophysin-positive distended terminals (Masliah et al., 1993a). 
Others have used confocal microscopy to investigate various aspects of senile plaque 
morphology in end-stage AD cases (Schmidt et al., 1995; Cruz et al., 1997) and also the 
relationship between senile plaques and astrocytes (Kato et al., 1998). In the current 
investigation confocal microscopy was utilised to accurately quantitate the various plaque 
morphological types in both preclinical and end-stage AD cases and furthermore investigate 
their association with clusters of DNs. 
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4.2 	Experimental procedures 
4.2.1 Case details  
The samples used in the current confocal microscopy investigations included five cases of 
confirmed AD (74, 74, 83, 88 and 92 years of age) and five preclinical AD cases (78, 81, 
84,90 and 91 years of age) (Table 2.1 for source and fixation details). 
4.2.2 Staining 
To investigate the morphology of B-amyloid plaques, 100 pm sections of SFG from the 
preclinical and end-stage AD cases (Table 2.1) were stained with thioflavine S (Sigma) for 
three minutes at room temperature, protected from the light. After staining, sections were 
differentiated in two, ten minute rinses of 50% ethanol and 50% 0.01 M PBS before final 
washes in 0.01 M PBS. 
4.2.3 Immunohistochemistry  
The basic double-labelling immunohistochemistry protocol was utilised as outlined in 
Chapter 2, any changes or additions to this protocol are described below. The relationship 
between NF immunoreactive DNs and 13-amyloid was investigated in all cases. Sections in 
which B-amyloid was to be visualised were pre-treated in 90% formic acid prior to 
incubation in either primary antibody. A rabbit-antibody which recognises all carboxy-
terminal variants of B-amyloid (A131-40 and A131-42(43)), pan B-amyloid, was combined 
alternatively with mouse monoclonal antibodies to modified (phosphorylated (SMI312) and 
dephosphorylated (SMI32)) NFs in both preclinical and end-stage AD cases. The 
colocalisation patterns of cytoskeletal proteins (NF, tau) within individual abnormal 
neurites was also investigated using double labelling immunohistochemistry by combining 
the rabbit antibodies to 4Rtau (four MT binding domains) with the SMI312 mouse 
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monoclonal NF antibody. To determine the effect of 13-amyloid plaque development on 
surrounding processes, preclinical and end-stage AD material was double labelled with the 
pan 13-amyloid antibody and the mouse monoclonal antibody to MAP2 (see Tables 2.3 and 
2.4 for primary antibody details). For all fluorescence labelling, mouse monoclonal 
antibodies were visualised with a horse anti-mouse secondary antibody conjugated to FITC 
whereas the rabbit polyclonals were visualised with a goat anti-rabbit antibody conjugated 
to biotin followed by streptavidin Texas Red avidin D (Table 2.5). 
4.2.3 Confocal Microscopy  
Laser confocal scanning microscopy, using an Optiscan F900e krypton/argon system 
attached to an Olympus microscope, was utilised to investigate the morphology of various 
plaque types and the localisation patterns of DNs within the plaque substructure. 
Fluorescein and Texas Red labelled preparations were recorded simultaneously in separate 
channels. Representative plaques were optically sectioned at intervals of 1-2 gm for 
distances of approximately 20-30 gm through a plaque. This information was then utilised 
to create three-dimensional images of the varying plaque types present throughout the 
cases. Plaques were categorised as either 'diffuse', 'dense-cored' or 'fibrillar'. Similar 
sectioning methods were utilised for material double labelled with the antibodies to 13- 
amyloid, however, distances of only 5-10 gm were sectioned due to antibody penetration 
limitations. Detailed analysis of the plaque substructure was performed using the Optimate 
5.2 program. Measurements of plaque size and core size were obtained. The prevalence of 
each plaque type was determined by examining in detail one hundred plaques, throughout 
all cortical layers, in all cases. Further to this, the proportion of each plaque type that was 
neuritic, ie associated with either NF labelled (preclinical AD cases) or tau labelled (end 
stage AD cases) abnormal neurites, was also determined. Diffuse amyloid was noted to be 
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highly variable in its size and deposition patterns. Therefore, for the purpose of these 
investigations, only spherical deposits with a minimum diameter of approximately 40 pm 
were considered. 
Confocal microscopy was further utilised to perform an analysis of the plaque associated 
DNs in the AD cases. The 40 pm sections double labelled with the rabbit antibody to tau 
and the mouse antibody to phosphorylated (SMI312) NFs were used for these analyses. 
Clusters of DNs were optically sectioned at 0.5-1 p.m intervals. `Optimate' was again 
utilised for size measurements. The proportion of NF immunoreactive DNs that had a tau 
immunoreactive core was quantified by sectioning through one hundred non continuous 
DNs labelled by either SMI312 or SMI32 per AD case. These counts were made throughout 
the layers, and included all morphological types of DNs. 
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4.3 Results 
4.3.1 Preclinical Alzheimer's disease  
Staining with thioflavine S and labelling with antibodies to B-amyloid revealed a number of 
morphologically distinct plaques. Serial sectioning throughout these plaques uncovered key 
features specific to each plaque type. A subset of plaques were notable for their dense-core 
of B-amyloid surrounded by indistinct wispy labelling (Figure 4.1). These plaques were 
approximately 40-60 um in diameter. Other plaques were coreless and were comprised of 
large numbers of distinct fibrils (Figure 4.2). These fibrillar plaques tended to have distinct 
pores and irregularities within their structure and were of a similar size to the dense-cored 
plaques ie 50-70 [tm. Of note, the B-amyloid labelling in the outer regions of both of these 
plaque types was confluent. Three dimensional visualisation of these structures suggested 
that these plaques were spherical. Sequential optical sectioning revealed distinct similarities 
between the fibrillar and dense-cored plaques at levels on and immediately below the 
surface. Diffuse deposits that were more variable in size (10-180 pm), irregular in shape, 
and without distinct edges were also present (Figure 4.3). Specific plaques type were not 
localised to particular layers, however, layer I was notable for its lack of any form of B-
amyloid labelling. Variation between cases was low with regards to patterns of B-amyloid 
labelling. Quantitation of the three plaque types revealed that the majority of B-amyloid 
deposits were diffuse (average of 54%). Dense-cored and fibrillar plaques accounted for the 
remaining 24% and 22% of plaques, respectively. 
Of the diffuse plaques counted per case, an average of 12% were associated with NF 
immunopositive DNs. However, 47% of fibrillar plaques and 82% of dense-cored plaques 
were neuritic. There was no correlation between laminar location and the association with 
DNs. The NF immunoreactive DNs exhibited a variety of morphological types including 
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Figure 4.1 
Nine sequential confocal images sectioned through a dense core plaque stained with 
thioflavine-S in a preclinical AD case (83 yrs). The images were captured at intervals of 
approximately 3.6 [im. The total depth of the sectioned plaque was 28.56 Rm. Images show 
a distinct central core of 13-amyloid surrounded by a void or clearing and then an outer rim 
off3-amyloid. 
Scale Bar = 20 lam 

Figure 4.2 
Nine sequential confocal images sectioned through a dense core plaque stained with 
thioflavine-S in a preclinical AD case (81 yrs). The images were captured at intervals of 
approximately 4.4 gm. The total depth of the sectioned plaque was 34.68 1.1m. The fibrillar 
plaques showed dense B-amyloid accumulations throughout the plaque structure. In the 
central regions these accumulations often appeared as spoke-like accumulations, emanating 
from a denser central accumulation. Distinct pores within the plaque were obvious in 
deeper sections. 
Scale Bar = 20 p.m 

Figure 4.3 
Six sequential confocal images sectioned through a diffuse plaque labelled with an antibody 
to B-amyloid in an end-stage AD case (74 yrs). The images were captured at intervals of 
approximately 0.8 pm. The total depth of the plaque that was sectioned was 5 pm. These 
deposits were generally larger in diameter, however, considerably smaller in depth. Only 
small changes in the plaque structure were noted in the different optical sections. 
Scale Bar = 50 pm 
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bulb and ring-like structures. These structures were labelled by both SMI32 and SMI312 
but not labelled by the antibody to tau. Optical sectioning through neuritic plaques 
indicated that the larger bulb-like neurites were generally located within larger pores or 
holes in the amyloid substructure (Figure 4.4). In the dense-cored plaques these pores 
mostly occupied the area directly adjacent to the B-amyloid core, whereas in diffuse and 
fibrillar plaques they were non-uniformly dispersed throughout the plaque. The larger bulb-
like DNs were often continuous with fine processes of normal diameter. Many of these 
processes appeared to be passing through holes in the plaque and then immediately 
terminated with a large swelling or NF accumulation (Figure 4.5). The ring-like structures 
also appeared to be co-located to cavities within the B-amyloid plaque. However, these 
cavities were smaller in dimension to those occupied by the larger bulbs. 
4.3.2 Alzheimer's disease 
The same categories of B-amyloid deposits were present in the end-stage AD cases as those 
noted in the preclinical material ie diffuse, fibrillar and dense-cored. B-amyloid labelling 
was, however, more intense and spread throughout the layers. Large numbers of diffuse 13- 
amyloid immunopositive deposits were present throughout layer I with many dense-cored 
plaques present within layer V. The prevalence of the three plaque types was notably 
different in the AD cases as compared to the preclinical AD cases. In these cases an 
average of 49% of spherical 13-amyloid deposits were fibrillar, 20% dense-cored and 31% 
diffuse. 
Double labelling with the antibodies to 13-amyloid and MAP2 revealed a distinct 
morphological change within the dendrites in close association with both fibrillar and 
dense-cored B-amyloid plaques. However, no changes in dendritic morphology or the 
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Figure 4.4 
Double labelling with antibodies to 13-amyloid (red) and phosphorylated NFs (green) 
showing the relationship between plaque morphology and the location of the abnormal 
neurites in preclinical AD cases. For each example (A (81 yrs) and B (91 yrs)) three optical 
sections throughout the fibrillar plaques (i, ii and iii) and a cumulative multiple brightness 
image (iv) are shown. Arrows indicate neurofilamentous bulb-like structures. 
Scale Bar = 20 p.m (A and B) 

Figure 4.5 
Double labelling with antibodies to 13-amyloid (red) and phosphorylated NFs (green) 
showing further examples of the relationship between plaque morphology and the location 
of the abnormal neurites in preclinical AD cases. For each example (A and B (81 yrs)) three 
optical sections throughout the dense cored plaques (i, ii and iii) and a cumulative multiple 
brightness image (iv) are shown. Arrowheads indicate neurofilamentous ring-like structures 
and arrows, bulb-like structures. 
Scale Bar =20 [im (A and B) 
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course of their growth was noted in processes associated with diffuse deposits (Figure 4.6). 
This pattern of labelling was consistent throughout both case types. 
Labelling of thioflavine-S stained material with an antibody to tau revealed that 82% of 
dense-cored plaques, 47% of fibrillar plaques and 12% of diffuse deposits were neuritic. 
The predominant morphological DN types were bulb-like structures of varying sizes (3-8 
1.1m) and also elongated, fusiform structures (10-20 um). Both forms exhibited 
immunoreactivity to anti-tau and anti-NF antibodies. The pattern of distribution of the bulb-
like DNs closely resembled that encountered for similar DNs in the preclinical cases. 
Generally, the bulb-like structures were located within the pores of the plaque (Figure 4.7). 
The more tortured and elongated DNs, had a somewhat different distribution within the B-
amyloid plaques. Rather than occupying pores they emerged from small pores and did not 
appear to cause changes to surrounding 13-amyloid. Consequently, they were located in all 
areas of plaques including within the central region (Figure 4.7). 
Analysis of the NF immunopositive DNs with the confocal microscope and optical 
sectioning through the structures confirmed the presence of a tau immunoreactive core 
within a subset of these pathological structures. Initially this pattern of labelling was 
thought to be restricted to the bulb-like DNs (Figure 4.8), however, confocal microscopy 
also revealed tau immunoreactive cores within the longer more cylindrical DNs (Figure 
4.9). In these structures only the very outer rim showed anti-NF labelling. Confocal 
investigation of non-connected NF immunopositive DNs revealed that an average of 30% 
had a tau core. Many of these cores were only visible after optically sectioning through the 
DN clusters. 
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Figure 4.6 
MAP2 labelled dendrites (green) showed distinct curving around dense cored plaques (A), 
whereas limited change was noted in similarly labelled processes associated with diffuse 13- 
amyloid deposits (B). For each example (A and B) three optical sections throughout the 
plaque (i, ii and iii) and a cumulative multiple brightness image (iv) are shown. Arrows 
indicate curved dendrites. Both sets of images were taken from an end-stage AD case, 73 
years of age. 
Scale Bar = 15 pm (A and B) 

Figure 4.7 
Double labelling with antibodies to B-amyloid (red) and tau (green) showing the 
relationship between plaque morphology and the location of the abnormal neurites in end 
stage AD cases. For each example (A (84 yrs) and B (92 yrs)) three optical sections 
throughout the plaque (i, ii and iii) and a cumulative multiple brightness image (iv) are 
shown. A) shows a diffuse plaque, associated with clusters of DNs. Arrowheads indicate 
long distended DNs exhibiting classical tau morphology, whereas arrows indicate 
neurofilamentous bulb-like accumulations of similar morphology to those noted in 
preclinical AD cases. 
Scale Bar = 15 pm (A and B) 
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Figure 4.8 
Double labelling of bulb-like NF (green) immunopositive DNs with tau cores (red) in AD 
cases (A(72 yrs), B(84 yrs), C(84 yrs) and D(74 yrs). 
Scale Bars = 15 pm (A, B and C) and 20 pm (D) 

Figure 4.9 
Double labelling of elongated fusiform NF (green) immunopositive DNs with tau cores in 
AD cases (red) (A(84 yrs), B(74 yrs), (72 yrs) and D(84 yrs). 
Scale Bars = 15 gm (A), 15 tm (B), 20 gm (C) and 15 gm (D) 
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4.4 	Discussion 
The current investigation confirms previous reports that B-amyloid plaques are not uniform 
structures (Ikeda et al., 1989; Wisniewski et al., 1989; Dickson, 1997). Both the preclinical 
and end-stage AD cases exhibited considerable diversity with regards to the morphological 
types of B-amyloid deposits that were present. Although, historically, plaques have been 
grouped into varying numbers of different morphological types this study found that all 
plaques investigated could adequately be assigned to one of three distinct types either 
dense-cored, fibrillar or diffuse. Confocal microscopy was utilised to section through 
amyloid deposits to accurately categorise plaque type and to investigate the composition of 
individual plaques. Importantly, this procedure revealed a potential for incorrect plaque 
classification if only one focal plane was considered, as is often the case with routine 
microscopy. This was particularly important when discriminating between fibrillar and 
dense-cored plaques. 
The presence of B-amyloid plaques of varying morphology has been noted by a number of 
investigators (Wisniewski & Terry, 1973; Ulrich, 1985; Masliah et al., 1993a; Schmidt et 
al., 1995; Dickson, 1997; Armstrong, 1998). Two main hypothesis have been developed to 
account for the observation. Firstly, that one type of plaque is converted into another, ie 
that the different plaque types represent stages in the life history of a single type of plaque 
(Ikeda et al., 1990). The second hypothesis is that each plaque type evolves independently 
of the others and, therefore, unique factors are involved in their formation (Armstrong, 
1998). In this investigation the prevalence of diffuse, fibrillar and dense-core plaques was 
variable between case types but did not correlate with disease progression as all plaque 
types were evident within both preclinical and end-stage AD. These data suggest that the 
life history theory of plaque development is unlikely to be strictly correct. Further to this, 
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the presence of dense-core plaques in preclinical AD cases suggests that these lesions are 
not confined to cases in the very end stages of the disease (Rozemuller et al., 1989; Ikeda et 
al., 1990). 
A common phenomena in AD is the association between plaques and clusters of DNs. As 
noted in the preceding chapter, all clusters of abnormal neurites were found to be localised 
with B-amyloid deposits, however, not all deposits were associated with DNs. Analysis 
revealed that this association was not governed by the morphological characteristics of the 
plaque as all plaque types were associated with DN clusters, albeit at varying rates. In 
addition, the rare but notable association of diffuse amyloid deposits with clusters of DNs, 
in both the preclinical and end stage AD cases, further argues against the likelihood of 
diffuse amyloid representing an early, transient and inert stage of plaque development 
(Yamaguchi et al., 1988). This less structured type of deposit is able to cause damage to 
surrounding nerve cell processes resulting in the development of clusters of NF and tau 
immunopositive DNs similar to those associated with the more defined and compact dense-
cored and fibrillar plaques. However, it should be noted that in accordance with other 
investigators, dense-cored and fibrillar plaques had a more pronounced effect on 
surrounding dendrites as compared to diffuse plaques (Knowles et al., 1999). These results 
suggests that the physical presence of certain plaque types is able to influence surrounding 
processes, however, a further non-morphological trait differentiates damaging and non-
damaging deposits. 
A notable morphological and neurochemical diversity has previously been reported in the 
abnormal neurites associated with B-amyloid deposits (Dickson et al., 1988; Vickers et al., 
1994b; Yasuhara et al., 1994; Wang & Munoz, 1995; Su et al., 1996; Saunders et al., 1998). 
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Confocal microscopy provided a means to investigate this diversity more fully and to 
consider the interrelationship between DNs and B-amyloid plaques in a manner not possible 
with a conventional microscope. Preclinical cases were again characterised by the presence 
of NF immunopositive bulb and ring-like DNs that were not labelled with antibodies to tau, 
and end stage cases, by NF and tau immunoreactive bulb-like neurites and swollen fusiform 
processes. The NF accumlations in the preclinical cases may represent one of the earliest 
pathological changes that occurs in AD (Vickers et al., 1996). In both preclinical and end 
stage AD cases the bulb-like DNs occupied large pores within the plaque substructure. Cruz 
and collegues also reported the occupation of such pores by cellular elements in AD cases 
(Cruz et al., 1997). Similar pores were present in non-neuritic plaques. Therefore, it is 
unlikely that the physical presence of the abnormal neurite results in the formation of the 
pore. The structures appear to form in the area of least resistance. The more elongated NF 
immunoreactive DNs are morphologically identical to those structures labelled by 
antibodies to tau in end stage AD cases. These structures appeared as torturous processes 
that seemed to taper at the end most closely associated with the B-amyloid deposit. This 
taper may represent a point of focal constriction exerted by the plaque which may initiate 
the accumulation of NFs within these processes. Other investigators have similarly 
described a swelling and disruption of normal morphology in axons (Benes et al., 1991) and 
dendrites (Knowles et al., 1999) observed passing through plaques. Optical sectioning 
revealed that the DNs observed in the current investigation were mostly non-continuous as 
opposed to single branched processes, which has previously been proposed (Masliah et al., 
1993a). 
Double labelling with antibodies to phosphorylated NFs (SMI312) and tau again revealed 
the presence of NF immunoreactive bulb-like structures with a tau core which may 
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correspond to a transitional stage of DN development. Optical sectioning allowed for 
accurate quantitation of this class of abnormal neurite. Approximately 30% of NF 
immunoreactive DNs in end-stage AD cases were found to have a tau immunoreactive 
central region. Further to this, whereas previous reports describe this pattern of labelling in 
bulb-like DNs it is now clear that this distinct pattern of labelling is also present in a 
proportion of classical elongated tau immuoreactive DNs. These results further implicate 
NFs in the development of not only the earliest abnormal neurites associated with plaque 
development but also the accumulation of tau within these process. 
In this investigation, through the use of confocal imaging techniques, it was concluded that 
B-amyloid plaques are morphologically diverse. All plaque types are present in both the 
early and late stages of AD and are associated with large clusters of abnormal neurites. The 
subtype of DN found within these clusters is not related to plaque morphology, however, 
the location within the f3-amyloid deposit did correlate with particular features of the plaque 
structure. Furthermore, the density of the plaque was found to influence the distribution of 
surrounding dendritic processes. Results suggest that a further plaque attribute is 
responsible for the differential association between some 13-amyloid deposits and DN 
clusters. The lack of correlation between the density of DNs and their proximity to plaques 
suggests that this attribute is unlikely to be associated with B-amyloid toxicity. 
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RELATIONSHIP BETWEEN APOLIPOPROTEIN E AND THE AMYLOID 
DEPOSITS AND DYSTROPHIC NEURITES OF ALZHEIMER'S DISEASE 
5.1 	Introduction 
ApoE has been identified as performing a number of roles in cell biology, including the 
transport of cholesterol and other lipids throughout the body (Mahley et al, 1988). It has 
also been implicated in the reactive response of neurons following damage (Poirier, 
1994). Inheritance of the 64 allelic version of the ApoE gene is a risk factor for the 
development of AD (Corder et al., 1993; Saunders et al., 1993). It is notable that head 
injury and ApoE genotype may act synergestically to increase risk for AD (Mayeux et 
al., 1995) and that poor clinical outcome from head trauma is also associated with 
inheritance of 64 alleles (Jordan et al., 1997; Teasdale et al., 1997; Friedman et al., 
1999). The mechanisms underlying the role of ApoE in responses to injury and also AD 
are yet to be clarified. 
Immunohistochemical studies have shown that ApoE is localised to the pathological 
hallmarks of AD, such as plaques (Wisniewski & Frangione, 1992; Han et al., 1994; 
Kida et al., 1994; Gearing et al., 1995; Uchihara et al., 1995; Sheng et al., 1996) and 
possibly also NFTs (Han et al., 1994; Benzing & Mufson, 1995). Single labelling 
immunoperoxidase studies have described a degree of discordance in the distribution of 
ApoE and B-amyloid labelling between and within specific brain structures (Han et al., 
1994; Kida et al., 1994; Gearing et al., 1995; Uchihara, et al., 1995; Sheng et al., 1996). 
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In this investigation the relationship between ApoE immunolabelling and B-amyloid 
deposition, neuritic plaques and NFTs was examined using immunofluorescent double 
labelling techniques. Multiple labelling fluorescent methods provided an opportunity to 
directly examine specific hypotheses on the relevance of ApoE localisation to the 
development of the pathological hallmarks of AD. Thus, B-amyloid plaques of varying 
morphology throughout the cortical layers were investigated for their degree of 
colocalisation with ApoE immunoreactivity. In addition the localisation of ApoE 
labelling with respect to neurofibrillary pathology was examined. Finally, aged non-
demented cases that contain cortical 13-amyloid plaques, and may represent preclinical 
AD (Morris et al., 1996), were utilised to investigated the localisation of ApoE labelling 
in the early stages of AD. Determination of the role of the ApoE protein in AD is 
crucial for elucidating the sequence of pathological events that ultimately result in 
dementia. 
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5.2 	Experimental procedures 
5.2.1 Case details  
In these experiments investigating the relationships between ApoE, B-amyloid plaques 
and neurofibrillary pathology six cases of confirmed AD (65, 66, 71, 72, 73, and 74 
years of age) and four preclinical AD cases (61, 62, 70 and 71 years of age) (Tables 2.1 
and 2.2 for source and fixation details) were utilised. 
5.2.2 Immunohistochemistry 
Both single labelling (chromogen precipitation) and double labelling (fluorescence) 
methods were used to visualise ApoE and 13-amyloid immunoreactivity. Basic 
immunohistochemistry protocol was utilised as previously outlined in Chapter 2, any 
changes or additions to this protocol are described below. 
Sections of the superior frontal gyms in which 13-amyloid was to be visualised were pre-
treated with 90% formic acid and then extensively washed in PBS prior to primary 
antibody incubations. Antibodies utilised for this study are described in Tables 2.3 and 
2.4. For single-labelled, immunoperoxidase preparations, mouse monoclonal antibodies 
to B-amyloid and ApoE were used. For double labelling preparations, the mouse 
monoclonal antibody to ApoE was combined either with the rabbit polyclonal antibody 
to ApoE or one of the two rabbit antibodies to B-amyloid. For further investigation of 
ApoE and its relationship with DNs in AD cases, the mouse monoclonal ApoE antibody 
was combined alternatively with rabbit polyclonal antibodies to ubiquitin and tau. The 
degree of colocalisation was determined by counting the proportion of ApoE positive 
plaques colocalised with DNs present in either layers II and III or V and VI. One 
hundred plaques were counted, from these supra- and infra-granular areas, of each case. 
For the purpose of quantitation neuritic plaques were classified as either sparse, (1-5 
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DNs per plaque in the plane of focus), or clustered, (>5 DNs). Double labelling was also 
conducted between the mouse antibody to B-amyloid and the rabbit antibodies to tau 
and ubiquitin. 
The rabbit polyclonal antibody to ApoE was used in double labelling investigations in 
conjunction with the mouse monoclonal SMI310, as the latter antibody labels the early 
to middle stages of NET formation (Vickers et al., 1992b). The proportion of 
immunopositive tangles that were ApoE and/or SMI310 immunopositive, in layers V 
and VI, was determined. Similarly the ApoE antibody was used in conjunction with the 
mouse monoclonal antibody SMI32 to investigate the association of ApoE with the 
early stages of DN formation in plaque-containing non-demented cases (Vickers et al., 
1996). 
In all double labelling immunofluorescence investigations, antibodies were visualised 
with a horse anti-mouse IgG conjugated to FITC and a goat anti-rabbit IgG conjugated 
to biotin, followed by streptavidin Texas Red (Table 2.5). 
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5.3 	Results 
5.3.1 Single labelling for ApoE and B-amyloid  
The distribution of immunoperoxidase labelling for ApoE in the SFG of the AD cases 
was similar across all individuals and closely resembled previous reports (Wisniewski 
& Frangione, 1992; Rebeck et al., 1993; Han et al., 1994; Kida et al., 1994; Benzing & 
Mufson, 1995; Gearing et al., 1995; Uchihara et al., 1995; Sheng et al., 1996). Of note, 
the intensity of immunolabelling for ApoE was highest in formic acid pretreated 
sections. ApoE-labelled structures in the prefrontal cortex of AD cases included 
plaques, small cells with astrocyte-like morphology and arterioles (Figure 5.1). Similar 
patterns of ApoE labelling were present in the entorhinal, occipitotemporal and inferior 
temporal cortices of AD cases (Figure 5.1). In addition, the anti-ApoE antibodies 
labelled NFTs in layer II of the entorhinal cortex, most of which were likely to be 
extracellular (Vickers et al., 1992b). In preclinical AD individuals, ApoE 
immunoreactivity was found in plaque-like structures only in the cases showing B-
amyloid immunoreactive deposits. In all preclinical AD cases, ApoE immunoreactivity 
was also present in arterioles principally localised to the underlying white matter and 
glial cells. The immunohistochemical profile obtained was consistent throughout AD 
cases and throughout preclinical AD cases regardless of post mortem interval and 
variations in fixation protocol. 
5.3.2 Double labelling for ApoE and B-amyloid  
Double labelling with the mouse and rabbit antibodies to ApoE verified that both of 
these antibodies were labelling the same structures in tissue sections. Double labelling 
immunofluorescence was utilised to directly examine the relationship between ApoE 
and B-amyloid immunoreactivity in frontal cortex sections (Figure 5.2). Many of the 
spherical and diffuse plaque-like structures immunoreactive for B-amyloid in layer I and 
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Figure 5.1 
Single labelling for ApoE in the SFG (A), and entorhinal cortex (B), of an AD case (layers 
indicated on the left). In the SFG, ApoE labelled plaques are particularly predominant in 
layers II, HI and V (eg arrows). In the entorhinal cortex ApoE labels plaques (eg arrow) and 
also extracellular tangles in layer H (arrowhead). 
Scale bar = 100 pm (A and B) 

Figure 5.2 
Double labelling for B-amyloid (A) and ApoE (B) in the superior frontal gyms of a 66 year 
old AD case (layers indicated on left). The 13-amyloid plaques localised to layer I are not 
immunoreactive for ApoE. In other supragranular layers there is a high degree of 
colocalisation of these markers to individual plaques. 
Scale bar =100 pm (A and B) 
is • 
. • 	
v• 	• 
.1 * 	*, 
• 
Chapter 5 
the outer region of layer II were consistently unlabelled for ApoE (Figure 5.2). The 
same observations were made in all AD cases. In other cortical layers, there was a high 
degree of colocalisation of ApoE and B-amyloid to plaques. For all dense-core plaques, 
the core structure was consistently labelled for both ApoE and B-amyloid, but the outer 
portions were often immunoreactive only for B-amyloid (Figure 5.3). Many other 
plaque-like structures were incompletely labelled for ApoE relative to B-amyloid 
(Figure 5.3), with only the innermost regions of the plaque showing ApoE 
immunoreactivity. Most of the plaques displaying extensive ApoE immunoreactivity 
were spherical and localised to layer III and the deeper portions of layers II and V. 
There were no plaque-like structures labelled for ApoE that were not also 
immunoreactive for B-amyloid. Some plaques contained small spherical structures (2-5 
p.m) which were labelled for ApoE but not B-amyloid (Figure 5.3). 
Where ApoE and f3-amyloid were colocalised, immunoreactivity for both was present in 
the same fibrillar material. Arterioles showing strong ApoE immunoreactivity in these 
cases were either faintly immunolabelled or non-immunoreactive for B-amyloid. AgoE-
labelled blood vessels and astrocytes did not show a specific association with plaques. 
In all preclinical AD cases containing 13-amyloid plaques, most, but not all, spherical 
and diffuse B-amyloid deposits were also variably labelled for ApoE (Figure 5.3). 
Conversely, there were no ApoE immunoreactive plaques that were not also 
immunoreactive for B-amyloid. As described above for clinical AD cases, small 
spherical ApoE immunopositive structures were occasionally observed in association 
with the ApoE plaques in preclinical AD cases and these were not immunopositive for 
B-amyloid (Figure 5.3). 
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Figure 5.3 
Double labelling for B-amyloid (A,C,E) and ApoE (B,D,F) in the SFG. A and B show a 
dense-core plaque in layer II of a 66 year old AD case. The core is well labelled by both 
markers, but the remaining plaque is more extensively immunoreactive for B-amyloid 
relative to ApoE. In layer V of a 72 year old AD case (C,D), not all B-amyloid plaques (C) 
are ApoE immunoreactive (D) (arrows), and some B-amyloid deposits are incompletely 
labelled for ApoE (arrowhead). In layer II of a 61 year old, preclinical AD case, a 13- 
amyloid deposit (E) is incompletely labelled for ApoE (F). The arrow in F indicates a 
spherical structure associated with the plaque that is labelled for ApoE but not for 13- 
amyloid. 
Scale bar = 25 pm (A,B,E and F) and 50 pm (C and D) 
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5.3.3 Association between ApoE and dystrophic neurites  
All ApoE labelled plaques in the AD cases could be classified as neuritic, based on the 
presence of tau/ubiquitin immunoreactive DNs in double labelling preparations (Figure 
5.4). Conversely, not all 13-amyloid labelled plaques were associated with DNs, with 
plaques in layer I notably lacking a neuritic component. The number of DNs present 
within ApoE labelled plaques was, however, variable. Therefore, for the purpose of 
quantitation, neuritic plaques were classified as either sparse (1-5 DNs) or clustered (>5 
DNs). Quantitation of double labelled preparations demonstrated a greater proportion of 
ApoE immunopositive plaques associated with ubiquitin-labelled, clustered DNs in 
layers II and III (68±7% (S.D.)) relative to cortical layers V and VI (32±5%). Parallel 
investigations of double labelling using 13-amyloid with tau gave similar results ie. 
59±2% of 3-amyloid immunopositive plaques in layers II and III contained clusters of 
DNs (highly neuritic) compared to 34±8% in layers V and VI. 
Plaque-associated DNs in preclinical AD cases containing 13-amyloid deposits are 
labelled with NF antibodies but not with markers for tau or ubiquitin (Su et al., 1996; 
Vickers et al., 1996), and clusters of these abnormal neurites are preferentially located 
to cortical layers II and III (Vickers et al., 1996). In this investigation, double labelling 
in such cases demonstrated that all clusters of NF immunoreactive DNs were present 
within ApoE labelled plaque-like structures, but not all ApoE immunoreactive plaques 
were associated with abnormal neurites (Figure 5.4). 
Notably, the ApoE-labelled spherical structures associated with plaques were not 
labelled with DN markers in either the clinical or preclinical AD cases. 
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Figure 5.4 
Double labelling for ApoE (A,C,E) and markers for neurofibrillary pathology (B,D,F) in 
the SFG. A and B show double labelling with ApoE and tau in layer II of a 72 year old AD 
case. One plaque is associated with a cluster of DNs (arrow) whereas a nearby plaque 
(arrowhead) is less neuritic. Double labelling with ApoE (C) and S1VI32 (D) in layer If of 
62 year old preclinical AD case shows an association between ApoE positive plaques and 
clusters of SMI32 immunopositive DNs. Similarly, double labelling for ApoE (E) and 
SMI310 (F) in an 86 year old with end stage AD shows a NFT that is immunopositive for 
both markers (arrowhead) in association with other NFTs that are ApoE immunopositive 
only (eg arrows). 
Scale bar = 50 p.m (A,B,C,D,E and F) 
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5.3.4 ApoE and neurofibrillary tangles in Alzheimer's disease 
Earlier studies have demonstrated that the series of AD cases utilised in this 
investigation could be subdivided into high and low NFT density categories (Sampson 
et al., 1997). In this respect, the most severely affected AD case (NFT density more than 
twice that of any other AD case) contained both cell bodies and NFTs that were labelled 
for ApoE (Figure 5.4). In contrast, no NFTs were ApoE immunoreactive in the SFG of 
the other five AD samples. In formic acid treated sections from AD cases, the NF 
antibody, 5MI310, is a marker for the early to middle stages of NFT formation (Vickers 
et al., 1994b, 1996). Therefore, this antibody was utilised in double labelling 
investigations to determine the proportion of ApoE labelled NFTs that were intracellular 
(SMI310 immunopositive) and the proportion that were extracellular (SMI310 
immunonegative) in the high NFT density AD case described above. Quantitation 
showed that only 10% of ApoE positive NFTs in layer V were also labelled with 
SMI310 (Figure 5.4). Conversely, 68% of the 5M1113 10-labelled NFTs were not labelled 
for ApoE. This indicates that most ApoE labelled NFTs in the prefrontal cortex of this 
case are likely to be extracellular end-stage forms. 
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5.4 	Discussion 
Double labelling immunohistochemistry was utilised in this chapter to directly examine 
the localisation of ApoE in relation to the pathological hallmarks of AD. Although the 
specific ApoE genotype is not known for the cases investigated in this study, highly 
consistent patterns of ApoE localisation, particularly relative to B-amyloid deposition, 
were observed. Similarly, the same general pattern of ApoE immunolabelling has been 
reported in AD cases across ApoE genotypes (Price et al., 1991; Han et al., 1994; 
Gearing et al., 1995; Sheng et al., 1996). The results obtained confirm that ApoE 
immunoreactivity is principally localised to plaques, and also show that this protein is 
present within a specific subset of the plaques labelled for 13-amyloid. In this respect, 13- 
amyloid plaques located in cortical layer I were consistently unlabelled for ApoE. 
Furthermore, even where ApoE and 13-amyloid were present in the same plaque, ApoE 
immunoreactivity within the plaque was usually incomplete relative to 13-amyloid. 
Dense-core plaques typically had only the most central elements labelled for ApoE. 
These data indicate that the involvement of ApoE in plaque formation is likely to be 
secondary to that of 13-amyloid (ie all plaques contain B-amyloid but not necessarily 
ApoE), and that the presence of ApoE in some plaques reflects a very specific feature of 
the disease. 
ApoE has been shown to bind to 13-amyloid both in vitro (Strittmatter et al., 1993a, 
1993b; LaDu et al., 1994) and in vivo (Namba et al., 1991; Wisniewski et al., 1992; 
Russo et al., 1998). It is also colocalised with fibrillar B-amyloid in APP''' transgenic 
mice (Bales et al., 1999) and has been shown to have a pro-fibrillogenic activity in vitro 
(Gallo et al., 1994; Ma et al., 1994). Therefore, it has been suggested that ApoE may 
operate as a chaperone-like factor in B-amyloid plaque formation, by promoting the 
assembly of insoluble B-amyloid (Wisniewski & Frangione, 1992; Ma et al., 1994). 
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Thus, the localisation of ApoE to a specific subset of plaques may serve to augment B-
amyloid fibril formation in these deposits. The presence of ApoE in plaques, in cases 
that may correspond to preclinical AD, indicates that this protein may be involved in the 
early stages of formation of certain plaques. This may serve to further enhance the 
insolubility of certain plaques prior to dementia. 
Double labelling verified that the ApoE-positive plaques corresponded to the 'neuritic' 
forms of B-amyloid plaques (see also chromogen based double labelling results - 
Uchihara et al., 1995; Sheng et al., 1996), although the degree to which they were 
associated with abnormal neurites varied with the laminar location of the plaque. 
Results detailed in the previous two chapters provide evidence that the development of a 
subset of plaques causes physical damage to surrounding axons which leads to reactive 
cytoskeletal changes, eventually resulting in neurofibrillary pathology (Vickers et al., 
1996; King et al., 1997; Vickers, 1997). Interestingly, neuritic plaques are more 
commonly found in the supragranular layers in both preclinical (Vickers et al., 1996) 
and clinical (Masliah et al., 1993a) AD cases, which may reflect the susceptibility of 
neuronal connections whose axons terminate in these layers (Vickers et al., 1996). This 
suggests that ApoE, by contributing to the fibrillogenesis of certain plaques, may 
enhance their ability to cause damage to axons. This hypothesis is strongly supported by 
recent data obtained from studies utilising the APP' transgenic mouse line (Bales et 
al., 1997; 1999; Holtzman et al., 2000). These mice were manipulated to express mouse, 
human or no ApoE. A severe plaque associated neuritc dystrophy was noted in the 
transgenic mice expressing mouse or human ApoE. Further to this expression of ApoE4 
resulted in substantially more fibrillar deposits as compared to ApoE3 (Holtzman et al., 
2000). Collectively these results indicate a critical role for ApoE in neuritic plaque 
formation. 
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Alternatively, ApoE may have a functional role in the remodelling and sprouting of 
damaged neuritic processes (Su et al., 1996; Stone et al., 1998; Horsburgh et al., 1999; 
Teter et al., 1999a, 1999b) , indicating that the localisation of ApoE to certain plaques 
may be secondary to their role in the neuronal changes that lead to DN formation (Su et 
al., 1996). However, ApoE labelling was also present in plaques in the infragranular 
layers that had a relatively low neuritic component, and many plaques containing ApoE 
labelling in the preclinical cases were not associated with DNs. Coupled with the 
observation of the consistent presence of ApoE in specific domains of certain plaques in 
AD, this suggests that ApoE may have a more direct role in B-amyloid plaque formation 
rather than the neuronal reaction to injury. The former possibility is strengthened by 
observations of the association of other apolipoproteins with B-amyloid formation in 
AD (Wisniewski & Frangione, 1992), as well as the possible role of ApoE in promoting 
other amyloidegenic diseases (Wisniewski & Frangione, 1992; Kindy et al., 1995; 
Chargé et al., 1996). 
It is important to note that ApoE also labelled spherical structures within some plaques 
and these were not immunoreactive with antibodies to B-amyloid or the markers for 
DNs. It is possible that these may correspond to microglial cells (Uchihara et al., 1995). 
It has been suggested that ApoE may be present in DNs within plaques (Han et al., 
1994), although double labelling in the current study indicates that antibodies to ApoE 
do not label either the early or late stages of DN formation. In addition, it has been 
reported that ApoE immunoreactivity is present in NFTs (Han et al., 1994; Benzing & 
Mufson, 1995). In the current report, only the case with the highest NFT density showed 
ApoE labelling of NFTs in the prefrontal cortex, and double labelling demonstrated that 
the great majority of these were end-stage, extracellular forms of this pathological 
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hallmark. In addition, ApoE labelling was also present in the extracellular NFTs located 
in the outer layers of the entorhinal cortex of the AD cases. This data confirms a 
previous report stating that ApoE may be binding principally to the extracellular forms 
of NFTs (Benzing & Mufson, 1995). These cumulative data suggest that ApoE is 
unlikely to have a direct role in the generation of the cytoskeletal pathology that 
comprises DNs or NFTs. 
Therefore, in this investigation it was concluded that ApoE binds, in an incomplete 
fashion, to a specific subset of plaques in AD and that this may assist fibrillogenesis in 
these plaques and possibly enhance their ability to cause physical damage to 
surrounding axons. Allelic variations of ApoE may contribute differentially towards the 
relative insolubility of plaques, thus explaining the greater number of neuritic plaques 
associated with inheritance of particular ApoE genotypes (Rebeck et al., 1993; 
Schmechel et al 1993; Corder et al., 1994; Olichney et al., 1996). 
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THE SEQUENCE OF CELLULAR CHANGES FOLLOWING LOCALISED 
AXOTOMY TO CORTICAL NEURONS IN GLIA-FREE CULTURE MI1VHC THE 
DEVELOPMENT OF DYSTROPHIC NEURITES IN ALZHEIMER'S DISEASE 
6.1 	Introduction 
It has been proposed that many of the cytoskeletal changes following a direct form of cortical 
neuron damage (King et al., 1997, 2000; Adlard, In Press; Chapter 3) are similar to the 
reactive changes described in both human and experimental brain injury studies (Maxwell et 
al, 1997). Of particular interest are the similarities between the neuronal response to injury and 
the specific early forms of abnormal neurites associated with B-amyloid plaque formation in 
AD (see Chapter 3) (Vickers et al., 1996; King et al., 1997). This similarity has led to the 
novel hypothesis that plaque formation in AD causes deformation of the neuropil, 
compression of axons and the triggering of the neuronal response to injury followed by 
abnormal axonal sprouting. 
Both the neuronal changes associated with 13-amyloid plaque formation and following various 
forms of brain injury have been purported to be influenced by the actions of non-neuronal 
cells such as oligodendroglia, astrocytes and microglia (Vickers et al., 2000), but the precise 
role of these cell types in directing the neuronal response is unclear. For example, some 
research groups emphasise the deleterious effect of glia on post-injury regeneration in central 
neurons, either, for example, by the inhibitory action of myelin-associated proteins (Bregman 
et al., 1995), glial-associated growth-inhibitory factors (e.g. metallothionein III (Uchida et al., 
1991) or extracellular matrix proteins (Fawcett, 1997; Fitch & Silver, 1997), whereas recent 
studies also note that specific glia cell types produce growth factors which may encourage 
neurite growth (Batchelor et al., 1999). The formulation of a specialised neuron specific 
media, NeurobasalTM, optimised for the survival and differentiation of embryonic neurons in 
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the absence of glial cell types, has recently permitted the growth of pure neuronal cultures in 
vitro (Brewer et al., 1993). This provides a unique opportunity to study an isolated neuronal 
response to injury without the confounding results introduced by the presence of non-
neuronal cells. 
In this study, an in vitro model of axonal damage, utilising the NeurobasalTM  culture media 
(Brewer et al., 1993), was developed to study the intrinsically derived reaction of central 
neurons to injury. Investigations had a focus on the time course of cytoskeletal changes 
following injury as well as the temporal association of reactive and regenerative cellular 
alterations. Alterations in neuronal cytoskeletal proteins appear to be a crucial event in the 
initial reactive changes following physical damage to nerve cells. In this respect, preliminary 
evidence indicates a loss of normal microtubular structures (Meller et al., 1987; Maxwell et al., 
1997) and a specific misalignment, accumulation and dephosphorylation of NFs (Meller et al., 
1993a, 1994; Pettus & Povlishock, 1996; King et al., 1997). Many of these changes are 
thought to be preparative for an attempt at adaptive sprouting or regeneration (Ditella et al., 
1994). Therefore, in the current study, markers for NFs and the growth-associated protein, 
GAP43, were utilised. In particular, the primary goal of these studies was to determine 
whether an in vitro model of axonal injury would replicate the neuritic changes associated with 
in vivo cortical neuron axotomy as well as the early stages of neuronal pathology in AD. 
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6.2 	Experimental procedures 
6.2.1 In vitro neuronal injury model 
Neuronal cultures were prepared according to the protocol outlined in Chapter 2. One day 
before performing injury investigations, coverslips were transferred to individual sterile petri 
dishes and allowed to reacclimatise to incubator conditions. On DIV 14 and 21, injuries were 
performed by transecting individual axonal bundles under microscope guidance (Leitz 
Fluovert, inverted microscope), using a size fifteen sterile scalpel blade. Cuts were made at a 
distance of between approximately 50-150 tun from the cell body clusters (Figure 6.1). Two 
axon bundle transections per coverslip were made. Non-injured control monolayers were 
processed concurrently. Digital images were captured before and after injury to aid relocation 
of the cut site using a CCD camera (Ikegami ICD-4CE, Tsushinki Co) attached to a Power 
PC Macintosh computer using NIH Image software (version 1.61). After injury, cells were 
returned to the incubator for varying time periods before fixation with 4% paraformaldehyde 
for immunohistochemistry. 
6.2.2 Immunohistochemistry 
The damaged axons were investigated at pre-established time intervals of 1, 6, 12, 24 and 72 
hours post injury (PI) using immunohistochemistry. The distribution and degree of 
colocalization of the growth associated protein, GAP43, and the high molecular weight subunit 
of the NF triplet, NF-H, was determined using double labelling immunohistochemistry. A 
rabbit polyclonal antibody to NF-H (R-NFH) (Serotec, 1:1000) was combined with a mouse 
antibody to GAP43 (Boeringher Mannheim, 1:1000) for experimental and control cultures. 
To investigate the prevalence of non-neuronal cells, mouse monoclonal antibodies to glial 
fibrillary acidic protein (GFAP) (DAKO, 1:2000) and ferritin (ICN Biomedicals Incorporated, 
1:5000) were utilised. Further double labelling was performed with a rabbit polyclonal 
antibody to the calcium binding protein calretinin (Swant®, 1:2000) and a mouse monoclonal 
antibody to non-phosphorylated NFs, SMI32 (Sternberger Monoclonals Incorporated, 
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Figure 6.1 
Neuronal cultures at DIV 21, before (A) and after (B) localised physical injury. Arrow 
indicates point of transection. 
Scale Bar = 125 gm 
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1:2000), to investigate the relationship between cortical non-pyramidal and pyramidal neurons 
in culture. 
The mouse monoclonal antibodies were visualised with a horse anti-mouse secondary 
antibody conjugated to FITC whereas the rabbit polyclonal was visualised with a goat anti-
rabbit antibody conjugated to biotin followed by streptavidin Texas Red. Fluorescence-
labelled coverslips were mounted using Permafluor (Immunotech) and viewed with a Leica 
fluorescence microscope. Images were again digitally captured using a CCD camera (Ikegami 
ICD-4CE, Tsushinki Co) attached to a Power PC Macintosh computer. Laser confocal 
scanning microscopy, using an Optiscan F900e krypton/argon system attached to an 
Olympus BX50 microscope, was utilised to investigate the localisation patterns of GAP43 and 
NF-H within damaged axons. 
6.2.3 Electron microscopy 
Coverslips were prepared according to routine electron microscopy techniques as outlined in 
Chapter 2.7. After the coverslips had been infiltrated with resin they were embedded and 
polymerised. In this respect, beam capsules were filled with resin and then the individual 
coverslips were inverted and placed on top. They were then placed in an oven at 60°C for 48 
hours to polymerise the resin. After polymerisation and cooling, the beam capsule can be 
removed, leaving the coverslip attached to the resin stud. The glass coverslip was removed 
(leaving the intact cells within the resin) by alternatively dipping the stud, with coverslip 
attached, into boiling water for two minutes and then into liquid nitrogen for two minutes. The 
differential rates of expansion and contraction of the resin and glass causes the coverslip to 
shatter and to detach from the resin (Withers & Banker, 1998). The embedded cells were 
examined with a disecting microscope and areas of interest marked. The stud was trimmed 
back to this area for sectioning. The protocol outlined above enables sections parallel to the 
substrate to be cut, thereby allowing visualisation of large areas of culture in a single section. 
After embedding standard sectioning and staining protocols were utilised (Chapter 2.7). 
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6.3 	Results 
6.3.1 Neuronal development in vitro 
Cortical cultures have been shown to develop through a series of well-defined steps (Dotti & 
Banker, 1987; De Lima et al., 1997). The utilization of the NeurobasalTM media did not appear 
to alter the early growth patterns in neurons. Briefly, soon after seeding, the cells partly 
reaggregated and attached to the coverslip. The adhered neurons appeared as rounded, 
dissociated single cells with either no processes or fine poorly defined single processes 
(Figure 6.2A). On the third day in vitro (DIV 3), multiple process formation began. Processes 
were clearly differentiated, morphologically, with both long axons and branching dendrites 
present (Figure 6.2B). At these early time points there was considerable cell death as indicated 
by the large amount of non-adhered debris and loosely attached cells. A large proportion of 
these dying cells were likely to correspond to the non-neuronal population whose survival is 
selected against by the NeurobasalTM media (Brewer et al., 1993; Brewer et al., 1995, 1997). 
On DIV 5, most cells were adhered as large clusters of cell bodies. Many of these cell clusters 
had small caliber processes, with interconnecting bundles of processes between them (Figure 
6.2C). The leading tips of most processes had distinct triangular growth cone-like 
morphology, and showed concentrated labelling with the antibody to GAP43. The complexity 
of these process networks continued to increase with time until DIV 21, with the axonal 
bundles between clustered cells becoming thicker (Figure 6.2D). From this time point 
onwards, no further axonal projections or dendritic branching was evident. There were no 
growth cones on the ends of projections and GAP43 labelling was uniform throughout. On 
DIV 21 occasional R-NFH labelled, ring-like structures were observed. These structures were 
variable both in size and thickness. The larger (. 3 gm) R-NFH immunopositive rings were 
often continuous with fine axons and more irregular in shape as compared to the smaller rings 
1.5 1.1m). These ring-like structures were intermittently present throughout the axonal 
fasciculations of the mature cultures (DIV 21 onwards). Neither form of ring-like structure 
showed labelling with antibodies to GAP43. 
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Figure 6.2 
Neuronal development in vitro at DIV 1 (A), 3 (B), 5 (C) and 21 (D). The cultures 
developed from single neurons (A) to small cell clusters with distinct axons and dendrites 
(B). As the culture matured more extensive cell body clusters joined by fine axons 
developed (C). Finally by DIV 21, a complex array of cell clusters with an extensive 
network of interconnecting axonal bundles were present (D). 
Scale Bar = 25 pm (A and B), 50 pm (C) and 125 p.m (D) 
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The antibodies SMI32 and anti-calretinin are routinely used to selectively label pyramidal cell 
bodies and non-pyramidal interneurons, respectively (Sampson et al., 1997). In a similar 
fashion to the mature neocortex, double labelling for these two markers demonstrated that no 
nerve cells were labelled for both NFs and calretinin. 5MI32 and anti-MAP2 labelling was 
present in most nerve cells, particularly those contained in clusters (Figure 6.3A). Calretinin 
immunopositive interneurons were present occasionally within the clusters, however, most 
neurons of this type were growing either singularly or in smaller groups of 1-5 cells (Figure 
6.3B). Calretinin immunopositive neurons accounted for less than 5% of the total cell 
population. Similarly, immunolabelling of cell monolayers with antibodies to GFAP and 
ferritin confirmed that non-neuronal glial cells were not present. A minority of fibres within 
the axonal bundles were found to be labelled with the antibody to MAP2 suggesting that they 
may correspond to dendrites (Figure 6.3C). Considerably more of these fibres were 
immunopositive with antibodies to NFs, a specific marker for axons (Figure 6.3D). 
6.3.2 Ultrastructure of neuronal cultures 
To further characterise the neuronal cultures the ultrastructure of the mature cell monolayers 
(DIV 21) was investigated using transmission electron microscopy (Figure 6.4). The large 
interconnecting process bundles, emanated from within the cell body cluster (Figure 6.4A). 
Close examination of the bundles, revealed the presence of both MTs and NFs within the 
nerve cell processes (Figures 6.4B, 6.4C, 6.4D). Oligodendrocytes were not present, and 
axons were notably non-myelinated. 
6.3.3 Neuronal response to localised trauma 
At DIV 7, the neuronal cultures demonstrated continued development, as evidenced by the 
GAP43 labelling of growth cones at axonal tips. Furthermore, prominent axonal connections 
between nerve cell clusters were not present, therefore, they were not used for the transection 
investigations. While transected fibres were apparent, no other specific morphological changes 
were observed following NF-H or GAP43 immunolabelling at any of the time points PI, in the 
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Figure 6.3 
MAP2 labelling (A) of the predominant cell type found throughout the cell clusters. 
Calretinin immunopositive interneurons were also present, however, with considerably 
lower frequency compared to NF labelled cells (B). Occasional fibres within the connecting 
fibre bundles were labelled for MAP2 (C), however, the majority of fibres were NF-H 
immunopositive (D). Arrow heads indicate a fibre immunopositive for MAP2 but not 
labelled by antibodies to NF-H. 
Scale Bar = 30 pm (A), 20 pm (B) and 30 pm (C and D) 

Figure 6.4 
Ultrastructure of normal growth in pure neuronal cultures at DIV 21. Large interconnecting 
process bundles, emanated from within the cell body cluster. Neuronal cells (n) flanked 
both sides of the process bundle (p), prior to the interconnecting processes leaving the 
cluster (A). Both MTs (arrows) (B and C) and NFs (arrowhead) (D) were evident within the 
nerve cell processes. 
Magnification = 10400x (A), 16900x (B and C) and 31000x (D) 
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DIV 14 cultures (Figure 6.5A). Similarly, no NF (Figure 6.5B) or GAP43 (Figure 6.5C) 
immunolabelled axons emanated from the cut axonal stump at three days after injury. 
Very few changes within axons were present at one hour post transection in cultured neurons 
injured after DIV 21 (Figure 6.6A and 6.6B). Some NF-H labelled axonal thickening had 
occurred but no GAP43 immunopositive alterations were present. However, in these mature 
cultures at six and twelve hours after injury, distinct changes were evident that were not 
present in the immature cultures at the same time points. There were extensive accumulations 
of ten to twenty NF-H immunopositive ring-like structures within the cut stumps. These rings 
were variable in size with an average diameter of approximately 2 pm. Their shape was 
generally irregular and many were continuous with the labelled fine processes. No GAP43 
labelling was present throughout, or associated with, the ring-like structures (Figure 6.6C). 
Similar changes were present on both sides of the transected axonal bundle. 
At 24 hours PI, NF-H immunopositive ring-like structures were present within the axonal 
stump, however, their frequency had decreased to approximately one to five per transected 
axonal bundle. Bulb-like accumulations of NF-H immunoreactivity were now also present 
within the transected axon bundles (Figure 6.6D and 6.6E). Some bulbs had fine processes or 
sprout-like protuberances associated with them. These bulb- and ring- like structures were not 
labelled for GAP43. However, there was an increase in punctate GAP43 labelling throughout 
the damaged area, particularly localised to the cut stump region (Figure 6.6F). 
At three days PI in the DIV 21 cultures another series of changes were present. There were no 
distinctly labelled NF-H immunopositive ring- or bulb- like structures. A number of fine 
processes, a single axon in thickness, extended from the cut face of the axonal bundle. These 
processes were GAP43 and NF-H immunopositive, with GAP43 labelled growth cones at 
their tip (Figure 6.7A). High magnification investigation of the growth cones revealed strong 
GAP43 labelling and a lack of NF labelling within the growth cone extremities (Figure 6.7B). 
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Figure 6.5 
Cultures injured at DIV 14 showed no NF-H labelled ring- or bulb-like reactive changes at 
twelve hours PI (A). Similarly no NF-H (B) or GAP43 (C) immunopositive axons or fibres 
were present beyond the cut face of the axonal bundles three days after injury in the DIV 14 
cultures. 
Scale Bar =20 pm (A) and 20 pm (B and C) 

Figure 6.6 
Confocal scanning laser microscope image showing no NF-H (A) or GAP43 (B) 
immunopositive reactive structures within transected axons (DIV 21) at one hour PI. Arrow 
indicates slight axonal thickening. Distinct changes were evident at twelve hours after 
injury in mature (DIV 21) cultures (C). Confocal image shows labeling for GAP43 (green) 
was increased within transected axons. NF-H labeling (red) showed extensive 
accumulations of NFs which appeared as ring-like structures, as indicated by the arrows. At 
24 hours PI occasional NF-H immunopositive rings were still present (arrows), in addition 
to distinct NF labelled bulb-like structures (arrow heads) (D and E). Confocal image 
showing no direct colocalization of NF-H (red) immunopositive rings and GAP43 (green) 
at this time point (F). 
Scale Bar = 10p.m (A, B and F), 15 p.m (C) and 20 p.m (D and E) 
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Figure 6.7 
At three days PI in the DIV 21 cultures a number of fine processes, a single axon in 
thickness, emanated from the cut face of the axonal bundle. These processes were GAP43 
(A) and NF-H immunopositive with GAP43 labelled growth cones at their tip (arrows). 
NFH labelling was present throughout the axon (red), as indicated by the arrow head, but 
was absent from the GAP43 labelled (green) growth cones (arrows) (B). 
Scale Bar =25 p.m (A) and 5 pm (B) 
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The results obtained at all time points were the same for both of the two tansections per 
coverslip and were consistent throughout the five series of separate culture experiments. 
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6.4 	Discussion 
The process of cellular differentiation of cerebral cortical neurons in vitro resembled the 
development of these cells in the intact tissue (Dotti & Banker, 1987). Although confined to a 
two dimensional substrate, the axons and dendrites that develop in neuronal cultures differ 
from one another in form, in molecular composition and in synaptic polarity, just as their 
counterparts in situ do (Bartlett & Banker, 1984; Dotti et al., 1988). The cultured cortical 
neurons in the current study could be differentiated into subtypes based on their 
neurochemical identity, which were similar to subgroups of pyramidal and non-pyramidal 
cells in vivo (Sampson et al., 1997), supporting the proposal that organised cell migration is 
not a prerequisite for the differentiation of single cortical neurons (De Lima et al., 1997). 
In cortical and hippocampal cultures the presence of process connections between large cell 
body clusters is routinely reported. These networks have alternatively been termed neurite 
bundles (Sole, 1980), process networks (Murphy & Horrocks, 1993a, 1993b), multifiber 
bundles (Mire et al., 1970; Bird, 1978) and fasciculations (DeLima et al., 1997). Similar 
patterns of growth were noted in this investigation where the neuronal selective media 
Neurobasal' was utilised. The extensive formation of neuritic bundles between cell clusters 
enabled ease of transection under microscopic guidance. 
Two general approaches to axon transection in vitro have been previously utilised in 'mixed' 
neuron/glial cultures. These models primarily differ with regards to whether the initial insult is 
delivered non specifically, to all cells within a culture monolayer (Tecoma et al., 1989; Muhkin 
et al., 1997), or to a limited number of cells (Levi & Meyer, 1945; Shaw & Bray, 1977; Gross 
et al., 1983; Yawo & Kuno, 1983; Lucas et al., 1985). Whereas the responses of dendrites to 
transection in mixed dissociated hippocampal cultures have been extensively investigated 
(Dotti & Banker, 1987; Emery et al., 1987; Banker & Goslin, 1991), similar investigations 
have not been performed on neocortical axons per se in a purely neuronal environment. 
However, a recent investigation involving the stretching of single axons in a neuron-like cell 
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line (N-Tera2) demonstrates that primary neuritic damage is associated with misprocessing of 
cytoskeletal elements such as NFs (Smith et al., 1999), as suggested by numerous in vivo 
studies (Maxwell et al., 1997). In the current study the fate of damaged axons was revealed by 
specific markers including antibodies to GAP43 and phosphorylated NFs. 
The axonal changes that occur following injury with the current model were shown to follow a 
'stereotypy' in their response. The initial reactive changes in axons involving NFs 
demonstrate specific morphological features, including bulb- and ring-like structures 
(Guillery, 1965; Meller et al., 1993a, 1994; Vickers et al., 1996; King et al., 1997, 2000). 
Examination of the time course of appearance of these structures showed that the presence of 
NF-containing rings, the classic distal reaction of traumatised axons (Guillery, 1965; Vickers, 
1997) clearly preceded the development of NF immunopositive bulb-like structures. 
Ultrastructural analysis of morphologically identical structures in an in vivo model of cortical 
physical damage showed that the ring-like structures correspond to accumulations of 
filaments surrounding a core of 1-2 mitochondria, whereas bulbs consisted of swollen 
myelinated and some non-myelinated processes (King et al., 2000). Additionally, both forms 
of neuritic pathology demonstrated a loss of microtubules in vivo. The mid-axonal location of 
the ring-like structures suggests that it is unlikely that they correspond to axonal terminals as 
previously proposed (Guillery, 1965; Roots, 1983) and may instead be indicative of more 
generalised axonal cytoskeletal alterations. It may be that the ring-like structures in the in vitro 
and in vivo experimental models represent 'collapsed' axons where the loss of microtubules 
and compaction of NFs results in general cytoskeletal disarrangement and the accumulation of 
organelles. Bulb-like structures may therefore represent expanded axonal segments. Similar 
neurofilamentous changes have been noted in other models of physical damage and also in the 
very early stages of AI) (Chapter 3; Guillery, 1965; Meller et al., 1993a, 1994; Vickers et al., 
1996; King et al., 1997; King et al., 2000). 
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NF alterations in injured neurons appear to play an important role in the subsequent attempt 
by neurons to sprout, as indicated by poor regeneration in NF deficient mice (Zhu et al., 1997) 
and quail (Jiang et al., 1996) following peripheral nerve injury. Further to this, it has been 
demonstrated in vivo that diffusely injured axons can mount a sustained regenerative attempt 
that is associated with a reorganisation of their cytoskeleton and accompanied by an up 
regulation of GAP43 (Christman et al., 1997). In the current in vitro investigation, following 
the initial NF changes, at twelve hours PI, the stereotypical reaction to injury also involved an 
accumulation of GAP43 and subsequent sprouting. In addition, there was distinct GAP43 
labelling of axonal sprouts and growth cones emanating from the cut axonal stump at three 
days PI. Interestingly, the GAP43 and NF reactive changes that occur post-transection appear 
to be confined to different cellular compartments, as indicated by the lack of colocalisation. 
This suggests that GAP43, and not NFs, is associated with the distal response of the injured 
axon. It cannot be determined definitively whether the regenerating axons emerge from 
previously damaged neurites or from uninjured neurons in the cell clusters — this may be 
achieved by following the reaction of single cultured nerve cells in future studies. However, it 
is notable that three weeks of growth and differentiation by these neurons is required for this 
sprouting response whereas neurons at 14 DIV show markedly reduced ability to regenerate 
post-injury, although many of the neurons in clusters would be still in the process of 
elaborating their axonal process. This would indicate that the sprouting response may be more 
closely associated with the differentiation state of the injured neurons, rather than emanating 
from undamaged cell bodies. 
Ultrastructural studies have supported the proposition that sprouting processes emerge from 
reactive axons (Yaghmai & Povlishock, 1992) and the proximal axonal stump (McHale et al., 
1995) following injury to the CNS. Furthermore, labelling for GAP43, has been localised to 
sprouting axons several days after both traumatic brain injury (Christman et al., 1997) and 
following axonal transection in hippocampal slices in vitro (McKinney et al., 1997). In the 
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latter study it was proposed that such injury-related sprouting may ultimately give rise to 
epileptiform activity within the brain (McKinney et al., 1997). 
Finally, the neurofilamentous changes identified in the current model were rarely observed PI 
in DIV 14 cultures but were numerous in DIV 21 injured axons, indicating that cultured 
neurons have to reach a certain level of maturity before responding in the above outlined 
stereotypical fashion. Similar age dependent reactive changes have been reported by Murphy 
and Horrocks (1993b) in their investigations of the effects of ischaemia and glutamate toxicity 
on neurons in mixed culture. They concluded that neurons in culture for between two to three 
weeks (DIV14-21) mature and this maturation increases the susceptibility to ischaemic injury. 
Cells in culture for less than two weeks were unaffected by the same level of ischaemia. These 
data clearly indicate that neuronal responses to both mechanical and physiological insults is 
governed by the maturity of the cell. 
The current study has demonstrated that the neuronal alterations following axotomy in vitro 
resemble the changes observed in vivo in adult animals (Guillery, 1965; Meller et al., 1993a, 
1994; King et al., 1997, 2000). In addition, as the culturing conditions do not support glial 
cells, it suggests that the stereotypical changes that occur represent an internal neuronal 
response and do not require external factors possibly derived from non-neuronal cells. This in 
vitro model is also relevant to AD as it replicates the early cytoskeletal pathology of this 
condition in the form of bulb- and ring-like structures showing an accumulation of NFs 
(Chapter 3; Vickers et al., 1996; King et al., 1997). In a similar fashion to the subtypes of 
plaque-associated DNs in AD (Chapter 3), neurites responding to injury in the current study 
could be distinguished by their content of either NF or sprouting-related markers. 
The current in vitro model may also be used to investigate therapeutic agents that may inhibit 
deleterious aspects of the neuronal response to injury. For example, we have recently utilised 
an in vivo model of brain injury to examine whether cytoskeletal stabilising drugs may inhibit 
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the neuronal reaction to injury (Adlard, In Press), a strategy that may be helpful in preventing 
post-trauma cytoskeletal disruption and/or aberrant sprouting, and perhaps the evolution of 
neuronal pathology in Alzheimer's disease. The ability to replicate key injury-related neuronal 
changes in culture will enable the more rapid screening of potentially clinically relevant 
neuroactive agents. 
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GENERAL DISCUSSION 
7.1 	Discussion 
While there have been major advances in unravelling important features of the pathology, 
epidemiology and genetics of AD in recent years, progress in determining a therapeutic 
strategy to prevent, attenuate or effectively treat AD has been hampered by the lack of 
understanding of the cellular mechanism leading to neuronal degenerations and dementia. 
The central aim of this thesis is to contribute towards a greater understanding of this 
mechanism, particularly with regards to the role of NFs in the development of 
neurofibrillary pathology. 
The introductory chapter in this thesis presented a review of the literature on both the 
neuronal cytoskeleton and the pathological hallmarks of AD, with a particular emphasis on 
the relationship between the two. It was noted that most investigators of cytoskeletal 
alterations in AD focus on the MT associated protein, tau, that is present in neurofibrillary 
pathology as PHFs (Wischik et al., 1988). However, more recent investigations found that 
abnormal tau is absent from the DNs that are present within presymptomatic or preclinical 
AD cases. Instead the predominant cytoskeletal alteration in these cases is the abnormal 
accumulation of NFs. Furthermore, evidence suggesting selective vulnerability to NET 
development of NF immunopositive neurons (Vickers et al., 1992b, Hof et al., 1990) further 
implicated NFs as playing an important role in the pathogenesis of AD. A widely reported 
phenomena in this area is the association between clusters of DNs and 13—amyloid deposits 
(Hof & Morrison, 1994). There is considerable controversy within the literature regarding 
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which of these hallmark structures is the initiating pathological lesion. Several hypotheses 
have been proposed to explain this association, however, all are yet to be proven 
unequivocally. This background information prompted an initial investigation of the 
relationship between 13-amyloid deposits and abnormal or dystrophic neurites. 
Some investigators propose that not all clusters of DNs are associated with 13—amyloid 
plaques, therefore, suggesting the possibility that neuritic abnormalities may precede B-
amyloid deposition (Martin et al., 1994). In this investigation, experiments utilising double 
labelling immunohistochemistry confirmed that all clusters of DNs in both preclinical and 
end-stage AD cases were associated with B-amyloid plaques, however, not all amyloid 
deposits were neuritic. These results support the hypothesis that the initiating pathological 
lesion in AD is the B-amyloid plaque and that neurofibrillary pathology is a secondary 
change (Selkoe, 1994). This association was not dependent on the morphology of the 
plaque with all plaque types, including diffuse deposits, associated with clusters of DNs. 
Further to this, all plaque types were present in both preclinical and end-stage AD, 
including dense-cored plaques. This result further supports the premise that the 
morphologically variable plaque types, that are widely reported by investigators, are likely 
to represent independently evolved structures (Armstrong, 1998) and challenges the 
assumption that they are indicative of the stages of the life history of a single plaque (Ikeda 
etal., 1990). 
The lack of correlation between the morphology of B-amyloid plaques and their tendency to 
cause damage to surrounding nerve cell processes implied that a further factor differentiates 
damaging from non-damaging plaques. The protein ApoE has been suspected as having a 
role in AD primarily due to the identification of the E4 allele as a genetic risk factor for the 
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disease (Corder et al., 1993), however, this role has not been fully elucidated. Several 
reports have emphasised the association of ApoE with either B-amyloid plaque formation 
(Wisniewski & Frangione, 1992; Kida et al., 1994; Gearing et al., 1995; Sheng et al., 1996) 
or the development of neurofibrillary pathology (Benzing & Mufson, 1995; Han et al., 
1994). In this thesis, the association between ApoE and the pathological hallmarks of AD in 
preclinical and end-stage AD cases was determined, with the view of investigating the 
hypothesis that the protein ApoE contributes to the formation of AD pathology. 
Utilisation of multiple label immunohistochemical methods enabled the direct examination 
of the localisation of ApoE immunoreactivity relative to B-amyloid plaques, DNs and 
NFTs. In AD cases, 13-amyloid plaques showing high ApoE immunoreactivity were 
localised to layers II, III and V of the neocortex. In layer I, B-amyloid plaques were 
unlabelled for ApoE, and plaques in other layers were typically incompletely labelled for 
ApoE relative to B-amyloid. Dense-core plaques labelled for B-amyloid often had only the 
central portions labelled for ApoE. Unlike 13-amyloid labelled plaques, all ApoE 
immunoreactive plaques were associated with DNs. In preclinical AD cases, most plaques 
were double labelled for B-amyloid and ApoE. ApoE did not label DNs or the early stages 
of NFT formation, indicating that ApoE may not be directly involved in neurofibrillary 
pathology. The specific presence of ApoE in plaques associated with DNs in demented 
cases suggests that ApoE may contribute toward a higher degree of 13-amyloid 
fibrillogenesis, enhancing the ability of certain plaques to cause damage to surrounding 
axons. Alternatively, as ApoE has been demonstrated to have a role in the remodelling and 
sprouting of axons and synaptic terminals following neural damage (Poirier, 1994), it may 
be acting to mobilise and redistribute cholesterol following plaque-induced damage, 
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promoting the reformation of membranous structures and subsequent 
sprouting/regeneration. 
DNs are complex structures exhibiting immunoreactivity to a wide range of proteins 
including various components of the cytoskeleton. There has been some controversy over 
the origin of DNs, although the balance of evidence suggest that they represent altered, 
probably abnormally sprouting axons (Masliah et al., 1993b; Praprotnik et al., 1996; 
Vickers et al., 1996). One of the specific aims of this thesis was to investigate the diversity 
of plaque-associated DNs in both the early and late stages of AD. In the studies addressing 
this aim, a particular emphasis was placed on clarifying the role of NFs in the development 
of this pathological hallmark. 
Preclinical AD was characterised by the presence of abnormal neurites containing either NF 
or CgA immunoreactivity in the absence of tau labelling. NF immunoreactive DNs in 
preclinical AD could be further subclassified into bulb- and ring-like structures. These 
abnormal neurites contained both phosphorylated and dephosphorylated NF epitopes. 
Therefore, an abnormal accumulation of variably phosphorylated NFs represent the earliest 
cytoskeletal alteration associated with DN formation and, therefore, one of the earliest 
pathological phenomena associated with the disease. Identification of the earliest form of 
neuronal pathology of AD holds the key to understanding the relationship between 13- 
amyloid plaque formation and neuronal degeneration. The elucidation of this early 
preclinical stage of the disease provides another potential target for the development of 
effective therapeutic strategies aimed at preventing or slowing the development of classical 
PHF-tau pathology and nerve cell death. 
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DNs in AD could be subdivided into predominantly NF, tau or CgA immunolabelled forms. 
The NF immunopositive DNs expressed the same complement of phosphorylation- and 
dephosphorylation-dependent epitopes as observed in preclinical cases. These DNs could 
again be subclassified based on their morphology, into bulb-like structures and also 
swollen, torturous neurites. NF immunopositive ring-like structures were not present in 
these cases, and supported the premise that this form of DN was transient and characteristic 
of the very early stages of neuritc pathology development in AD. Immunohistochemical 
labelling of the end-stage AD material demonstrated that the majority of NF 
immunoreactive DNs were bulb-like, whereas most of the more swollen and elongated 
processes were tau immunopositive. Close examination of the end-stage AD material 
double labelled for both NFs and tau revealed a distinct third class of abnormal neurite, NF 
immunoreactive bulb-like neurites with a core region labelled for tau. It was proposed that 
this class of abnormal neurites may represent an important transitional stage in DN 
development that is currently rarely recognised by many investigators. Using the confocal 
microscope to optically section through NF immunoreactive DNs, it was possible to 
quantitate the proportion of neurites that show this association between the two cytoskeletal 
proteins. Data showed that this labelling pattern was considerably more prevalent than 
initial examination using standard fluorescent microscopy suggested. Whereas the stages of 
NFT formation and development have been widely investigated, similar detail regarding 
DN formation has not been established. The results of this thesis indicate that DNs may 
'mature' through NF-abundant forms to the neurites containing the profoundly altered 
filaments labelled for tau and confirm a role for NF in the development of the DNs 
associated with 13-amyloid plaques. 
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Thus the initial AD neuronal pathology is characterised by an accumulation of NFs. While 
the studies on preclinical AD have supported the proposal that cellular changes involving 
NFs may be important in the staging of neurofibrillary pathology, it was the morphological 
forms of the early DNs that provided a crucial clue as to how B—amyloid plaques cause 
neuronal pathology. Recently, our laboratory determined that the NF immunopositive bulb-
and ring-like DNs associated with plaques in preclinical AD were morphologically identical 
to changes that occur within damaged axons in a rodent experimental model of localised 
brain trauma (King et al., 1997). This initial observations lead to the preliminary hypothesis 
that physically damaged rat cortical axons may serve as a model for the early neuronal 
pathology of AD. 
In the current investigations, the neurochemical heterogeneity of the DNs present in 
preclinical and end-stage AD was assessed. The distribution and degree of colocalisation of 
various components of the NF triplet in various phosphorylation states, was determined 
using multiple double labelling immunohistochemistry. A distinct expression pattern of NF 
epitopes was present in both the preclinical and end-stage AD cases. Interestingly, similarly 
detailed immunohistochemical analysis in the rodent in vivo experimental model revealed 
the same expression pattern of NF epitopes (King et al., 2000). Therefore, the rigorous 
investigation of the exact complement of NF epitopes localised to preclinical AD DNs 
provided further support for the preliminary hypothesis that the axonal changes that occur 
in response to physical damage model the earliest neurofibrillary pathological changes that 
occur in axons in response to B-amyloid plaque formation. Thus, the gradual emergence of 
plaques from the late middle age onwards may cause physical damage to surrounding 
axons, resulting in a sprouting response by the affected neuron. Ultimately, the chronic 
persistent stimulation of this sprouting response results in abnormal neuronal filamentous 
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pathology throughout the nerve cells, eventually leading to degeneration of specific cortical 
connections and dementia (Vickers et al., 1996; King et al., 1997; Vickers, 1997; King et 
al., 2000). 
Nerve cells respond to structural injury with a complex set of morphological, 
neurochemical and gene expression changes, most of which are directed towards an attempt 
by the neuron to adapt to such trauma by sprouting and regeneration. Consideration of the 
literature uncovers many parallels between the neuronal response to physical trauma and 
the changes that occur with DN and NFT formation in AD. 
NFs are normally excluded from the synaptic terminals in most axons, but ring-like 
accumulations of NFs occur in this neuronal domain following axonal damage (Gray & 
Hamlyn, 1962; Guillery, 1965). Neurofilamentous hypertrophy also occurs in the proximal 
and distal stumps of transected central and peripheral axons, with distal segments of 
damaged axons gradually undergoing Wallarian degeneration (Ramon y Cajal, 1928; 
Lanners & Grafstein, 1980; Meller, 1987; Hall et al, 1989; Tetzlaff & Bisby, 1989; McHale 
et al., 1995). The morphology of the proximal and distal segments of the physically 
damaged axons resemble the bulb- and ring-like DNs of preclinical AD (King et al., 1997, 
2000). Similarly, an accumulation of perikaryal NFs is also reported in the cell body 
reaction to physical injury (Torvick, 1976; Schlaepfer, 1987; Silveira et al., 1994) and in 
AD (Vickers et al., 1992b, 1994b; Nakamura et al., 1997). 
Phosphorylation-dependent NF epitopes, normally localised to the axonal domain 
(Sternberger & Sternberger, 1993), appear in the cell bodies of acutely damaged neurons. 
Similarly, phosphorylated NF epitopes have been localised to cortical nerve cell bodies in 
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AD (Masliah et al., 1993b). The reverse modification occurs in axons. After physical 
trauma dephosphorylated NF epitopes, normally localised to the perikaryal domain 
(Sternberger & Sternberger, 1983), transiently occur in damaged axons as well as in distal 
axonal segments following Wallarian degeneration (Meller et al., 1993b, 1994; King et al., 
1997). Dephosphorylated NFs were likewise localised to the DNs of both preclinical and 
end-stage AD in the current investigations. 
Many central neurons, when damaged exhibit some form of sprouting (Wigley & Berry, 
1988; Hopkins & Bunge, 1991; Deller & Frotscher, 1997; McKinney et al., 1997). This 
attempt at regeneration may, however, lead to inappropriate new connections that can cause 
elevated epileptiform activity (McKinney et al., 1997). Interestingly, in this investigation, 
and other recent studies, subgroups of DNs localised to plaques that generally lack 
cytoskeletal epitopes but contain synaptic markers indicative of adaptive sprouting have 
been identified (Chapter 3; Saunders et al., 1998; Su et al., 1998). The AD related changes 
in tau may also follow the neuronal reaction to physical damage. For example, increased 
expression of the developmental form of the tau protein occurs following physical injury in 
adult animals (Chambers & Muma, 1997), and this isoform of tau is an intrinsic component 
of neurofibrillary pathology (Jakes et al., 1991). Furthermore, tau proteins are enriched in 
regenerating axons (Yin et al., 1995) and the abnormally phosphorylated sites on tau in AD 
recapitulate tau modification during axonal growth (Pope et al., 1993). 
Finally, further evidence linking physical injury and AD, is the identification of head 
trauma as a risk factor. Both single episodes and repeated head injury, as in the case of 
boxers (dementia pugilistica) have been identified as increasing the risk of AD (Heyman et 
al., 1984; Mortimer et al., 1985; Graves et al., 1990; Mortimer et al., 1991; Katzman & 
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Kawas, 1994). Furthermore, the NFTs characteristic of AD are very similar to those that 
occur following repetitive head injury, as experienced by boxers (Lampert & Hardman, 
1984; Roberts et al., 1990; Tokuda etal., 1991; Geddes et al., 1996, 1999) or by individuals 
demonstrating self-abuse behaviour (Hof et al., 1991b). 
The final aim of this thesis was to develop an in vitro model that mimics the effects of B-
amyloid plaques on surrounding neuronal processes and, therefore, complements the 
existing in vivo model. The advantages of in vitro models of neuronal responses to injury 
include the ability to control and manipulate the extracellular environment, elimination of 
often confounding effects introduced by the circulatory system such as hypoxia and 
ischemia and the possibility of low cost screening of potential therapeutic agents. The 
current investigation had a focus on the time course of cytoskeletal changes following 
physical injury to axons as well as the temporal association of reactive and regenerative 
cellular alterations. Therefore, isolated pure neuronal cultures with markers for NFs and the 
growth-associated protein, GAP43, were utilised. 
The neuronal response to axotomy was closely linked with nerve cell maturity. In summary, 
after transection, mature cortical neurons underwent a series of stereotypical changes that 
are independent of the presence of other confounding cells (astroglia, microglia, 
oligodendrocytes etc) and factors, such as cytolcines, chemolcines, interleukins and growth 
factors that may be released by these cell types. These reactive changes, which occurred 
independent of the presence or effects of glial cell populations, involved the development of 
NF-labelled ring- and bulb-like structures, followed by GAP43 accumulation and ultimately 
culminated in a sprouting response. These reactive cellular changes faithfully modelled the 
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consequences of in vivo axotomy as well as the earliest stages of DN formation in response 
to B-amyloid plaque formation in AD. 
Collectively the results obtained from the investigations outlined in this thesis, in the light 
of work by other investigators, dispute a number of the popular theories developed to 
explain the mechanism underlying AD. Furthermore, these results support a newly evolving 
hypothesis that links two of the pathological hallmark changes of AD, the B-amyloid plaque 
and the DN. 
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7.2 	Final conclusions 
With the changing demographics of society world wide, disorders that affect the elderly are 
increasingly prevalent (Price et al., 1998). Because of this prevalence and the magnitude of 
the morbidity associated with AD it is imperative that a greater understanding of the 
pathogenic mechanisms involved in AD is obtained. This will ultimately lead to the 
development of more effective treatments that either prevent or ameliorate this disease. In 
conclusion, in this study, the following contributions to a greater understanding of the 
cellular mechanism underlying AD were made. Figure 7.2 shows a diagramatic 
representation of these findings. 
• NFs have a role in the development of neurofibrillary pathology in AD. 
The results of this thesis challenge one of the common assumptions made in AD research, 
that is that the changes associated with tau are the primary cytoskeletal alteration in AD 
and, furthermore, NFs play no significant role in the development of neurofibrillary 
pathology. Accumulations of NFs as distinct bulb and ring-like structures were identified as 
the earliest form of axonal pathology in preclinical AD, preceding classical PITF-tau 
pathology. The following transitional stage in DN development, the formation of a tau core 
within the NF immunopositive bulb-like structures, was also identified and further 
characterised. 
• ft-atnyloid plaques may cause physical damage to surrounding axons. 
A pervading belief among supporters of the amyloid cascade hypothesis is that 13—amyloid 
is toxic to nerve cells. Based on the similarities between preclinical AD DNs and the 
abnormal neurites that develop following physical trauma to axons it has recently been 
proposed that 13-amyloid plaque deposition in AD may cause physical damage to 
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surrounding processes (King et al., 1997, 2000; Vickers, 1997) as opposed to toxic damage. 
Alternatively, axons may have a limited repertoire of responses to any insult, such that a 
toxic factor within the plaque cannot not be totally excluded as the initiator of 
neurofibrillary pathology. 
• ApoE may contribute to the ability of plaques to damage surrounding processes. 
The protein ApoE colocalised selectively with those B-amyloid plaques associated with 
clusters of DNs. These results imply that ApoE may play a role in determining the ability of 
plaques to injure processes, perhaps through increased fibrillogenesis. 
• An in vitro model of axonal injury replicates preclinical AD neuronal pathology. 
At present there is no model that effectively replicates all aspects of the complicated AD 
paradigm. In this investigation a model of the very earliest neurofibrillary changes that 
occur in AD was developed. The advantages of this model include its relative 
inexpensiveness, as compared to the funds required for the development of transgenic 
models, and more importantly as this system models the earliest preclinical changes that 
occur in AD it provides a new tool for assessing the effectiveness of potential therapeutic 
agents which are aimed at stabilising the cytoskelton before the development of NFT, nerve 
cell degeneration and dementia. 
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APPENDIX A 
0.01M PBS, pH 7.4 (4°C): 
100 ml 	10X saline stock (90 g NaC1 (BDH) per litre MilliQ® water) 
40 ml 	Na2HPO4 (BDH) (28.4 g per litre MilliQ ® water) 
10 ml 	NaH2PO42H20 (BDH) (31.2 g per litre MilliQ° water) 
80 ml 
Tissue storage solution (4°C): 
0.01 M PBS 
0.1% Sodium azide (Sigma) 
Tissue storage solution (-20°C): 
300 ml 	glycerol (BDH) 
300 ml 	ethylene glycol (BDH) 
300 ml 	MilliQ® 
80 ml 	Na2HPO4 (BDH) (28.4 g per litre MilliQe water) 
20 ml 	NaH2PO42H20 (BDH) (31.2 g per litre MilliQ® water) 
4% Parafornuddehyde solution: 
40 g 	Paraformaldehyde (BDH Laboratory Supplies) 
100 ml 	NaH2PO42H20 (BDH) (31.2 g per litre MilliQ ® water) 
400 ml 	Na2HPO4 (BDH) (28.4 g per litre MilliQ® water) 
500 ml 	MilliQ® 
Solution heated until dissolved 
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Chrome alum: 
2.5 g 	Gelatine 
0.25 g 	Chrom alum 
500 ml 	MilliQ® 
Solution was heated until disolved and then filtered before use. 
Borate buffer: 
9.54 g 	disodium tetraborate 
250 ml 	MilHQ® 
Add to boric acid solution (24.74 g in four litres Million, until pH reaches 7.4. 
1.5M Tris-HC1, pH 8.8: 
18.5 g 	Tris-base (Sigma) 
. 100 ml 
pH adjusted to 8.8 with 6M HC1, made up to 100 ml with MilliQ ® then filtered 
0.5M Tris-HC1, pH 6.8: 
6 g 	Tr is-base (Sigma) 
. 100 ml 	MilliQ® 
pH adjusted to 6.8 with 6M HC1, made up to 100 ml with MilliQ ® then filtered 
10% Sodium dodecyl sulphate (SDS): 
10 g 	SDS (Bio-Rad Laboratories) 
. 100 ml 	MilliQ® 
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Stacking gel, 4%: 
1.33 ml 	acrylamide (Bio-Rad Laboratories) 
2.5 ml 	0.5M Tris-HCI 
100 [4.1 	10% SDS 
6.1 ml 	MilliQ® 
Add 50 j.tl 10% ammonium persuplhate and 10 1.1.1 Tetra-methylethylenediamine (TEMED) 
Separating gel, 7.5%: 
2.5 ml 	acrylamide (Bio-Rad Laboratories) 
2.5 ml 	1.5M Tris-HC1 
100 ill 	10% SDS 
4.85 ml 	MilliQ® 
Add 50 p.1 10% ammonium persuplhate and 5 p1 TEMED 
5x Running buffer, pH 8.3: 
15 g 	Tris-base (Sigma) 
72 g 	glycine (Bio-Rad Laboratories) 
5 g 	SDS (Bio-Rad Laboratories) 
Make up to one litre with MilliQ ®. Dilute 60 ml with 240 ml of 	for one run. 
Blotting transfer buffer (25nM Tris, 192mM glycine, 20% v/v methanol, pH 8.3): 
3.03 g 	Tris-base (Sigma) 
14.4 g 	glycine (Bio-Rad Laboratories) 
200 ml 	methanol (BDH) 
Make up to 1 litre with MilliQ ® 
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Tris buffered saline (TBS) (20 nM Tris-HC1, 500 mM NaCL, pH 7.5): 
4.84 g 	Tris-base (Sigma 
58.48 g 	NaC1 (BDH) 
1.5L 
pH adjusted to 7.5 with 6M HC1, made up to 2 litre with MilliQ ® 
Tris buffered saline with tween: 
700 ml 	TBS 
350 p.1 	Tween 20 (Bio-Rad Laboratories) 
Epon resin: 
11.66 g 	Procure 812 (ProSciTech) 
3.30 g 	Dodecenyl Succinic Anhydride (ProSciTech) 
8.41 g 	Nadic Methyl Anhydride (Probing & Structure) 
Mix slowly, for 10 minutes with magnetic stirrer. Then add 0.3 g of 2,4,8 — Tri 
dimethylaminoethyl phenol (Probing & Structure). 
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